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Introduction to PD
Parkinson's disease (PD) is a progressive neurodegenera tive  d isorder w ith  an 
estim ated prevalence o f 0.5-1% above the age o f 60 years and m ore than 4% above 
80.12 In the  Netherlands, approx im ate ly  5.000 peop le  are new ly d iagnosed w ith  PD 
every year3 and th is num ber w ill on ly  increase w ith  the  expand ing elderly 
po pu la tion .4 However, PD can also affect younger peop le  in the  prim e o f the ir life, 
som etim es before the  age o f 40, resu lting in w o rk  absenteism  and a m ajor im pact 
on the ir qu a lity  o f life. Men are affected 1.5 to  2 tim es m ore o ften  than w om en.12 In 
term s o f e tio logy, PD is considered a m u ltifa c to ria l disease w ith  d iffe ren t underly ing 
causes in d iffe ren t patients. Main e tio log ica l factors include (a com b ina tion  of) 
gene tic  defects, environm enta l toxins, horm onal influences, head traum a and life 
style.
The d iagnosis o f PD is based on the  UK PD Society Brain Bank Criteria w h ich  dem and 
the  presence o f the  fo llo w in g  sym ptom s: (1) rest trem or, (2) bradykinesia or akinesia, 
(3) r ig id ity , and (4) postural in s ta b ility  and ga it disturbances.5 These are all c lin ica lly 
recogn izab le m o to r sym ptom s, w h ich  gradua lly  em erge and worsen w ith  
progressing disease. Postural in s ta b ility  however should no t be p ro m ine n t in the  
early stages and if so, should be a w arn ing  sign to  consider o ther diagnoses in the 
spectrum  o f parkisonism . A de fin ite  diagnosis o f PD can on ly  be made post-m ortem , 
w hen a lpha-synucle in pa tho log y  is fou nd  in bra instem  nucle i (e.g. nucleus 
o lfactorius, pon tine  tegm en tum , substantia nigra and locus coeruleus), in nuclear 
gray m atte r o f the  basal fo rebra in , and in advanced stages in the  neocortex, 
com bined w ith  the  loss o f specific subsets o f m e lan in -con ta in ing  dopam inerg ic  
neurons in the  substantia nigra pars com pacta.6
Early non-motor symptoms and their significance 
to the diagnosis of PD
A ltho ug h  the diagnosis o f PD is still based on the  m o to r sym ptom s m en tioned 
above, PD is increasing ly recognized as a m ultisystem  disorder, also a ffec ting  the 
noradrenerg ic, sero tonerg ic, cho line rg ic  and o ther neuro transm itte r systems.6 This 
has lead to  the  recogn ition  o f several no n -m o to r sym ptom s, w h ich  may present 
bo th  du ring  the  course o f the  disease and also p rio r to  the  clinical diagnosis. This
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includes au tonom ic dys func tion  (e.g. o rthos ta tic  hypotension, b lurred vision, 
constipa tion , b ladder dysfunction , erectile  dysfunction), affective and behavioral 
prob lem s (e.g. depression, anx ie ty  and obsessive-com pulsive behavior), cogn itive  
im pa irm ent, and sleep disturbances (e.g. REM sleep behavior disorder).7,8
Despite these advancing insights, a p robab le  diagnosis o f PD can on ly  be made 
w hen the  disease has reached the stage o f ove rt m o to r dysfunction , w h ile  at tha t 
tim e  the  underly ing  disease process has already been active fo r at least several 
years and approx im ate ly  60% o f the  dopam ine rg ic  neurons have been lo s t.910 
These early stages o f PD, the  so-called p rem oto r or preclin ica l stages, have rap id ly 
ga ined in terest du ring  the  last tw o  decades. There are at least tw o  im p o rtan t 
reasons w hy a tten tion  is sh ifting  tow ards th is  p rem oto r phase. First, p ro m p t and 
early recogn ition  o f PD is im p o rta n t fo r  the  pa tien t w ho  may in itia lly  experience 
vague b u t d is tu rb ing  -and perhaps fr ig h te n in g - changes in his fu n c tio n in g , such as 
dizziness, p roblem s w ith  overseeing com plex s itua tions or the  a b ility  to  m ultitask, 
or a general fee ling  o f pain, d iscom fort and fa tigue . Some o f these no n -m o to r 
sym ptom s can be treated satisfactorily.1112 The second reason to  gain be tte r ins igh t 
in to  the  early stages o f PD may even be m ore critica l. Evolving neuropro tective  and 
d isease-m odulating therapies should idea lly  be insta lled at the  earliest stages of 
neurodegenera tion , w hen the  least am oun t o f pa tho log ica l changes (and neuronal 
loss in particular) has occured. Therefore, a screening too l is needed to  id en tify  
subjects in the  p rem oto r stages o f PD w ho  are at risk o f deve lop ing  fu ll-b lo w n  PD. 
This has lead to  the  investiga tion  o f b io log ica l markers (in b lood, cerebrospinal 
flu id , etc.), w ith  the  aim o f id e n tify in g  early stages o f PD and to  d is tingu ish  PD from  
o ther parkinsonian syndrom es.13 To date, no such b iom arker has been found  
sensitive and specific enough to  be app lied  on a large scale or w ith in  a clinical 
se tting .
A new and po ten tia lly  in te resting  approach to  the  p rem oto r phase o f PD relates to 
the  behavioral and cogn itive  changes w h ich  are a re flection  o f a gradua lly  changing 
dopam ine rg ic  state. Reduced centra l dopam ine rg ic  transm ission at levels th a t can 
still upho ld  norm al m o to r perfo rm ance m ig h t be low  enough to  cause changes in
e.g. character or personality. Such changes may becom e v is ib le  in the  life sty le  and 
jo b  preferences o f affected subjects long before m o to r sym ptom s em erge. Perhaps, 
the  reduced risk o f PD associated w ith  sm oking should be in te rp re ted  reversely, in a 
way th a t p rem oto r ind iv idua ls smoke less than healthy peop le (possib ly due to
12
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decreased fee lings o f reward). Reduced dopam ine rg ic  a c tiv ity  may also lead to  a 
preference fo r  specific occupations th a t require litt le  fle x ib ility . Research based on 
th is  approach has ye t to  be expanded.
Subtle subclinical motor dysfunction and 
how it could be detected
Besides the  use o f no n -m o to r disease markers, h igh ly  sensitive and m ainly 
com puterized m o to r assessments (such as quan tified  fing e r tap p in g  tests) are also 
be ing evaluated as candidate screening too ls. However, to  date, the  go ld  standard 
to  assess m o to r fu n c tio n  in PD still is the  Unified Parkinson Disease Rating Scale 
(UPDRS) pa rt III (i.e. the  m o to r part), and m ost recently its revised version 
(MDS-UPDRS).14 However, th is  c lin im e tric  approach is no t a suitable m ethod  to 
d e tec t subtle  m o to r dys func tion  because o f several im p o rta n t disadvantages. For 
exam ple, the  UPDRS is qu ite  tim e-consum ing , the  scoring is subjective, and it lacks 
sensitiv ity, especially in the  early clinical stages. New reliable, ob jective  and sensitive 
m ethods are the re fo re  needed fo r th is purpose.
Outline of this dissertation
This thesis describes the  results o f several studies w h ich  are all related to  the  early 
stages o f PD, ranging from  the ve ry  early preclin ica l period to  the  firs t years after 
m o to r sym ptom  onset (bu t p rio r to  the  in itia tio n  o f dopam ine rg ic  m edica tion). Both 
m o to r and no n -m o to r aspects o f the  disease are addressed. The com m on them e 
th ro u g h o u t th is thesis w ill be the  search fo r a deeper understand ing o f the  p a th o ­
physio log ica l mechanisms underly ing  the  early stages o f PD.
Various m ethods were used to  ga ther the  data needed in th is search. M oto r 
fu n c tio n in g  was assessed w ith  a tim ed  m o to r test b a tte ry  w h ich  was com pared to  
the  UPDRS-III. To be able to  re liab ly  register subtle d ifferences in m o to r fun c tion ing  
be tw een and w ith in  patien ts in a lo ng itud ina l manner, the  t im ed  m o to r test ba tte ry  
needed to  be va lida ted firs t. This explains the  pos ition  o f one "techn ica l" chapter 
(chapter 3.1) am idst the  m ore re flective them es o f the  rem ain ing chapters.
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In C h a p te r 2, we exam ine the  issue o f gender d ifferences in PD. C onflic ting  evidence 
exists on the  incidence o f PD in men versus w om en, and on the  possible role fo r 
estrogens as neuropro tec tive  agents p reven ting  the  deve lopm en t o f PD. We 
exam ined w h e the r 253 consecutive men and w om en w ith  PD d iffe red w ith  respect 
to  th e ir age at m o to r sym ptom  onset, typ e  o f m o to r sym ptom s, disease course until 
the  in itia tio n  o f dopam ine rg ic  m ed ica tion , and w h e the r the  estrogen status o f the 
w om en could be related to  the ir clinical p resenta tion . All pa tien ts were assessed 
w ith  the  UDPRS-III (i.e. m o to r section) every 3 to  6 m onths, and the w om en 
com ple ted a questionnaire  w ith  respect to  the ir life tim e  estrogen status (age o f 
menarche and m enopause, num ber o f ch ildren, etc). F ifty -n ine  patien ts underw en t 
[123I] FP-CIT SPECT scanning to  relate n igrostria ta l dopam ine  to  gender effects.
C h a p te r 3 describes a tim ed  m o to r test (TMT) ba tte ry  tha t can qu a n tify  the 
fo llo w in g  aspects: (a) w a lk ing , (b) w ritin g , (c) single and doub le -handed pegboard 
perfo rm ance, (d) fing e r tap p in g , and (e) rapid a lte rna ting  forearm  m ovem ents. 
C h a p te r 3.1 com pares the  TMT ba tte ry  to  the  c lin ical go ld  standard to  assess m oto r 
fu n c tio n  in PD (UPDRS-III). For th is purpose, the  TMT ba tte ry  was va lida ted on a 
sam ple o f 288 patients. In C h a p te r 3 .2 , the  TMT battery, and pa rticu la rly  one o f the 
test com ponents  (the pegboard d e x te rity  test), is fu rth e r exam ined fo r its a b ility  to 
de tec t subtle m o to r dys func tion  in early PD patients, as com pared to  healthy 
subjects. To challenge the  test to  its lim its, it was app lied  on the  c lin ica lly  still 
unaffected body  side o f PD patien ts w ith  a s tr ic tly  un ila teral p resenta tion o f the ir 
disease.
In C h a p te r 4, using the  pegboard  de x te rity  test, we assessed forearm  m otor 
fu n c tio n  o f bo th  arms in 186 patien ts w ith  e ither righ t- or le ft-s ided sym ptom  
onset (C hap te r 4.1). Our aim was to  ve rify  w h e the r fu n c tiona l hem ispheric 
d ifferences w ou ld  be associated w ith  the  side o f sym ptom  onset. C h a p te r 4 .2  also 
deals w ith  asym m etry in hem ispheric fun c tio n , a lthough  from  a d iffe ren t 
perspective. Specifically, it describes the  d iagnostic  value o f asym m etric striatal D2 
receptor up regu la tion  in PD, as assessed w ith  IBZM and FP-CIT SPECT scans.
C h a p te r 5 is dedicated to  early no n -m o to r changes in PD, a im ing to  shed new ligh t 
on earlier reports  tha t m en tioned  an increased risk o f deve lop ing PD in peop le w ith  
a certain subset o f occupations. We tested the  hypothesis tha t the  increased risk of 
PD may be a re flec tion  o f an already chang ing dopam ine rg ic  state, w h ich  leads to  a
14
General in troduc tion  and ou tline  o f the  thesis
1
preference fo r specific jo bs  tha t do no t require a fu lly  in tact dopam ine rg ic  system. 
How th is m ig h t relate to  a decreased risk o f PD fo r a rtis tic  professions w ill be 
discussed and substantia ted.
The find ings  and significance o f these various approaches to  the  early stages o f PD 
com e tog e the r in C h a p te r 6, in w h ich  a m ultid im ens iona l im age o f PD is sketched. 
This synthesis in tu rn  generates some im p o rta n t questions to  be addressed in 
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Chapter 2
Abstract
O bjective: To investigate gender differences in basic disease characteristics, m o to r 
de te rio ra tion  and n igrostria ta l degenera tion  in Parkinson's disease (PD).
Methods: We stud ied 253 consecutive PD patien ts w ho  were no t receiving levodopa 
or dopam ine  agonists (disease du ra tion  <10 years). We investigated the  in fluence of 
gender and estrogen status on: (1) age at onset, (2) presenting sym ptom , (3) severity 
and progression o f m o to r sym ptom s (UPDRS-III scores) and (4) am oun t and 
progression o f n ig rostria ta l degenera tion  ([123I] FP-CIT SPECT scans).
Results: Age at onset was 2.1 years later in w om en (53.4 years) than in men (51.3 
years). In w om en, age at onset corre lated pos itive ly  w ith  parity, age at menopause 
and fe rtile  life span. W om en presented w ith  trem or m ore o ften  (67%) than men 
(48%). Overall, pa tien ts presenting w ith  trem or had a 3.6 year h igher age at onset 
and a 38% slower UPDRS-III de te rio ra tion . Mean UPDRS-III scores at disease onset 
were equal fo r bo th  genders, as was the  rate o f de te rio ra tion . W om en had a 16% 
higher striatal [123I] FP-CIT b ind ing  than men at sym ptom  onset and th ro u g h o u t the 
course o f PD.
Conclusions: Our results suggest tha t, in w om en, the  deve lopm en t o f sym ptom atic  
PD may be delayed by h igher physio log ica l striata l dopam ine levels, possib ly due to 
the  a c tiv ity  o f estrogens. This could expla in the  ep idem io log ica l observations o f a 
low er incidence and h igher age at onset in w om en. W om en also presented w ith  
tre m o r m ore often , w h ich  in tu rn  is associated w ith  m ilder m o to r de te rio ra tion  and 
striatal degenera tion . Taken toge ther, these find ings  suggest a m ore benign 
pheno type  in w om en w ith  PD.
Abbreviations: PD, Parkinson's disease; SPECT, single ph o ton  emission com puted 
tom og raphy ; UPDRS-III, Unified Parkinson's Disease Rating Scale III; sUPDRS-III, 
selection o f item s o f the  UPDRS-III
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Introduction
There are several ind ica tions o f gender d ifferences in Parkinson's disease (PD). Epi­
dem io log ica l studies have shown tha t bo th  incidence and prevalence o f PD are 1.5 
to  2 tim es h igher in men than in w om en.1-6 Furtherm ore, in 6 o u t o f 8 incidence 
studies m en tion ing  gender specified age at onset, onset in w om en was s ligh tly  later 
than in men (by a mean o f 2.2 years (range 1-4)).7 A fte r progression in to  the  clinical 
phase o f the  disease, w om en had be tte r Unified Parkinson's Disease Rating Scale 
(UPDRS) m o to r scores8 bu t a greater prevalence o f dyskinesias8,9 com pared w ith  
men (at a disease du ra tion  o f m ore than five years). Furtherm ore, men reported  
several parkinsonian sym ptom s m ore fre q u e n tly  than w om en w hen asked at a 
disease du ra tion  o f n ine years.10 G ender differences in the  earlier stage o f PD, before 
in itia tio n  o f dopam ine agonists or levodopa, have no t been investigated.
The reported gender d ifferences -b o th  before and a fte r sym ptom  onset - could be 
related to  d iffe re n t levels o f c ircu la ting  estrogens in men and w om en. Several 
f ind ings  ind ica te tha t estrogens may play a role in PD. In animal m odels o f PD, 
estrogens had a neuropro tective  e ffect w hen adm in istered prio r to  or co inc id ing  
w ith  a tox ic  insult.11-13 Secondly, the  dopam ine rg ic  neurons in the  substantia nigra 
and the  striatal dopam ine  con ten t were m ore vu lne rab le  to  chem ical lesion ing at 
d i-estrus (low  estrogen) than at pro-estrus (h igh estrogen).14 However, the  possibly 
beneficial effects o f estrogens suggested by these reports  could no t be confirm ed 
in humans. Specifically, postm enopausal estrogen use in w om en was associated 
w ith  bo th  higher, low er and equal risks o f PD.15-17 Furtherm ore, tria ls of 
postm enopausal estrogen supp lem en ta tion , w h ich  started a fte r sym ptom  onset, 
d id  no t a ffect parkinsonian sym ptom s.18, 19 However, w om en w ho  had undergone 
ova riec tom y or hysterectom y had an increased risk o f PD.20, 21 Thus the  precise 
nature and ex te n t o f gender d ifferences and the  role o f estrogens in PD remain 
unclear.
Here we investigated w h e the r and how  gender affects bo th  the  preclin ica l and 
clinical disease stages, reflected by (1) the  age o f PD onset, (2) the  presenting 
sym ptom , (3) the  severity and progression o f m o to r sym ptom s assessed w ith  UPDRS 
derived variab les and (4) the  am oun t and progression o f n ig rostria ta l degenera tion 






The s tudy po pu la tio n  was selected from  a prospective ly  co llected and lo ng itud ina lly  
observed coh o rt o f all consecutive PD patien ts w ho, be tw een 1988 and 2003, visited 
the  m ovem ent d isorders o u tp a tie n t clin ic o f the  Radboud University N ijm egen 
M edical Centre (fig. 1). As soon as the  UK PD Society Brain Bank crite ria22 became 
genera lly applied , pa tien ts were re-evaluated to  ensure a correct clinical diagnosis 
o f PD according to  these criteria. Patients were no t included in the  long itud ina l 
database in cases of: (a) dem entia, (b) physical d isab ilities resulting from  any o ther 
disease w h ich  could in te rfe re  w ith  the  ra ting o f PD severity, (c) m o to r fluc tu a tion s  at 
the  firs t v is it and (d) non-PD m ed ica tion  tha t could in te rfe re  w ith  extrapyram idal 
m o to r fu n c tio n . Patients were assessed by the  same neuro log is t (MH) w h o  was also 
the  trea ting  physician. In th is study, we on ly  included data ob ta ined  du ring  the  firs t 
ten years a fte r sym ptom  onset and before in itia tio n  o f levodopa or dopam ine 
agonists in order to  com pare the  natural course o f PD betw een men and wom en. 
This y ie lded  a to ta l o f 253 e lig ib le  patien ts (62% men; tab le  1). A m in o rity  o f the 
patien ts (<25%) used seleg iline, am antad ine or o rphenadrine, anti-PD drugs w ith  a 
ve ry  m odest e ffect on m o to r fun c tio n . Ne ither the  percentage o f men and w om en 
using these drugs nor the  doses o f these drugs d iffe red be tw een the sexes.
Ethics
Patients were assessed w ith  the  UPDRS-III as pa rt o f a standard care program . [123I] 
FP-CIT SPECT was carried o u t fo r  rou tine  d iagnostic  procedures or as pa rt o f scientific 
research program s at our depa rtm ent. In the  la tte r case, in fo rm ed consent was 
ob ta ined , as approved by the  local eth ics com m ittee .
Age at onset and presenting symptom
Age at onset and presenting sym ptom s were retrieved from  the  pa tien t's  history, 
taken du ring  the  firs t v is it. Age at onset was de term ined as the  age at w h ich  the  
pa tien t had firs t no ticed any parkinsonian m o to r sym ptom s.
Motor examination
A to ta l o f 253 patien ts (156 men, 97 w om en) were lo n g itu d in a lly  assessed using a 
selection o f 7 item s o f the  UPDRS pa rt III (sU PDRS-111: speech, facial expression, 
tre m o r at rest r ig h t/le ft ,  r ig id ity  r ig h t/le ft ,  rapid a lte rna ting  hand m ovem ents r ig h t/
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Fig. 1 Data co llection .
Each patien t unde rw en t D opam ine Transporter Single Photon Emission C om puted Tom ography 
(SPECT) scanning. The arrow  indicates th a t the  disease dura tion  at the  m om ent o f  scanning varied 
among patients, ranging from 0.7 to 9.9 years. UPDRS-III: Unified Parkinson's Disease Rating Scale III.
2
le ft, posture and body bradykinesia), y ie ld ing  10 variables tha t were recorded every 
3-6 m onths du ring  the  course o f the  disease (834 observations, range 1-20 per 
patient). This selection o f UPDRS item s results from  the  fact tha t we o rig ina lly  used 
the  W ebster Scale before the  UPDRS becam e genera lly accepted.
SPECT imaging
A pprox im ate ly  th ree hours a fte r in travenous in jec tion  o f 200 MBq [123I] FP-CIT 
(DaTSCAN; Am ersham  Health, E indhoven, the  Netherlands), SPECT was pe rfo rm ed 
w ith  a M ultiS pect 2 dual headed gam m a camera, connected to  an ICON com puter 
(Siemens, Hoffm an Estates, Illinois, USA). The d ig ita l images (128x128 m atrix, 64 
angles) were reconstructed using a B u tte rw orth  f ilte r (0.6 Nyquist, o rder 7) and 
reorien ted in the  canthus-m eatus plane. The th ree consecutive slices w ith  the 
highest striatal uptake (total thickness 14.6 mm) were selected fo r quan tita tive  
analysis. Fixed size regions o f in terest (derived from  an anatom ical brain atlas) were 
b ila te ra lly  drawn over the  caudate nucleus, pu tam en and the  occip ita l cortex (the 
la tte r serving as the  reference region). Ratios o f the  [123I] FP-CIT uptake in the  caudate 
nucleus and occipital cortex and in the  putam en and occipital cortex were calculated 
and norm alized to  data derived from  m easurem ents o f A lderson's phantom .
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O nly patien ts w ith o u t in te rfe ring  drugs unde rw en t [123I] FP-CIT SPECT im aging. Each 
pa tien t unde rw en t a single SPECT scan. Disease du ra tion  at the  m om ent o f scanning 
varied am ong patients, ranging from  0.7 to  9.9 years (indicated by the  arrow  in fig. 
1). This y ie lded  59 SPECT scan results. N ineteen add itiona l SPECT scans were 
ob ta ined  from  the  G roningen University Medical Centre, as well as 32 SPECT scans 
from  the  Academ ic M edical Centre, Am sterdam , all m eeting  the  study's inclusion 
criteria.
Estrogen status
In 2004, all w om en w ho  had undergone UPDRS testing  were asked to  com p le te  a 
questionna ire  w ith  respect to  the ir estrogen status th ro u g h o u t th e ir lives. The 
estrogen status inc luded the  age at menarche, age at m enopause, pa rity  and use 
o f postm enopausal estrogen rep lacem ent therapy. This y ie lded 77 com ple ted 
questionnaires.
Data analysis
All analyses were pe rfo rm ed by a professional s tatistic ian (GFB). Mean age at onset 
was com pared betw een men and w om en using the  S tudent's t-test. Incidence of 
presenting sym ptom s (trem or versus b radyk ines ia /rig id ity ) was analyzed using 
log istic  regression w ith  the  covariates gender and age at onset. SPECT results were 
log transfo rm ed and analyzed using linear regression analysis w ith  the  covariates 
gender, age at onset, presenting sym ptom , disease du ra tion  and hospita l w here  the 
scan was pe rfo rm ed . The loga rithm ic  transfo rm a tion  made it possible to  ad just for 
scale differences be tw een the  hospita ls by inc lud ing  the  add itiona l covariate 
''hosp ita l''. It also rem oved the skewness in the  data and allow ed d irec t estim ation 
o f the  relative changes (percentage change). The graph was used to  in d ire c tly  in fer 
in itia l tracer uptake fo r the  groups, tog e the r w ith  the  rate o f de te rio ra tion . The 
sUPDRS-III score was calculated as the  mean o f the  scores on the  ind iv idua l m oto r 
items. If the  scores fo r  m ore than tw o  item s were m issing, the  overall score was not 
calculated. As m ost pa tien ts had been tested on m u ltip le  occasions, a random  
effects regression m odel was used w ith  the  levels pa tien t and test. The independent 
variab les inc luded in the  analysis were gender, age at onset, presenting sym ptom  
and disease du ra tion . Linear regression was used to  analyze the  e ffect o f age at 
menarche, age at menopause, du ra tion  o f the  fe rtile  life span and pa rity  at age at 
onset, presenting sym ptom , sUPDRS-III and SPECT m easurem ents. The g roup  of 
w om en w ho  had taken estrogen rep lacem ent the rapy was to o  small to  use in the
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Table 1 Subject characteristics.
Men Women p value
Age at disease onset (years) 51.3 (25-77) 53.4 (28-74) 0.06
Age at time of first sUPDRS-III (years) 53.4 (28-79) 54 (31-75) n.s.
Age at time of SPECT (years) 52.8 (35-72) 54.2 (31-68) n.s.
Disease duration at time of first sUPDRS-III (years) 2.5 (0.4-9.9) 2.7 (0.2-10.0) n.s.
Disease duration at time of SPECT (years) 4.3 (0.7-9.9) 4.3 (1.6-8.5) n.s.
Number of subjects in age at onset and symptom 
analysis
156 97
Number of subjects in sUPDRS-III analysis 156 97
Number of subjects in SPECT analysis 74 36
Proportion (%) of patients taking: Selegiline 25.2 24.2 n.s.
Amantadine 26.6 22.1 n.s.
Orphenadrine 7.2 9.3 n.s.
SPECT: single p ho ton  em ission com puted  tom ography; sUPDRS-III: se lection o f item s o f the  Unified 
Parkinson's Disease Rating Scale part III (m otor part). Values are mean (range) unless o therw ise stated.
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statistical analyses. C oncerning all research questions, we used exp lo ra to ry  analyses 
fo r in te ractions be tw een the  various independen t variables and appropria te 
quadra tic  term s were included in each m odel in order to  investigate non-linear 
trends. In the  fina l analyses, all main effects were kept in the  m odels; in teractions 
and h igher o rder term s were on ly  inc luded w hen they  were sta tis tica lly  sign ificant 
(p<0.05; tw o-s ided). The level o f statistical significance o f in te ractions w ith  gender
- the  main sub ject o f in terest - was set at p<0.10 in o rder no t to  miss relevant 
differences w ith  respect to  gender due to  a low er sens itiv ity  o f in te raction  tests. 





At sym ptom  onset, wom en were 2.1 (95% CI -0.1 to  4.1) years o lder than men (women, 
mean 53.4 years; men, mean 51.3 years; p=0.06).
Presenting symptom
W om en presented s ign ifican tly  m ore o ften  (67%) w ith  trem or at sym ptom  onset 
than men (48%), irrespective o f age at onset (p=0.001) (fig. 2A). The in fluence o f age 
at onset on trem or incidence (2% increase in trem or presenta tion fo r each add itiona l 
year) d id  no t d iffe r be tw een the  sexes. W hen presenting w ith  tre m o r as opposed to  
bradyk ines ia /rig id ity , age at onset was 3.6 years later fo r bo th  sexes (95% CI 1.5 to  
5.7; p=0.001) (fig. 2B).
Fig. 2 Presenting sym ptom . (A) W om en presented m ore o ften  w ith  trem or 
(84/125 = 67%) than men, across all age groups (107/221 = 48%).
(B) W hen presenting w ith  tre m o r as opposed to  b radyk inesia-rig id ity , 
age at onset was 3.6 years later fo r bo th  sexes.
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sUPDRS-III
Mean sUPDRS-III scores d id  no t d iffe r be tw een men and w om en w ith  PD, at onset or 
du ring  disease progression (p=0.55) (fig. 3). For bo th  sexes, the  scores increased by 
0.09 po in ts /yea r (95% CI 0.08 to  0.10; p<0.0001). Interestingly, trem or dom inan t 
patien ts showed a 38% slower increase in sUPDRS-III scores (i.e. slower deterio ra tion ) 
than bradyk ine tic -rig id  pa tien ts (p<0.0001) (fig. 3).
Fig. 3 Trem or do m inan t versus no n -trem o r dom inan t patients. Data shown 
fo r pa tien ts w ith  age at onset o f 50 years. W ith  increasing age at onset, 
the  mean in itia l sUPDRS (selection o f item s o f the  Unified Parkinson's 
Disease Rating Scale III) increases w ithou t changing the rate o f deterioration. 
The regression lines show  the estim ated increase in mean sUPDRS-III 
scores for patients presenting w ith  or w ithou t tremor. Patients presenting 
w ith  trem or showed a 38% low er rate o f de te rio ra tion  (angle p=  0.08 
po in ts/year) than patien ts presenting w ith  b ra dyk ines ia /rig id ity  (angle 




W om en had 16% higher [123I] FP-CIT b ind ing  than men at sym ptom  onset (95% CI 3.0 
to  32%; p=0.01; fig . 4). However, the  rate o f decline in tracer b ind ing  (3.1%/year) did 
no t d iffe r be tw een the  sexes. Trem or dom inan t pa tien ts tended to  have a low er rate 
o f decline than b radyk ine tic -rig id  patients, a lthough  th is e ffec t d id no t reach 
significance (8.7%; p=0.1). The fac t tha t the  SPECT sam ple was no t fu lly  identica l to 
the  sUPDRS-III sam ple d id no t a ffect these find ings; the  same results were ob ta ined 
w hen analyzing on ly  those patien ts w ith  bo th  SPECT and sUPDRS-III assessments.
Fig. 4 Mean striata l [123I] FP-CIT b ind ing . The lines show  the estim ated decrease 
in mean tracer b ind ing  fo r men and w om en w ith  age at onset o f 50 
years. A h igher age at onset was accom panied by low er in itia l striatal 
tracer b ind ing  in bo th  men and w om en. W om en had 16% h igher [123I] 
FP-CIT b ind ing  than men. The p lo tte d  observed values are those o f all 
pa tien ts in the  study, irrespective o f age at onset.
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Estrogen status
Several estrogen status item s were associated w ith  age at onset. Parity correlated 
pos itive ly  w ith  age at onset: the  m ore ch ildren a w om an had before PD onset, the 
h igher the  age at onset (2.7 years later onset per child; 95% CI 0.8 to  4.6; p=0.007) 
(fig. 5A), the  on ly  exception be ing w om en w ith o u t ch ildren. These w om en may have 
a d iffe ren t basal estrogen status than w om en w ith  ch ildren. Furtherm ore, in wom en 
w ith  an early PD onset, the  choice to  have (fewer) ch ildren m ig h t be in fluenced by 
the  burden o f PD, the reby  possib ly inverting  the  re la tionship be tw een age at onset 
and parity. To con tro l fo r this, we repeated the  analyses fo r the  subgroup o f w om en 
w ith  ch ildren (n=67) and fo r the  subgroup o f w om en w ith  an age at onset >40 years 
(n=67) and fou nd  the  same results.
C om bin ing bo th  selection criteria (n=58) d id  no t change these results. Age at 
m enopause corre lated w ith  the  age at onset w hen tak ing  those w om en w ith  
sym ptom  onset a fte r m enopause (0.5 years la ter onset per year; 95% CI 0.1 to  0.8; 
p=0.009). In these w om en, the  du ra tion  o f the  fe rtile  life span was associated w ith  a 
0.5 year la ter onset per year (95% CI 0.2 to  0.9; p=0.001) (fig. 5B). W ith o u t the 
selection based on the  order o f m enopause and sym ptom  onset, the  corre la tion  of 
age at m enopause (p=0.02) and o f du ra tion  o f the  fe rtile  life span (p=0.05) w ith  age 
at onset rem ained sign ificant. Age at menarche did no t corre late w ith  age at onset 
(p=0.2). No association was found  fo r any o f the  estrogen status item s w ith  




Several find ings  in th is s tudy suggested a m ore benign PD pheno type  in w om en 
com pared w ith  men. The benefits fo r w om en seemed to  app ly  m ain ly  to  the  events 
preceding ove rt PD. Firstly, w om en tended to  be o lde r than men at sym ptom  onset. 
Secondly, w om en presented m ore o ften  than men w ith  a trem or do m in an t fo rm  o f 
PD, w h ich  in tu rn  was associated w ith  a slower disease progression. Third ly, at onset 
o f the  disease, w om en had h igher levels o f striata l dopam ine  b ind ing  than men. 
These benefits in the  preclin ica l phase could be related to  estrogen status, because 
pa rity  (num ber o f children), age at m enopause and du ra tion  o f the  fe rtile  life span 
were all associated w ith  a later age at onset o f PD. However, w om en seemed to  have 
no fu rth e r advantage over m en once PD had becom e c lin ica lly  m anifest. Thus the 
rates o f disease progression, as indexed by bo th  clin ical scores and m easurem ents 
o f striata l dopam ine  b ind ing , were com parable be tw een men and w om en w ith  
ove rt sym ptom s. In the  next paragraphs, we discuss these find ings  in m ore detail.
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Gender differences preceding clinical PD
The tw o  year d ifference in age at PD onset be tw een men and w om en observed here 
is com parable w ith  the  d ifference fou nd  in m ost ep idem io log ica l studies.7 It 
suggests th a t the  deve lopm en t o f sym ptom atic  PD is s ligh tly  delayed in w om en 
com pared w ith  men. This could be exp la ined by h igher in itia l striatal dopam ine 
levels in w om en com pared w ith  men, as noted in th is study. Those h igher in itia l 
dopam ine  levels could delay the  m om en t o f reaching a critica l th resho ld  o f striatal 
dopam ine depletion and hence postpone the developm ent o f parkinsonian symptoms. 
Several observations sup po rt th is exp lanation. In our study, at sym ptom  onset and 
th ro u g h o u t the  course o f the  disease, w om en had 16% h igher striatal [123I] FP-CIT 
b ind ing  than men. This suggests th a t the  critica l th resho ld  o f dopam ine dep le tion  
at w h ich  sym ptom s em erge is 16% h igher in w om en than in men. However, w om en 
becom e sym ptom atic  tw o  years later than men. This could be exp la ined by a sim ilar 
re lative loss o f dopam ine required fo r sym ptom  onset in men and w om en, b u t a 
h igher in itia l dopam ine  con ten t in w om en. Furtherm ore, healthy w om en have 
h igher striatal dopam ine  transporte r b ind ing  than healthy m en.23-25 The gender 
d iffe rence in striatal dopam ine  transporte r b ind ing  noted in our s tudy thus appears 
to  be physio log ica l and no t specifica lly PD related. This is supported  by the  fac t tha t 
healthy w om en have a low er postsynap tic  dopam ine  D2 receptor a ffin ity  than 
healthy m en,26 p robab ly  re flec ting  D2 receptor do w n regu la tion  induced by high 
presynaptic striata l dopam ine levels. Anim al experim ents con firm  a physio log ica l 
gender d ifference: in bo th  healthy rats and MPTP lesioned mice, the  density  of 
dopam ine  transporters and striatal dopam ine concentra tions were h igher in 
fem ales than in males.27-29 Secondly, in animal studies, expression o f striatal 
dopam ine  transporters appeared to  be de te rm ined  by estrogen2830 and closely 
paralle led the  level o f striatal dopam ine .31 Consequently, a s itua tion  in w h ich 
in tracerebral estrogen levels increase (e.g., pregnancy) w ill lead to  up regu la tion  of 
s triatal dopam ine  transporters, in tu rn  resu lting in h igher striatal dopam ine  levels. 
A ltho ug h  ex trapo la ting  animal data to  humans requires caution, our data w ou ld  
f i t  in to  th is concept. We found  th a t pa rity  - the  result o f pregnancy, a s itua tion  of 
h igh c ircu la ting  estrogen levels - corre lated pos itive ly  w ith  age at onset, a fa c t not 
reported  previously. However, a re la tionship betw een pa rity  and PD irrespective of 
age at onset has been reported  previously: w om en w ith  PD had reduced parity  
com pared w ith  healthy w om en .32 M oreover, m edical cond itions leading to  estrogen 
d e p le tion  (e.g., hysterectom y, o o ph orec to m y or sho rt fe rtile  life span) increased the 
risk o f PD20, 21 33 w h ile  a reduced risk was fou nd  fo r postm enopausal estrogen use,
31
Chapter 2
w h ich  increases cum ula tive  estrogen levels.16,17 Our s tudy showed th a t a later 
m enopause and a longer fe rtile  life span - also increasing cum ula tive  estrogen 
levels - delayed the  age at onset. This has no t been reported previously.
Gender differences in overt PD
The rate o f decline in SPECT b ind ing  did  no t d iffe r be tw een the sexes. M ost o ther 
studies show  rates o f decline s im ilar to  ours, a lthough  no t specified fo r  gender.34-37 
The results suggest th a t once the  critica l th resho ld  o f striatal dopam ine dep le tion  
has been exceeded, disease progression does no t d iffe r be tw een men and wom en. 
In o the r words, estrogens may exert some fo rm  o f ne u rop ro tec tion  in the  preclin ical 
stage o f PD, or may even postpone the be g inn ing  o f the  degenera tive process, bu t 
fa il once sym ptom s have becom e clin ica lly  apparent. This idea is supported  by 
anim al w ork: estrogens may p ro tec t against n igrostria ta l degenera tion  in animal 
m odels o f PD w hen adm in istered prio r to  the  insu lt11-13 b u t do no t exert any 
beneficia l effects w hen adm in istered afte r n igrostria ta l dam age has occurred.12, 13 
This may help to  understand the fa ilu re  o f estrogen rep lacem ent the rapy in slow ing 
the  progression o f ove rt PD in w om en. Thus a doub le  b lind , placebo con tro lled 
s tudy o f h igh dose transderm al 17b-estradio l in postm enopausal w om en w ith  PD 
showed no e ffect on m o to r scores.19 Furtherm ore, a p lacebo-con tro lled , random ized, 
doub le  b lind  tria l in postm enopausal w om en w ith  PD fou nd  no s ign ifican t e ffec t of 
o ra lly  adm in istered estrad io l on ob jective  and sub jective parkinsonian sym ptom s.18 
An add itiona l exp lanation could be th a t bo th  ora lly  and transderm a lly  adm in istered 
estrogens do no t lead to  h igh enough estrogen concentra tions w ith in  the 
b lood -b ra in  barrier to  exert any e ffec t at all.
W hile denom ina ting  a variab le (i.e., estrogen) as a possible e tio log ica l fac to r in a 
disease process, one should take in to  account th a t th is variab le m ig h t coexist w ith  
or in fluence another, perhaps unknow n, fac to r w h ich  is actua lly  responsible fo r  the 
observed effect. For exam ple, a long fe rtile  life span may have increased the  risk of 
iron de fic iency because o f iron loss du ring  menses and pregnancies. Iron, in turn, 
has been im p lica ted as an im p o rta n t fac to r in the  ox idative processes w ith in  the 
nig rostria ta l system a lthough  its precise role remains unclear. Consequently, we 
cannot exclude the  fac t th a t the  iron status o f the  w om en in our s tudy could have 
con tribu te d  to  the  find ings  w h ich  we associated w ith  estrogens. Trem or dom inan t 
patients, bo th  men and w om en, were 3.6 years o lde r at sym ptom  onset than 
patien ts presenting w ith  the  hypok ine tic -rig id  sub type o f PD. The trem or dom inan t 
pa tien t g roup  also showed a 38% slower increase (i.e., s lower de terio ra tion ) in
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sUPDRS-III scores, a fin d in g  consistent w ith  previous suggestions o f a m ore benign 
course fo r th is PD sub type.37-40 A dd itiona lly , [123I] FP-CIT b ind ing  tended to  decrease 
less fast in the  trem or do m in an t patients. Together w ith  a la ter onset and a more 
fre q u e n t onset w ith  trem or in w om en, these find ings  suggest th a t w om en are more 
like ly than men to  acquire the  ben ign trem or do m in an t PD subtype.
Methodological issues
This s tudy was no t w ith o u t drawbacks. Firstly, our d e pa rtm e n t is a dedicated referral 
centre fo r  pa tien ts w ith  m ovem ent disorders, and th is  may have affected the  basic 
characteristics o f our s tudy popu la tion . It w ou ld  seem unlikely, however, tha t 
referral bias con founded our questions regard ing the  in fluence o f gender on PD. 
The percentage o f men and w om en w ith  PD in our popu la tion  was sim ilar to 
po pu la tio n  based num bers. A no ther issue could be th a t referrals from  a greater 
d istance to  our c lin ic could have represented d iffe re n t (m ore com plica ted) PD 
patien ts than the ones from  nearby. However, we com pared the  pa tien t character­
istics from  those referred w ith in  the  area o f N ijm egen w ith  those com ing from  other 
geograph ica l regions and did  no t find  any s ign ificant differences. Furtherm ore, we 
analyzed the  SPECT results ob ta ined  from  the  three d iffe ren t hospita ls located in 
th ree  d is tan t regions o f the  Netherlands separately, before poo ling  them . We found 
the  same results fo r bo th  separate and com bined analyses. Therefore, we feel tha t 
the  m ost im p o rta n t referral biases have been excluded. Moreover, the  m agnitude 
o f th is PD coh o rt enabled us to  select many patien ts w ith  a disease du ra tion  o f up to 
10 years b u t w ith o u t exposure to  levodopa or dopam ine agonists. This created the 
o p p o rtu n ity  to  s tudy the  unm edicated, natural course o f PD.
Secondly, estrogen status was ascertained retrospective ly, w h ich  could have 
in troduced  recall bias. However, the  m ost im p o rta n t estrogen status item , parity, is 
un like ly  to  be sub ject to  recall bias. Finally, the  estrogen status analyses were based 
on a lim ited  sample size. Therefore, e x trapo la ting  our find ings  to  all w om en w ith  PD 
requires caution . Nevertheless, our s tudy may in itia te  im p o rta n t fu tu re  research 
in to  the  hypotheses and exp lanations we suggested.
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Abstract
Background: The m ost w ide ly  used scale curren tly  available fo r  the  clinical 
eva luation o f m o to r dys func tion  in Parkinson's disease (PD) - the  Unified Parkinson's 
Disease Rating Scale-III (UPDRS-III) - is tim e-consum ing , subjective, and has 
subop tim a l sensitiv ity. A b rie f tim ed  m o to r test (TMT) b a tte ry  could possib ly 
overcom e these drawbacks.
M ethods: Two hundred e ig h ty -e ig h t PD patien ts (disease du ra tion  3.1 years; 
p reced ing dopam ine rg ic  trea tm e n t in itia tion ) were assessed w ith  the  UPDRS-III and 
nine TMTs based on aspects o f (a) w a lk ing , (b) w ritin g , (c) single and doub le-handed 
pegboard  perform ance, (d) fing e r tap p in g , and (e) rapid a lte rna ting  forearm  
m ovem ents. We investigated va lid ity , re liab ility , responsiveness, and feasib ility . 
Results: C om ple ting  the  TMT ba tte ry  to o k  less than five m inutes. The TMT corre lated 
w e ll w ith  UPDRS-III and disease du ra tion . Two factors exp la ined 61% o f the  TMT 
variance, the  firs t represented m ain ly  upper ex tre m ity  fun c tio n , the  second m ainly 
axial and low er ex tre m ity  fun c tio n . Cronbach's a was equal fo r  the  TMT and the 
UPDRS-III (0.8). Test-retest re liab ility  o f the  TMT sumscore was 0.93 to  0.89 fo r 
m easurem ents separated by 3 up to  24 m onths, whereas UPDRS-III corre lations 
were 0.88 to  0.84.
W hen app ly ing  the  TMT ba tte ry  in a tria l using ''change from  baseline '' as endpo in t 
w ou ld  require on ly  75% o f the  patien ts needed w ith  the  UPDRS-III, and 57% using 
the  pegboard d e x te rity  test. A t pa tien t level, TMT and UPDRS-III were equally 
responsive.
Conclusions: The TMT ba tte ry  described here is va lid , reliable, and feasible. 
Com pared to  the  UPDRS-III, it is m ore ob jec tive  and m ore sensitive to  change. 
Therefore, it could be a useful too l fo r  bo th  practical and scientific  purposes.
Key words: Parkinson's disease; UPDRS; tim ed  m oto r tests; m etric  a ttribu tes; rating 
scales
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Introduction
In Parkinson's disease (PD), c lin im e tric  m easurem ents are applied bo th  in scientific 
research and in da ily  clinical practice. Examples include the  de tec tion  o f signs and 
sym ptom s in the  earliest stages o f the  disease, m on ito rin g  disease progression in 
ove rt PD, and the  eva luation o f in te rven tions. The Unified Parkinson's Disease 
Rating Scale (UPDRS) is the  m ost w ide ly  evaluated and re liab le c lin im e tric  scale 
curren tly  available in PD. However, it is re la tive ly  tim econsum ing1 and contains 
redundan t item s.2 O ther shortcom ings o f the  present version o f the  UPDRS include 
flo o r effects, am biguous w o rd in g  o f instructions, and some m etric  flaws.3-5 To 
overcom e these drawbacks, abbreviated versions o f the  UPDRS have been 
proposed,26,7 and a revised UPDRS is cu rren tly  be ing deve loped .8 
A general p rob lem  to  clinical ra ting scales remains th e ir sem i-quan tita tive  and 
sub jective scoring system, w h ich  may cause insuffic ien t sensitiv ity, especially in 
pa tien ts w ith  re la tive ly  m ild  dysfunction . Q uantita tive  m o to r tests have been 
created to  resolve these issues. Several continuous, qu an tita tive  -and consequently 
m ore ob jective  - tests have been proposed (see e.g., Refs. 9-24). O nly few  o f these 
tests have been investigated fo r the ir m etric  p roperties .25 Moreover, m ost o f them  
are still t im e  consum ing, expensive, or com plica ted. This may expla in w hy they are 
no t w ide ly  used in clinical practice or in scientific  trials. Here, we evaluate a ba tte ry  
o f nine sim ple, inexpensive tim ed  m o to r tests (TMTs) fo r th e ir a b ility  to  m on ito r 
m o to r dys func tion  in early PD patients. We exam ined construct va lid ity , internal 
consistency, test-re test re liab ility  over serial assessments, responsiveness to 
changes before and a fte r in itia tio n  o f levodopa or a dopam ine  agonist, and 
feasib ility .
Patients and m ethods
Patients
The s tudy po pu la tio n  was selected from  a prospective ly  co llected and lo ng itud ina lly  
observed coh ort o f all consecutive PD patien ts w ho, be tw een 1988 and 2003, visited 
the  M ovem ent D isorders O u tpa tien t Clinic o f the  Radboud University N ijm egen 
M edical Centre. All pa tien ts had a clin ical diagnosis o f PD according to  the  U.K. PD 
Society Brain Bank criteria .26 Patients were no t inc luded in the  lo ng itud ina l database 
in case o f (a) cogn itive  dysfunction , de fined as the  in a b ility  to  understand the  TMT
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afte r tw o  practice trials, (b) severe physical d isab ilities resu lting from  any o ther 
disease th a t could in te rfe re  w ith  m o to r tes ting , (c) m o to r fluc tua tions  at firs t visit, 
(d) in a b ility  to  v is it the  de pa rtm e n t at least tw ice  a year, and (e) non-Parkinson 
m ed ica tion  th a t could in te rfe re  w ith  extrapyram idal m o to r fu n c tio n . In th is study, 
we on ly  included data ob ta ined  du ring  the  firs t ten years afte r sym ptom  onset and 
before in itia tio n  o f levodopa or dopam ine agonists to  prevent drug induced 
in terfe rence w ith  the  pure parkinsonian m o to r dysfunction . An exception was made 
fo r  the  dopa-respons iv ity  analysis in w h ich  we used add itiona l data from  the firs t 
assessment a fte r in itia tio n  o f dopam ine rg ic  m ed ica tion . A m in o rity  (<20%) of 
pa tien ts used anti-Parkinson drugs w ith  a m odest e ffect on m o to r fun c tio n  
(selegiline, am antadine, or o rphenadrine) and were the re fo re  no t excluded. This 
y ie lded  a to ta l o f 288 e lig ib le  patien ts and 958 assessments (table 1).
Table 1
Subject characteristics
Number of patients 288 (63% men)
Age at onset (years) median 51.3 (range 25.0 -  76.2)
Age (years) median 54.0 (range 30.9 -  79.3)
Disease duration (years) median 2.7 (range 0.4 -  9.9)
Total number of assessments3 958 (68% in men)
Number of follow-up assessments per patient median 6 (range 1-22)
Individual sUPDRS-III sumscore median 11.0 (range 1.5 -  22)b
a an assessment consisted o f bo th  TMT and sUPDRS-III measurements.
b sUDPRS-III scores ranged from  0 to  3 per item , the  score '4' (i.e. m ost severe) was n o t reached in this 
pa tie n t popu la tion .
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Motor Assessments
All m o to r assessments to o k  place every 3 to  6 m onths du ring  the  course o f the 
disease and were pe rfo rm ed by a single neuro log is t (MH).
Timed M otor Tests
All tests are described in de ta il in tab le  2 and displayed in fig . 1. Briefly, e igh t TMTs 
based on (a) w a lk ing , (b) w ritin g  a sentence, (c) single and doub le -handed pegboard 
perform ance, (d) fing e r tap p in g , and (e) rapid a lte rna ting  forearm  m ovem ents, 
y ie lded  fifte e n  variables. We chose sim ple, brief, and noncom pute rized  m o to r tests, 
large ly related to  UPDRS-III items, and w ith  an unam biguous scoring system tha t 
could be applied by re la tive ly  un tra ined personnel. Except fo r  the  item s ''w a lk ing '' 
and ''w r it in g  a sentence'', pe rfo rm ance o f the  r ig h t and le ft side was assessed 
separately. Speech could no t be evaluated in a com parable m anner due to  the  lack 
o f a sim ple, noncom puterized test. Before the  eva luation , pa tien ts received fu lly  
standard ized verbal ins truc tions and were fam ilia rized w ith  the  tasks du ring  tw o  
practice tria ls be fore eva luation to  avoid learn ing and tra in in g  effects du ring  the 
eva luation . The tim e  needed to  com p le te  the  entire  TMT ba tte ry  was less than five 
m inutes.
UPDRS-III
We used a selection o f Unified Parkinson's Disease Rating Scale-III (UPDRS-III) items 
as previously
described27 (speech, facial expression, trem or at rest r/l, r ig id ity  r/l, rapid a lte rna ting  
hand m ovem ents r/l, arm sw ing r/l, posture, and body bradykinesia). This selection 
results from  the  fac t th a t we o rig in a lly  used the  W ebster Scale before the  UPDRS 
becam e genera lly accepted. The W ebster scale has shown good  corre la tion  (>0.8) 
w ith  the  UPDRS-III in all Hoehn and Yahr stages.28
[123I] FP-CIT SPECT Imaging
T h irty -n ine  patien ts unde rw en t [123I] FP-CIT SPECT im aging w ith in  a few  days o f a 
m o to r assessment.27
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Table 2 Description o f the  TMT battery.
Item category Item (abbreviation) Test description
W alking’ WalkTime 1. Time (sec) needed to walk the final 11 of 15 
meters
WalkStrides 2. Number o f strides needed to walk the final 
11 of 15 meters
Writing-’ WriteTime 3. Time (sec) needed to write a standard 
sentenceb on blank paper using the dominant 
hand
WriteSpace 4. Horizontal space (cm) needed to perform the 
writing task
Pegboard-’
- Dexterity Dexterity_R 5. Time (sec) needed to turn eight round 
wooden pegs upside down using the right 
hand, from one hole into the next
Dexterity_L 6. Same, using the left hand
- Double-handed Peg2Hands 7. Time (sec) needed to interchange two 4-peg 
rows, 15 cm apart, twice, using both hands 
simultaneously0
- Single-handed Pegl Hand_R 8. Time (sec) needed to displace eight round 
wooden pegs using the right hand
Pegl Hand_L 9. Same, using the left hand
Finger tapping9
- On one key Tap1Key_R 10. Number o f hits on one keyboard key during 
5 seconds using the index finger of the right 
hand
Tap1Key_L 11. Same, using the index finger o f the left hand
- On two keys Tap2Keys_R 12. Sum o f hits on two adjacent keyboard keys 
during 10 seconds using the index finger of 
the right hand, alternating between the two 
keys
Tap2Keys_L 13. Same, using the index finger of the left hand
Diadochokinesisad Diadochokin_R 14. Number of table hits, alternating the palm 
and the back o f the hand, during 5 seconds 
using the right arm
Diadochokin_L 15. Same, using the left arm
a W alking and w rit in g  were perfo rm ed at norm al pace. Pegboard, finge r ta p p in g  and d iadochok ine - 
sis had to  be perfo rm ed as fast as possible. b "H e t is m ooi weer vandaag" (in English: "The w eather is 
nice today"). c Patients were instructed  to  cross th e ir forearm s, then  s im ultaneously  p ick up tw o  
w ooden  pegs oppos ite  to  each o the r a t the  le f t and r ig h t side o f the  pegboard , and place them  in 
th e ir oppos ite  holes. This was repeated fo r each row. d Rapid a lte rna ting  fo rearm  m ovem ents.
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Fig. 1 Pegboard d e x te rity  test, pegboard doub le -handed test and finge r 
tap p in g  test.
3
Ethics
Patients were assessed w ith  the  sUPDRS-III and TMT as pa rt o f a standard care 
program . [123I] FP-CIT SPECT was carried o u t fo r rou tine  d iagnostic  procedures or as 
pa rt o f scientific  research program s at our depa rtm ent. In the  la tte r case, in fo rm ed 
consent was ob ta ined , as approved by the  local e th ical com m ittee .
Data Analysis
Preparatory Calculations
As some TMT item  scores increase w ith  increasing severity o f PD w h ile  others 
decrease, we firs t ad justed them  in to  one d irec tion  such th a t h igher scores 
consistently ind ica ted worse perform ance fo r all variables. Mean scores were 
calculated fo r the  sUPDRS-III as w e ll as the  TMT scores th a t had been ob ta ined  for 
bo th  hands separately to  avoid in te rfe ring  effects o f righ t- or le fthandedness and o f 
the  m ost a ffected side. To com pare the  m etric  p roperties o f the  TMT ba tte ry  w ith  
the  sUPDRS-III, a TMT sumscore was created by add ing the  standard ized scores of 
the  ind iv idua l TMT items. First, a Z- trans fo rm a tion  was applied to  each subscore (for 
each subscore, the  mean o f all scores was subtracted from  the  score, and the  result 
was d iv ided  by the  standard devia tion). Then all subscores were added, w h ich 
resulted in sumscores ranging from  -11 to  +33. We preferred to  rescale them  fo r easy 
clin ical in te rp re ta tion  in to  positive scores, rough ly  ranging from  0 to  100, by adding 
15 to  the  sumscores and by m u ltip ly in g  the  result by 2. Thus, the  m in im um  score 





There are several m ethods to  choose the  main factors o f a fac to r analysis. We 
reta ined on ly  factors w ith  eigenvalues greater than one, as p robab ly  used m ost 
o ften  by many researchers. Because fac to r analysis requires independent 
observations, a random  sample o f one test m om ent per pa tien t was drawn. This 
resulted in 204 test m om ents w ith  com ple te  TMT and sUPDRSIII data. Next, an 
exp lo ra to ry  fac to r analysis was pe rfo rm ed w ith  the  extraction  m ethod  ''P rincipal 
C om ponent Analysis" w ith  ro ta tion  m ethod  ''Varim ax w ith  Kaiser N orm a liza tion" as 
pa rt o f SPSS rou tine  calculations. The values shown present the  ro ta ted so lu tion.
Correlation o f TMT w ith sUPDRS-III, SPECT and Disease Duration  
Pearson's corre la tion  coeffic ien ts were calculated betw een the  TMT sumscore on 
the  one hand, and the  sUPDRS-III sumscore, [123I] FP-CIT SPECT im aging results, and 
disease du ra tion  on the  o the r hand.
Reliability
Internal Consistency
Internal consistency o f the  TMT b a tte ry  and the  sUPDRS-III was evaluated th rough  
Cronbach's a-coeffic ients fo r m u lti- item  scales. Cronbach's a indicates how  well a 
set o f item s measures a single un id im ensional la tent construct.
Test-Retest Reliability
To estim ate the  test-re test re liab ility  o f the  TMT and sUPDRS-III, we calculated the 
corre la tions be tw een fo llo w -u p  assessments w ith in  each pa tien t. As the  corre la tion 
be tw een tw o  assessments may depend on the  interassessment in terval length, 
separate calcula tions were pe rfo rm ed fo r assessments w ith  in terva l lengths o f 3 
m onths, 4 to  6 m onths, 7 to  12 m onths, and 13 to  24 m onths. The corre lations 
measure w h e the r a pa tien t w ho, fo r exam ple, scored re la tive ly  h igh at one 
assessment (com pared to  the  mean score o f all patients) also scored re la tive ly  high 
at the  o ther assessments (com pared to  the  possib ly d iffe ren t mean score o f all 
pa tien ts at tha t assessment). Therefore, they are unaffected by the  general trend 
th a t pa tien ts showed de te rio ra tion  due to  increasing disease duration.
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Responsiveness
To com pare the  responsiveness (i.e., sens itiv ity  to  change) o f the  TMT and sUPDRS-III 
to  dopam ine rg ic  trea tm e n t (levodopa or a dopam ine agonist), we added the  firs t 
assessment pe rfo rm ed at 3 m onths afte r in itia tio n  o f these drugs to  the  database. 
We evaluated the  sens itiv ity  to  change at g roup  level and at pa tien t level.
Sensitivity a t Group Level
The sens itiv ity  to  change o f a test at g roup level g reatly  influences the  choice o f the 
e n d p o in t in a clinical tria l. A tria l based on a test w ith  a h igher sens itiv ity  requires 
few er patien ts fo r the  same power. The num ber o f pa tien ts required fo r a tria l w ith  
a certain pow er is inversely p ro po rtiona l to  the  square o f the  standard ized e ffect or 
standard ized change from  baseline. We the re fo re  calculated the  standardized 
change from  baseline and the  num ber o f pa tien ts required fo r  a tria l, choosing 
e ither the  TMT or the  sUPDRS-III sumscore as p rim ary  endpo in t.
Sensitivity a t Patient Level
We created tw o  pa tien t groups: (1) pa tien ts w h o  had started dopam inerg ic  
trea tm e n t du ring  the  preceding th ree  m onths consequently expected to  show a 
s ign ifican t change in m o to r scores and (2) pa tien ts w ho  had no t ye t started 
dopam ine rg ic  trea tm e n t expected to  have unrem arkable changes in m o to r scores 
du ring  the  preced ing three m onths. A h igher sens itiv ity  o f a test at pa tien t level was 
de fined as a greater a b ility  to  d is tingu ish  be tw een patien ts from  the tw o  groups. 
For th is  purpose, the  area under the  receiver opera ting  characteristic (ROC) curve 
(AUC) was calculated. ROC curves
are graphical p lo ts  o f the  sens itiv ity  (or true  positive rate: TPR) versus one m inus 
spec ific ity  (false positive rate: FPR) o f a test choosing vary ing d iscrim ination  
thresholds. In the  present parad igm , the  p lo t analyzes how  accurate TMT 
d iscrim inates be tw een the  m o to r status o f a pa tien t before and a fte r s tart o f 
dopam ine rg ic  therapy, th a t is, before and afte r a likely im p rovem en t in th e ir m oto r 
status. Each p o in t on the  ROC curve corresponds to  a certa in d iscrim ination  
th resho ld  and shows the  TPR and FPR if th a t th resho ld  was chosen as a crite rion  fo r 
im provem ent. The accuracy o f the  TMT is represented by the  area under the 
resu lting ROC curve. An area o f 1 represents a pe rfec t d is tinc tio n  (100% TPR and 0% 
FPR), and an area o f 0.5 represents no d iscrim inative properties o f the  test. In 
add ition , we calculated the  corre la tion  betw een the  pre and posttrea tm en t 
assessments. Finally, we used log is tic  regression to  exp lore w he the r one TMT or a
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com b ina tion  o f TMTs could have op tim a l sens itiv ity  at pa tien t level. To investigate 
w h e the r a TMT sumscore based on few er subscores w ou ld  lead to  approxim ate ly  
the  same sens itiv ity  and specific ity, we used log is tic  regression w ith  the  subscores 
as independen t variables. Based on fo rw a rd  and backward variab le  selection 
m ethods, we looked fo r sum scores tha t were based on as few  subscores as possible. 
Forward and backward m ethods were used, because the  fo rm er tends to  select 
m ore subscores com pared to  the  latter. In a sense, the  m ethods correspond w ith  a 




Two factors exp la ined 61% o f the  variance (table 3). The firs t fac to r (representing 
m ain ly  upper ex tre m ity  fun c tion ) exp la ined 47% o f the  variance, the  second 
(representing m ain ly  axial and low er ex tre m ity  m o to r fun c tio n ) exp la ined the 
add itiona l 14%.
Table 3 Factor analysis o f the  TMT battery.
Factor 1 Factor 2
Eigenvalue* 5.21 1.59
Percentage o f variance explained 47 14
Dexterity_mean r/l 0.84 -0.04
Peg2Hands 0.86 0.11
Peg1Hand_mean r/l 0.87 0.24
Tap2Keys_mean r/l 0.62 0.60
Diadochokin_mean r/l 0.62 0.53
WalkTime 0.36 0.70
WalkStrides 0.23 0.82
Tap1Key_mean r/l 0.57 0.57
WriteTime 0.39 0.16
WriteSpace 0.29 -0.51
* Only factors with eigenvalue >1 are shown.
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Correlation o f TMT w ith sUPDRS-III, [123I] FP-CIT SPECT, and disease duration  
The TMT sumscore corre lated well w ith  the  sUPDRS-III sumscore (fig. 2A). It d id  not 
corre late w ith  the  [123I] FP-CIT SPECT im aging results bu t corre lated sign ificantly  
w ith  disease du ra tion  (fig. 2B). Given the  considerable in te rind iv idua l variance, 
using the  mean p robab ly  b lurred the  re la tionship betw een the  TMT sumscore and 
[123I] FP-CIT SPECT b ind ing . To exp lore th is, we calculated the  corre la tion  between, 
on the  one hand, the  d ifference in r ig h t and le ft-s ided TMT z-sumscores w ith in  each 
pa tien t and the d ifference in in te rstria ta l [123I] FP-CIT SPECT b ind ing , on the  other 
hand. Using these pure (paired) differences, the  varia tion  in our data set resulting 
from  unequal base levels o f ind iv idua l subjects could be excluded. The difference 
scores from  the lateralized TMT z-sumscores w ith in  each pa tien t and the  in terstriata l 
[123I] FP-CIT SPECT d iffe rence scores (transform ed in to  z-scores) correlated 
s ign ifican tly  (r = 0.7; P < 0.0001; fig . 2C). The sUPDRS-III sumscore corre lated w ith  




Cronbach's a was 0.82 fo r the  TMT items, com pared to  0.79 fo r the  sUPDRS-III. 
Test-Retest Reliability
The corre la tions betw een TMT sumscores at consecutive assessments were 0.93 fo r 
interassessment intervals o f 3 m onths, 0.84 fo r 4 to  6 m onths, 0.89 fo r 7 to  12 
m onths, and 0.89 fo r 13 to  24 m onths. sUPDRS-III corre lations were 0.88 (3 months), 
0.89 (4 -6  months), 0.82 (7-12 m onths), and 0.84 (13-24 months).
Responsiveness
Sensitivity a t Group Level
The standard ized change from  baseline was 0.95 in case o f the  TMT versus 0.82 fo r 
the  sUPDRS-III. Consequently, a tria l using change from  baseline as en dp o in t w ou ld  
require on ly  (0.82/0.95)2 = 75% o f the  patien ts needed w ith  the  sUPDRS-III. A 
com parable d ifference in pa tien t num bers was found  w hen analysis o f covariance 
w ith  baseline scores as covariate was used.
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Fig. 2  A: Correla tion be tw een TMT sumscore and sUPDRS-III sumscore. n = 192; 
r = 0.76; P < 0.0001. B: C orre la tion be tw een TMT sumscore and disease 
du ra tion . n = 195; r = 0.B2; P < 0.0001. C: C orre la tion be tw een paired 
d ifferences o f le ft and rig h t TMT z-scores and le ft and rig h t striata l [12BI] 
FP-CIT- SPECT b ind ing  (z-scores). n = B4; r = 0.7; P < 0.0001.
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Sensitivity a t Patient Level
The corre la tions be tw een the  scores before and a fte r trea tm e n t in itia tio n  were 0.85 
fo r the  TMT sumscore and 0.55 fo r the  sUPDRS-III. The AUC fo r m ed ica tion  versus 
change in score was 0.80 fo r  bo th  the  TMT and the  sUPDRS-III sumscores. Logistic 
regression m ode ling  showed th a t o f all ind iv idua l and com binated TMT items, the 
pegboard  d e x te rity  test was the  m ost sensitive. On its own, it was as good as the 
to ta l sumscore, w ith  an AUC o f 0.90, and a corre la tion  be tw een m easurem ents 
before and afte r trea tm e n t in itia tio n  o f 0.95.
The Pegboard Dexterity Test Further Explored
We considered the  d e x te rity  test w o rth  exp lo ring  in to  de tail. Using the  change in 
d e x te rity  test score as p rim ary  ou tcom e in a tria l th a t evaluates dopam inerg ic  
trea tm e n t w ou ld  require as litt le  as (0.82/1.09)2 = 57% o f the  patien ts needed w ith  
the  sUPDRS-III. We also exam ined the  d e x te rity  test in re la tionship to  the  sUPDRS-III, 
[123I] FP-CIT SPECT, and disease du ra tion . It corre lated w ith  the  sUPDRS-III sumscore 
(fig. 3A), disease du ra tion  (fig. 3B), and [123I] FP-CITSPECT b ind ing  (fig. 3C). The te s t- 
retest re liab ility  exceeded the  results o f the  TMT sumscore, reaching corre lations of 




Fig. 3 A: Correlation between Dexterity score and sUPDRS-III sumscore. n = 192; 
r = 0.66; P < 0.0001. B: Corre la tion betw een D exte rity  score and disease 
du ra tion . n = 195; r 5 0 3 0 ; P < 0.0001. C: Corre la tion betw een D exte rity  
score and striata l [12BI]FP-CIT SPECT b ind ing  (mean L/R). n = B9; r = 0.47; 
P < 0.0001.
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Discussion
O ur results show th a t the  TMT battery, representing a con tinuous quan tita tive  
scoring system, is a valid and reliable ins trum en t to  measure m o to r dysfunction  in 
PD. W hile h igh ly  corre lated to  the  sUPDRS-III, it  is m ore ob jective  and m ore sensitive 
to  change. A ltho ug h  no t exp lic itly  investigated here, the  fast and s im ple design of 
the  TMT ba tte ry  - no t requ iring  extensive tra in in g  or the  experience o f a m ovem ent 
d isorders specia list - cou ld o ffe r an add itiona l advantage. Interestingly, o f all 
ind iv idua l TMT items, the  pegboard de x te rity  test surpassed the  qualities o f the 
en tire  TMT ba tte ry  as an ins trum en t to  m on ito r dopam ine rg ic  m o to r dysfunction  
and dopam ine rg ic  trea tm e n t effects in PD. The com b ina tion  o f these characteristics 
suggests th a t the  TMT batte ry, b u t perhaps even m ore so the  pegboard  de x te rity  
test as a single test, could be useful fo r  bo th  practical and scientific  purposes. In the 
next paragraphs, we w ill discuss th is in m ore detail.
Validity
The TMT b a tte ry  was m ain ly  de term ined by tw o  factors, one representing upper 
e x tre m ity  fu n c tio n  and the o ther axial plus low er ex tre m ity  fu n c tio n . The fac to r 
structure , we found , resembles those in studies o f the  UPDRS-III in PD.29-33 The TMT 
correlates w ell w ith  sUPDRS-III sumscores (fig. 2A) and w ith  the  du ra tion  o f PD (fig. 
2B). However, the  TMT sumscore visually showed a trend  tow ard  corre la tion  w ith  
SPECT b ind ing  bu t d id  no t reach significance, whereas the  sUPDRS-III sumscore had 
a s ign ifican t corre la tion  o f 0.4 w ith  [123I] FPCIT SPECT b ind ing . This la tte r fin d in g  is in 
line w ith  a corre la tion  o f approx im ate ly  0.5 be tw een the  UPDRS-III and FPCIT as well 
as beta-CIT SPECT im aging reported  by others.34-38 The considerable in te rind iv idua l 
variance in our s tudy p robab ly  b lurred the  re la tionship be tw een the TMT sumscore 
and [123I] FP-CIT SPECT b ind ing . We con firm ed th is by show ing a sign ificant 
corre la tion  fo r all the  lateralized TMT item s (fig. 2C), thus sup po rting  our explanation. 
Interestingly, the  mean o f le ft and rig h t pegboard de x te rity  test scores corre lated 
w e ll w ith  the  mean o f le ft and r ig h t [123I] FP-CIT SPECT b ind ing  values (fig. 3C). This 
m ig h t be exp la ined by a s tronger dopam ine rg ic  dependence o f the  pegboard 
d e x te rity  test. Indeed, th is  TMT had the  h ighest responsiveness to  dopam inerg ic  
m ed ica tion . A som ew hat s im ilar TMT described by others, the  Purdue pegboard 
test,39 also corre lated well w ith  the  n igrostria ta l de fic it in p d .20,40-43 Furtherm ore, in a 
previous s tudy in PD, ind iv idua l fing e r m ovem ents appeared to  be m ore im paired 
than gross hand m ovem ents.44 Our pegboard  de x te rity  test measures these fine
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fing e r m ovem ents, possib ly exp la in ing  its sensitiv ity. M oreover, a coin ro ta tion  task 
- requ iring  precise and coo rd inated independen t fing e r m ovem ents very  s im ilarly 
to  our d e x te rity  test - proved im paired in PD patien ts on dopam ine rg ic  m edica tion 
com pared to  contro ls, whereas fing e r tap p in g  did no t d iffe r be tw een these groups.45 
D epend ing on the  focus o f a fu tu re  study, the  pegboard de x te rity  test could be 
chosen fo r its dopam ine rg ic  features, the  TMT sumscore to  re flect the  overall m oto r 
status o f the  patien t.
Reliability
We found  the in terna l consistency o f the  TMT to  be equal to  the  sUPDRS-III 
(Cronbach's a fo r bo th  0.8) and to  a previous s tudy o f the  UPDRS-III.30 H igh internal 
consistency makes a test appropria te  fo r ind iv idua l com parisons. The next test 
qu a lity  investigated - re liab ility  o f serial assessments - is pa rticu la rly  im p o rta n t in 
m ovem ent d isorders and applies equa lly to  ra ting scales and test ba tte ries.46 The 
TMT ba tte ry  had a s ligh tly  h igher te s t-re te s t re liab ility  than the  sUPDRS-III. The 
retest corre la tion  is no t on ly  im p o rta n t because it shows th a t the  scores at a certain 
tim e  p o in t can also to  some ex te n t p re d ic t later scores, b u t it is also im p o rta n t when 
clin ical tria ls are p lanned. M aking use o f the  retest corre la tion  leads to  substantia lly  
sm aller tria ls.47 The pegboard  de x te rity  test rough ly  equaled the  TMT ba tte ry  fo r 
th is  quality . For the  UPDRS-III, the  Parkinson Study Group reported  a sim ilar 
test-re test re liab ility  o f 0.90.48 A ltho ug h  no t fo rm a lly  investigated here, the 
con tinuous and instrum enta l nature o f the  m o to r m easurem ents in the  TMT ba tte ry  
like ly results in a m ore ob jective  ra ting system w ith  a h igher in te rra te r re liab ility .49-54
Responsiveness
The a b ility  o f a test to  de tec t changes over t im e  is required to  ensure the  usefulness 
in the  lo ng itud ina l eva luation o f PD.5 A t g roup  level, th is responsiveness was higher 
fo r  the  TMT than the  sUPDRS-III, resu lting in a required pa tien t num ber o f on ly  75% 
com pared to  the  sUDPRS-III, needed to  de tec t a s ign ificant ''change from  baseline." 
A t pa tien t level, the  TMT sumscore had a much h igher corre la tion  than the  sUPDRS-III 
be tw een scores before and afte r dopam ine rg ic  trea tm e n t in itia tio n . The ratio 
sens itiv ity /spec ific ity  (or TPR/FPR) is im p o rtan t, because it indicates to  w ha t extent 
the  test can correctly  de tect changes in the  m o to r status o f the  pa tien t. An AUC of 
0.80 shows th a t the  sens itiv ity /spec ific ity  ra tio  was qu ite  good. Remarkably, the 
pegboard  d e x te rity  test reached a h igher corre la tion  be tw een pre and posttrea tm en t 
scores, a h igher AUC and a much h igher standard ized change, requ iring  even less
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patien ts (57% o f the  sUDPRS-III) fo r  a tria l than the  com p le te  TMT battery. Few 
studies investigated responsiveness o f m o to r scales, w ith o u t unequivocal 
conclusions.55-57 The UPDRS and the Short Parkinson's Evaluation Scale (SPES) were 
com pared afte r much shorte r assessment in tervals than those in our study, which 
makes a com parison to  our results im possib le. Both UPDRS and SPES showed a 
sim ilar a b ility  in de tec ting  trea tm e n t effects over tim e. A no the r s tudy evaluated the 
corre la tion  be tw een the  UPDRS on one hand, and a fing e r tap p in g  task and 
steady-state w a lk ing  on the  o ther hand57 and did no t find  a d iffe rence in pre and 
post-trea tm en t scores in e ither tim ed  test. However, they  fou nd  th a t ga it cadence 
was the  least dopa-responsive ga it variab le  and suggested th a t one could miss 
some im p o rta n t clinical changes w hen using on ly  the  UPDRS-III w ith o u t tim ed  gait 
eva luation . Indeed, many investigators believe th a t ga it reflects a un ique "d o m a in " 
o f PD th a t can be separated from  append icu lar m o to r signs.58 Our TMT ba tte ry  
contains tw o  ga it item s (walk ing tim e  and num ber o f strides), bo th  litt le  dopa-re- 
sponsive (data no t shown). Therefore, com p lem enting  the  pegboard de x te rity  test 
w ith  a ga it item  could ensure the  representation o f d is tinc t PD dom ains. From a 
clinical p o in t o f view, th is com b ina tion  w ou ld  o ffe r a feasib le and com prehensive 
ou tcom e measure representing bo th  axial, upper, and low er ex tre m ity  fun c tion .
Feasibility
A fte r tw o  practice tria ls, the  com ple te  TMT ba tte ry  to o k  on ly  abou t five m inutes to 
com ple te , w h ich  makes it feasib le fo r  app lica tion  in da ily  clinical practice. 
Furtherm ore, in our experience, the  TMT ba tte ry  does no t require extensive tra in ing  
or the  expertise o f a m ovem ent disorders specialist, w h ich  makes it accessible to  a 
w ide  range o f m edical personnel and obvia tes the  need fo r v id eo  recordings. In 
contrast, in studies using the  UPDRS to  assess m ild ly  im paired PD patients, 
v ideo-based tra in in g  proved especially im p o rta n t.59
Methodological Issues
The sUPDRS-III d id  no t conta in  a trem or score fo r  the  legs. However, poo led data of 
several studies using the  UPDRS-III revealed th a t in less than 4% o f PD patients, the 
trem or score o f the  legs was h igher than th a t o f the  arms, and on ly  2% exclusively 
had a trem or in the  legs.7 Therefore, a trem or score fo r the  legs p robab ly  does not 
add s ign ificant in fo rm a tion  to  the  issues addressed in our study.
The lo ng itud ina l database had some missing data. However, com parison o f the 
basic data coh o rt w ith  the  available data used in th is  s tudy revealed ve ry  sim ilar
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characteristics. Therefore, we fee l th a t the re  is no bias o f im portance due to  data 
selection. Finally, we should note tha t we created the  TMT sumscore preced ing the 
exp lo ra tion  o f the  data, the reby eva luating its perfo rm ance p rospective ly  on data 
th a t were independen t o f its construction . The pegboard  de x te rity  test, however, 
was exp lored a fte r eva luation o f the  data and evaluated on those same data, 
possib ly leading to  an overestim ation  o f its perform ance. A dd itiona l studies are 
required to  investigate in te rra ter re liab ility  and to  extend the  use o f the  TMTs to 
m ed ica tion  and surgical in te rven tion  trials.
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Chapter 3.2
Abstract
Background: Early diagnosis o f Parkinson's disease (PD) is im p o rta n t as pu ta tive  
neurop ro tec tive  therapies shoud idea lly  be in itia ted  in the  earliest stage o f the  
disease. We investigated w he the r a previously  va lida ted tim ed  m o to r test (TMT) 
b a tte ry  could de tect subtle  m o to r dys func tion  in early stage PD and even in 
c lin ica lly  unaffected lim bs o f s tric tly  hem iparkinson ian patients.
Methods: We assessed 107 PD patien ts (sym ptom  du ra tion  <2 years; dopa-naive) 
and 100 healthy, age-m atched contro ls w ith  e igh t sim ple TMTs based on aspects of 
(a) w a lk ing , (b) w ritin g , (c) single and doub le -handed pegboard  perform ance, (d) 
fing e r tap p in g , and (e) d iadochokinesis. We evaluated the  a b ility  o f ind iv idua l and 
com bined TMTs to  d iscrim inate patien ts from  contro ls using ROC curves. Second, 
we investigated w h e the r these TMTs could id e n tify  m o to r dys func tion  o f the 
c lin ica lly  unaffected lim b in 42 s tric tly  hem iparkinson ian patients.
Results: The pegboard  de x te rity  test had the  best ROC curve (AUC 0.97; 95% 
sensitiv ity, 89% specific ity) fo r  pa tien ts versus contro ls. It reta ined reasonable 
accuracy w hen testing  the  c lin ica lly  unaffected lim b o f hem iparkinson ian patients 
versus the  mean o f r ig h t and le ft-hand scores in contro ls (AUC 0.73).
Conclusions: The pegboard d e x te rity  test is a sensitive and inexpensive ins trum ent 
to  de tec t m o to r dys func tion  in early PD. Therefore, it may be w o rth  eva luating as a 
d iagnostic  too l in everyday clinical practice to  assess patien ts w ith  early sym ptom atic  
PD, or as pa rt o f a m ore e laborate screening ba tte ry  in a de fined po pu la tion  at risk.
Key words: Parkinson's disease; tim ed  m o to r tests; early diagnosis; hem ipark inso­
nian; preclin ical
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Introduction
The diagnosis o f Parkinson's disease (PD) is based on the  UK PD Society Brain Bank 
criteria w h ich  focus on ove rt m o to r signs.1 R ecognition o f these m o to r signs in an 
early stage o f the  disease can be d ifficu lt, even fo r experienced m ovem ent d isorder 
specialists. The presence o f aspecific m o to r signs, m im ick ing  o rtho pe d ic  or 
rheum ato log ic  disease, may fu rth e r delay the  correct diagnosis and trea tm e n t,2,3 
w h ich  in tu rn  can lead to  unnecessary d isab ility  and w ork  absenteeism. Prom pt 
recogn ition  o f PD is no t on ly  im p o rta n t in the  early clinical se tting  b u t also may be 
even m ore critica l fo r pu ta tive  neuropro tective  or d isease-m odulating therap ies4 
aim ed at the  earliest stage o f neurodegenera tion , w h ich  may w ell s ta rt years before 
c lin ica lly  recogn izab le m o to r sym ptom s em erge.2,5-9 Therefore, various features of 
PD have been exp lored as early disease markers in bo th  humans and animals.10-14 
Since biom arkers th a t re flect the  onset o f PD pa tho log y  are no t ye t available,10 a 
m arker o f the  earliest fun c tiona l changes in preclin ica l PD patien ts may be the  next 
best screening too l. An e legant way to  test fo r  subtle  m o to r dys func tion  w ou ld  be 
to  exam ine the  c lin ica lly  still unaffected lim b o f hem iparkinson ian patients, a 
pa tien t g roup  in w hom  SPECT and PET im aging studies have revealed a reduced 
signal o f the  contra la teral s tria tum  in the  absence o f clinical sym ptom s.15-17 In this 
"m o d e l"  fo r  preclin ica l PD, a m o to r test m ore sensitive than the pure clinical 
ju d g e m e n t w ou ld  berequired. To fac ilita te  large scale app lica tion , such a test should 
also be inexpensive, easily applicab le and ob jective . Recently, we assessed the 
m etric  qualities o f a sim ple, inexpensive tim ed m o to r test (TMT) b a tte ry  fo r 
lo ng itud ina l assessment o f PD patients.18 The TMT ba tte ry  showed good  re liab ility , 
feasib ility , and v a lid ity  (a.o. it corre lated w ell w ith  the  Unified Parkinson's Disease 
Rating Scale m o to r score, UPDRS-III). A clear advantage o f the  TMTs over the 
UPDRS-III was th e ir o b je c tiv ity  and h igher sens itiv ity  to  change. In th is study, we 
investigated w h e the r th is TMT ba tte ry  can be used in an early d iagnostic  se tting , to 
d is tingu ish  m o to r fu n c tio n  o f PD patien ts w ith in  tw o  years afte r sym ptom  onset 
from  healthy contro ls. We also exp lored w h e the r the  TMTs could de tect m oto r 






The s tudy popu la tion  was selected from  a previously described lo ng itud ina lly  
observed coh o rt o f consecutive patien ts w ith  PD w ho  vis ited the  M ovem ent 
Disorders o u tp a tie n t c lin ic o f the  Radboud University N ijm egen M edical Centre 
be tw een 1988 and 2004.19 All pa tien ts had a clinical diagnosis o f PD according to  the 
UK PD Society Brain Bank criteria.1 As we were in terested in patien ts representing 
the  earliest clinical stage o f PD, we focused on data ob ta ined  at the  firs t m easurem ent 
w ith in  the  firs t tw o  years a fte r sym ptom  onset and before in itia tio n  o f levodopa or 
a dopam ine  agonist, y ie ld ing  107 e lig ib le  patients. Hundred healthy, age-m atched 
subjects (pa tien ts ' spouses and co-workers o f the  departm ent) were recru ited as 
contro ls  at the  tim e  o f the  pa tien t assessments. All assessments were pa rt o f the 
standard PD pa tien t care program . All healthy subjects gave the ir in fo rm ed consent, 
as approved by the  local eth ics com m ittee .
Motor Assessments
All subjects were assessed by a single neuro log is t (MH) w ith  e igh t TMTs derived 
from  (a) w a lk ing , (b) w ritin g  a sentence, (c) single and doub le -handed pegboard 
perfo rm ance, (d) fing e r tap p in g , and (e) rapid a lte rna ting  forearm  m ovem ents, 
y ie ld ing  15 variables (see S upporting  In fo rm a tion  Table S-1). These TMTs are easily 
applicab le, inexpensive, large ly related to  UPDRS-III item s and have an unam biguous 
scoring system. The patien ts were also assessed w ith  the  sUPDRS-III, a selection of 
UPDRS-III item s (speech, facial expression, tre m o r at rest r/l, r ig id ity  r/l, rapid 
a lte rna ting  hand m ovem ents r/l, arm sw ing r/l, posture, and body bradykinesia). 
This se lection represents the  W ebster Scale, the  predecessor o f the  UPDRS-III, w hich 
has shown good  corre la tion  (>0.8) w ith  the  UPDRS-III20 as w ell as w ith  the  TMT 
ba tte ry  sumscore.18 The TMTs were consistently applied before the  clinical 
neuro log ica l assessment to  m axim ize ob je c tiv ity . TMT scores were stud ied in tw o  
parts. First, we investigated w h e the r the  TMT ba tte ry  could d is tingu ish  patients 
w ith  PD from  healthy contro ls (pa rt I). Second, we exp lo red w he the r the  TMTs could 
de tec t m o to r dys func tion  in the  c lin ica lly  still unaffected lim b in s tr ic tly  hem i­
parkinsonian patien ts com pared w ith  healthy contro ls  (part II). The sUPDRS-III 
scores were used exclusively to  classify lim bs o f PD patien ts as e ither c lin ica lly 
a ffected or c lin ica lly  unaffected.
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Table S-1 Description o f the  TMT battery.
Item category Item (abbreviation) Test description
W alking’ WalkTime 1. Time (sec) needed to walk the final 11 of 15 
meters
WalkStrides 2. Number of strides needed to walk the final 
11 of 15 meters
Writing-’ WriteTime 3. Time (sec) needed to write a standard 
sentenceb on blank paper using the dominant 
hand
WriteSpace 4. Horizontal space (cm) needed to perform the 
writing task
Pegboard’
- Dexterity Dexterity_R 5. Time (sec) needed to turn eight round 
wooden pegs upside down using the right 
hand, from one hole into the next
Dexterity_L 6. Same, using the left hand
- Double-handed Peg2Hands 7. Time (sec) needed to interchange two 4-peg 
rows, 15 cm apart, twice, using both hands 
simultaneously0
- Single-handed Peg1Hand_R 8. Time (sec) needed to displace eight round 
wooden pegs using the right hand
Peg1Hand_L 9. Same, using the left hand
Finger tapping’
- On one key Tapi Key_R 10. Number o f hits on one keyboard key during 
5 seconds using the index finger of the right 
hand
Tapi Key_L 11. Same, using the index finger of the left hand
- On two keys Tap2Keys_R 12. Sum o f hits on two adjacent keyboard keys 
during 10 seconds using the index finger of 
the right hand, alternating between the two 
keys
Tap2Keys_L 13. Same, using the index finger of the left hand
Diadochokinesisad Diadochokin_R 14. Number of table hits, alternating the palm 
and the back of the hand, during 5 seconds 
using the right arm
Diadochokin_L 15. Same, using the left arm
a W alking and w rit in g  were perfo rm ed  at norm al pace. Pegboard, fin ge r ta p p in g  and d iadochok ine - 
sis had to  be perfo rm ed  as fast as possible. b "H e t is m ooi weer vandaag" (in English: "The w eather is 
nice today"). c Patients were instructed  to  cross th e ir forearm s, then  s im ultaneously  p ick up tw o  
w ooden  pegs opposite  to  each o the r a t the  le ft and r ig h t side o f the  pegboard, and place them  in 





Table 1 TM T scores in  p a tie n ts  and  co n tro ls .
Description of TMT variable Abbreviation (measure) PD Controls P-value ROC (AUC)
Individual TMT item scores WalkTime (sec) 7.8 ± 1.35 7.5 ± 1.4 0.06 0.56
WalkStrides (no.) 15.7 ±2.0 15.2 ±1.9 0.03 0.53
WriteTime (sec) 12.4 ±4 .6 10.4 ±2.5 <0.0001 0.71
WriteSpace (cm) 8.1 ± 1.6 9.3 ± 1.3 <0.0001 0.73
Dexterity_R (sec) 13.2 ±5.8 8.8 ± 0.9 <0.0001 0.91
Dexterity_L (sec) 13.0 ±4 .6 9.2 ± 1.2 <0.0001 0.84
Peg2Hands (sec) 14.6 ±2 .6 12.7 ±3.3 <0.0001 0.87
Pegl Hand_R (sec) 16.2 ±3.2 14.4 ±2 .2 <0.0001 0.78
Pegl Hand_L (sec) 17.0 ±2.9 15.1 ±2.3 <0.0001 0.76
Tap1Key_R (no.) 28.8 ±8 .2 30.1 ±5.7 0.18 0.64
Tap1Key_L(no.) 25.9 ± 7.3 28.4 ±5.5 0.006 0.69
Tap2Keys_R (no.) 43.5 ± 9.9 47.2 ± 6.6 0.002 0.70
Tap2Keys_L (no.) 39.5 ±8.5 42.9 ± 6.2 0.002 0.65
Diadochokin_R (no.) 20.7 ±5.0 22.2 ±3.9 0.02 0.77
Diadochokin_L (no.) 19.8 ±5.2 21.4 ±3.9 0.01 0.75
TMT sumscore containing all 15 TMT items TMT_sum 34.6 ± 10.5 23.0 ± 7.7 <0.0001 0.82
Mean of right and left for bilateral TMT items Dext_mean (sec) 13.1 ±3 .8 9.0 ± 1.0 <0.0001 0.95
Peg_mean (sec) 16.6 ±2 .5 14.7 ±2.1 <0.0001 0.82
Tapi Key_mean (no.) 27.3 ± 6.4 29.3 ±5 .4 0.02 0.70
Tap2Keys_mean (no.) 41.5 ±7.8 45.0 ± 6.0 <0.0001 0.73
Diadochokin_mean (no.) 20.2 ±4.3 21.8 ±3 .8 0.006 0.79
Worst of R and L dexterity scores Dext_worst (sec) 15.6 ±6 .0 9.3 ± 1.1 <0.0001 0.97
Unilateral TMT sumscore, right side TMT_sum R 14.9 ±9 .6 6.8 ± 4.5 <0.0001 0.78
Unilateral TMT sumscore, le ft side TMT_sum L 17.2 ±8 .6 9.8 ± 4.9 <0.0001 0.77
Analysis part I. TMT scores in patients and controls for all individual TMT items as well as combinations o f items (mean ± SD, P-value, AUC). Patients scored worse 
than controls, except for the items WalkTime and Tap1Key_R. For explanation o f variables and abbreviations: see supplemental data, table S-1.
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Outcome Measures
Based on the  15 ind iv idua l TMT scores, the  fo llo w in g  com bined TMT scores were 
calculated: a TMT sumscore con ta in ing  all TMTs (described in a previous paper18), 
the  mean o f r ig h t and le ft-s ided scores o f the  b ilateral TMTs, and the  h igher (worse) 
o f the  r ig h t and le ft-s ided d e x te rity  scores. In add ition , a un ila teral TMT sumscore 
was calculated based on the  five  TMTs D exterity, S ingle-handed pegboard 
perform ance (Peg-1-Hand), F inger tap p in g  on one key (Tap1Key), F inger tapp ing  
a lte rna ting  be tw een tw o  keys (Tap2Keys), and Rapid a lte rna ting  forearm  m ovem ents 
(D iadochokin).
The item s W riteTim e and W riteSpace (tim e and space needed to  w rite  a standard 
sentence) were le ft ou t o f the  unilateral equa tion  as they were on ly  available fo r the 
d o m in an t hand. On the  basis o f the  results o f pa rt I, we investigated un ila teral righ t 
and le ft-s ided TMT sumscores and separate r ig h t and le ft-s ided pegboard de x te rity  
test scores in pa rt II. A poo led pegboard de x te rity  test variab le  was also created, 
con ta in ing  the  scores from  e ither the  r ig h t or le ft unaffected arm in patients, and 
the  mean o f rig h t and le ft-s ided scores in controls.
Statistical Analysis
Statistical analysis was carried ou t using SPSS version 16. Means o f ind iv idua l or 
com bined scores were com pared w ith  the  independen t samples f-test. Forward 
and backward regression analyses were app lied  to  exp lore w h e the r com binations 
o f TMTs rather than ind iv idua l TMTs im proved the d iscrim inative  ab ility . A level of 
P < 0.05 was considered sign ificant. Receiver opera ting  characteristic (ROC) curves 
were drawn to  visualize the  d iscrim inative  a b ility  o f each TMT in search fo r the 
h ighest sens itiv ity  and specific ity, and areas under the  curve (AUC) were calcula ted.21 




Patients and contro ls  were age-m atched (PD 53.7 ±  10.0 years, contro ls 51.2 ±  11.9 
years; P = 0.10) and had sim ilar d is tribu tions  o f le ft and r ig h t hand dom inance (10% 
left-handedness). Mean disease du ra tion  based on sym ptom  onset was 1.2 ±  0.5 
years. O f the  107 patients, 10 used selegiline, am antad ine or orphenadrine, 
anti-Parkinson drugs w ith  a very  m odest e ffect on m o to r fun c tion ; there fore, these 
patien ts were no t excluded. The PD group con ta ined a h igher p ro p o rtio n  o f men 
(67%) than the  con tro l g roup  (41%). However, in a previous study, we showed tha t 
the  m o to r scores o f men and w om en did  ne ithe r d iffe r at disease onset nor during 
the  firs t 10 years o f PD.19 F o rty -tw o  patien ts had an sUPDRS-III score o f zero on one 
side o f th e ir body  (congruent w ith  th e ir s tr ic tly  un ila teral com pla ints), w h ich  was 
the re fo re  labeled as ''c lin ica lly  unaffected.''
Part I: Discriminating PD from Controls
Patients scored worse than contro ls on all TMT item s except fo r W alkTime (tim e 
needed to  w a lk the  fina l 11 o f 15 m) and Tap1 Key_r (num ber o f h its on one keyboard 
key du ring  5 seconds using the  index fing e r o f the  rig h t hand). Table 1 lists the  mean 
scores per TMT item  and com b inations o f TMTs in patien ts and contro ls. In add ition , 
the  correspond ing ROC AUCs are given.
The TMT sumscore d iscrim inated patien ts from  contro ls w ith  an AUC o f 0.82 (fig. 1). 
A t a c u t-o ff p o in t o f 25, sens itiv ity  was 82% at 71% specific ity. In the  evaluation 
o f bo th  the  ind iv idua l and com bined TMTs, the  best ROC curve was reached fo r 
the  pegboard  d e x te rity  test w ith  an AUC o f 0.97 (fig. 1). A t a c u t-o ff o f 10 seconds, 
95% se n s itiv ity  corresponded w ith  89% spec ific ity . A d d itio n a l c u t-o ff po in ts 
w ith  correspond ing sens itiv ity  and specific ity  are listed in Supporting  In form a tion  
Table S2. A dd ing  o ther TMTs did  no t im prove these results.
Part II: Discriminating the Clinically Unaffected Limb in Strictly 
Hemiparkinsonian Patients from Controls
W hen we assessed the  unaffected body  side (sUPDRS-III = 0 and s tr ic tly  unilateral 
com pla ints) in patien ts and the  correspond ing body  side in contro ls, the  unilateral 
TMT sumscores did no t d iffe r be tw een patien ts and contro ls (table 2). This is 
re flected in the  ROC AUCs o f 0.49 (righ t arm) and 0.57 (le ft arm), ind ica ting  th a t the 
d iscrim inative  a b ility  o f the  un ila teral TMT sumscore was sim ilar to  chance. The 
pegboard  d e x te rity  test, however, reta ined reasonable d iscrim inative ab ility . The
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AUC for right-sided scores (n = 19) was 0.80, fo r left-sided scores (n = 23) 0.69 and for 
poo led righ t- and le ft-s ided scores 0.73 (fig. 2A). S upporting  In fo rm a tion  Table S3 
lists possible c u t-o ff po in ts  w ith  the ir corresponding sens itiv ity  and specific ity. 
D epending on the  se tting  in w h ich  the  test w ou ld  be used - requ iring  e ither a high 
sensitiv ity or a high specific ity - a cu t-o ff po in t o f >10 seconds w ou ld  de tect PD in 33% 
o f subjects w ho have la tent PD w ith  a 94% specific ity. W hen a h igher sens itiv ity  is 
needed, a c u t-o ff at >9 seconds w o u ld  de tec t PD in 83% o f the  affected subjects, but 
w ith  on ly 51% specificity. To investigate w hethe r handedness could have had a 
substantia l e ffec t on the  d iscrim inative  perfo rm ance o f the  un ila teral TMT sumscore 
and the  un ila teral pegboard  de x te rity  test scores, we pe rfo rm ed a post hoc analysis 
in w h ich  scores o f the  do m in an t and the  no nd om in an t hand were separated. The 
results rem ained essentia lly unchanged.
Fig. 1 ROC curve fo r the  TMT sumscore (do tted  line) and pegboard de x te rity  
test (continuous line, worse o f r ig h t and le ft-s ided scores) fo r all PD 
scores versus all control scores. AUC TMT sumscore = 0.82; AUC pegboard 
d e x te rity  test = 0.97.
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Table S-2 Sensitiv ity and spec ific ity  o f the  TMT sumscore and the pegboard 
de x te rity  test.
Abbreviation (measure) Cut-off Sensitivity Specificity
TMT sumscore > 8 1.00 0.06
> 12 0.98 0.06
> 16 0.98 0.17
> 20 0.94 0.29
> 24 0.85 0.66
> 27 0.76 0.80
> 29 0.71 0.83
> 33 0.53 0.89
> 37 0.38 0.94
> 41 0.25 1.00
Dexterity_worst (sec) > 7 1.00 0.00
> 8 0.99 0.18
> 9 0.98 0.63
> 10 0.95 0.89
> 11 0.81 0.92
> 12 0.72 0.97
> 13 0.56 1.00
Analysis p a rt I. The TMT items w ith  the  h ighest AUCs: the  TMT sumscore and the  w ors t o f R and L 
pegboard d e x te rity  test scores (cut-off, sensitiv ity, specific ity)
Table 2 TMT scores fo r unaffected PD arms versus healthy con tro l arms.




PD Controls P-value ROC
(AUC)
Unilateral TMT sumscore, R TMT_sum R unaffected 6.4 ± 4.0 6.8 ± 4.5 0.74 0.49
Unilateral TMT sumscore, L TMT_sum L unaffected 11.0 ± 5.7 9.8 ± 4.9 0.41 0.57
Pegboard dexterity test, R Dext_R unaff (sec) 9.7 ± 0.0 8.7 ± 0.8 <0.0001 0.80
Pegboard dexterity test, L Dext_L unaff (sec) 9.9 ± 1.5 9.0 ± 1.2 0.02 0.69
Pegboard dexterity test, R/L 
pooled
Dext_R/L unaff (sec) 9.8 ± 1.3 8.8 ± 0.9 <0.0001 0.73
Analysis p a rt II. TMT scores fo r unaffected  PD arms (sUPDRS-III=0) versus con tro l arms (mean ±  SD, 
P-value, AUC). H igher scores ind icate worse perfo rm ance fo r all results shown.
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Table S-3 Sensitiv ity and spec ific ity  o f the  pegboard d e x te rity  test: c lin ica lly  
unaffected PD arms versus healthy arms.
Abbreviation (measure) Cut-off Sensitivity Specificity
Dexterity_R/L unaffected (sec) > 7 0.98 0.00
> 8 0.98 0.14
> 8.5 0.88 0.29
> 9 0.83 0.51
> 9.5 0.55 0.77
> 10 0.33 0.94
> 10.5 0.26 0.94
> 11 0.10 0.94
> 12 0.07 1.00
Analysis p a rt II. The pegboard  d e x te rity  test: unaffected arms o f PD patien ts w ith  c lin ica lly  s tric tly  




Fig. 2 A: ROC curve fo r the  pegboard  d e x te rity  test fo r unaffected PD arms 
versus con tro l arms. Pooled R and L scores derived from  PD arms w ith  
sUPDRS-III=0 (one arm per patient), com pared w ith  the  mean o f healthy 
R and L scores. AUC = 0.73. B: S catte rp lo t fo r the  pegboard  de x te rity  
test. Unaffected PD arms versus con tro l arms. Pooled R and L scores 
derived from  PD arms w ith  sUPDRS-III=0 (one arm per patient), 
com pared w ith  the  mean o f healthy R and L scores. Y-axis: pegboard 
score (seconds), X-axis: PD and healthy contro ls  (CS). Horizonta l line 
indicates the  m edian test score.
Discussion
We have shown tha t a sim ple TMT ba tte ry  can d iscrim inate PD patien ts w ith in  tw o  
years a fte r sym ptom  onset from  healthy subjects, w h ich was the  firs t requ irem ent 
o f ou r search. O f all TMTs, the  pegboard de x te rity  test as a s ingle test was found  to  
have the  best d iscrim inative  p roperties w ith  an AUC o f 0.97, w h ich is considered 
exce llent fo r a po ten tia l d iagnostic  tes t.21 It cou ld replace the  entire  TMT ba tte ry  
due to  its h igher sensitiv ity, and the reby  save tim e.
W hy the  pegboard de x te rity  test in pa rticu la r can de tec t subtle  changes in m oto r 
fun c tio n  may be exp la ined by its requirem ents o f precise and coord inated 
independen t fing e r m ovem ents w h ich have previously been shown to  be im paired 
in PD.2223 Furtherm ore, these fing e r m ovem ents are accom panied by a ro ta ting
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a lte rna ting  w ris t m ovem ent w h ich  contains the  e lem ent o f d iadochokinesia (rapid 
sw itch ing  be tw een m ovem ent d irections). Dysdiadochokinesia is considered to 
re flect PD's cardinal features, brady- and akinesia. 24 The o ther TMTs rely on proxim al 
or axial m ovem ents as we ll, and the reby  prov ide ways to  com pensate fo r  distal 
m o to r problem s.
As a m odel fo r  preclin ica l PD, we selected the  c lin ica lly  unaffected side and 
evaluated the  pegboard  d e x te rity  test as w e ll as the  un ila te ra l TMT sumscores fo r 
th e ir d iscrim inative  ab ility . As expected, the  d iffe rence betw een scores o f the 
unaffected PD arms and the  con tro l arms was small, w ith  considerable overlap 
(fig. 2B). As a result, bo th  the  un ila teral TMT sumscore and the  pegboard de x te rity  
test lost pa rt o f th e ir d iscrim inative  ab ility , a lthough  the pegboard  de x te rity  test 
still retained an AUC o f 0.73. Q uantita tive  m o to r tests have been used by others to 
com pare patien ts w ith  PD and healthy subjects,25-27 b u t few  tests have been 
investigated fo r th e ir d iagnostic  perform ance, especially in untreated patients 
w ith in  tw o  years a fte r sym ptom  onset. For instance, a fing e r-tap p in g  test could not 
dem onstra te  a d iffe rence be tw een PD and con tro ls .28 A set o f quan tita tive  m oto r 
tests som ew hat s im ilar to  ours (the grooved pegboard test, finge r tap p in g  test, fo o t 
tap p in g  test, and trem or reg is tra tion  w ith  accelerometers) was able to  reach a 
com parable AUC (0.80) in a sample o f early PD patien ts and healthy subjects,29 bu t 
th is  was based on m easurem ents derived from  the m ost a ffected body side. In 
pa tien ts w ith  m ore advanced PD (H&Y stage 2 to  2.5), a com b ina tion  o f a m o to r test 
w ith  o lfa c tion  and m ood assessments was also exp lo red fo r d iagnostic  purposes.30 
Im portan tly , w hen applied p rospective ly  to  a sam ple o f suspected PD patien ts and 
healthy subjects, th is b a tte ry  m ain ta ined h igh specific ity  and sensitiv ity .31 Thus, 
prospective ly  app ly ing  the  pegboard d e x te rity  test to  a cohort o f asym ptom atic 
subjects w ith  a gene tica lly  de te rm ined  risk fo r  the  deve lopm en t o f PD sym ptom s 
w ou ld  be the  next step in its eva luation, realizing th a t by itse lf th is test is unable to 
make a pe rfec t separation be tw een c lin ica lly  p resym ptom atic  subjects and healthy 
persons. Therefore, in th is  sort o f p resym ptom atic  po pu la tion , the  pegboard 
d e x te rity  test should be used in com b ina tion  w ith  o ther tests, e ithe r m otor, 
non-m oto r, or bo th . The pegboard de x te rity  test had a be tte r d iscrim inative  a b ility  
fo r  assessing m ild ly  affected PD patients, w here it could be used as a quan tita tive  
screening too l, presum ably a long w ith  qua lita tive  clinical ratings such as the  UPDRS. 
Indeed, in a previous study, we evaluated the  m etric  a ttribu tes  o f the  pegboard 
d e x te rity  test fo r the  fo llo w -u p  o f early PD patients, and fou nd  a h igh va lid ity , 
re liab ility , and sens itiv ity  to  subtle  changes.18
73
Chapter 3.2
A ltho ug h  the results shown here seem cau tiously  prom ising, some critica l remarks 
should be made. As the  pegboard  de x te rity  test - at least in part- reflects the  level 
o f bradykinesia in the  hand and forearm , a concern may be no t be ing able to  de tect 
pa tien ts w h o  present w ith o u t bradykinesia as an early sym ptom , i.e., the  tre m o r­
do m in an t patients. However, in our pa tien t sample, none o f the  48 patien ts w ho 
experienced trem or as th e ir in itia l sym ptom  w ou ld  be false ly iden tified  as healthy at 
a c u t-o ff p o in t o f >9 seconds versus five  patien ts at a c u t-o ff p o in t o f >10. Accord ingly, 
th is  issue p robab ly  does no t im pose a m ajor prob lem  on screening.
A nother concern relates to  the  influence o f the relatively low  prevalence o f PD in the 
general popu lation on the perform ance o f any diagnostic test. A lthough the accuracy 
o f the  pegboard dexte rity  test may be reasonable, its diagnostic perform ance is best 
reflected by the positive predictive value (PPV) or post-test p robab ility  o f disease, 
which is d irectly proportiona l to  the prevalence o f the  disease.32 The PPV represents 
the  chance tha t - in case o f a positive test - the patient really has the disease. It can be 
calculated as follows: true positives/(true+false positives). The lower the  prevalence of 
a disease, the higher the p ropo rtion  o f false positives, resulting in a lower PPV. In this 
study popu lation o f 97 patients and 38 healthy subjects (PD prevalence 72%) o f whom  
bilateral dexterity  scores were available, the  PPV w ou ld  be 88/(88+5) = 95%, at a cut-o ff 
po in t >10 seconds, and 85% when restricted to  the unaffected arms in the PD group 
(PD prevalence 53%). However, when extrapolated to  the general popu lation over 60 
years o f age, in which the estimated PD prevalence is on ly 1%, the PPV w ou ld  be 5-7%.33 
We did  no t address the  spec ific ity  o f the  TMTs w ith  respect to  o ther parkinsonian, 
non-park inson ian neuro log ica l, or non-neuro log ica l disorders. This should p robab ly 
be the  greatest o f all concerns w hen the pegboard  d e x te rity  test is to  be used as a 
screening too l in the  general popu la tion , risking to  false ly id e n tify  subjects w ith  
im paired m ovem ents due to  any o the r disease (especially preparkinson-like 
com pla in ts  such as fib rom ya lg ia , a rth ritis  or depression) as PD patients. A dd ing a 
no nm o to r screening test to  the  pegboard de x te rity  test may the re fo re  im prove 
bo th  its accuracy as w e ll as its PPV.
Because o f its lim ita tions, th is s tudy should be seen as a cautious step in search fo r 
a preclin ica l PD de tec tion  too l in subjects w ho  do no t dem onstra te any clin ica lly 
recogn izab le signs at all. The pegboard de x te rity  test as such may lack specific ity 
w hen used in iso la tion, b u t its perform ance in th is s tudy provides sup po rt fo r its use 
as pa rt o f a m ore extensive test ba tte ry. Further w o rk  remains needed to  develop or 
fin e -tu n e  th is and o the r tim ed  m o to r tests to  op tim ize  the  d iagnostic  u t il ity  in 
preclin ica l popu lations.
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Abstract
Background: The healthy brain appears to  have an asym m etric dopam ine 
d is tr ibu tion , w ith  h igher levels o f dopam ine in the  le ft than in the  rig h t s triatum . 
Here, we test the  hypothesis th a t th is  neurochem ical asym m etry renders the  righ t 
s tria tum  re la tive ly  m ore vu lne rab le  to  the  effects o f dopam ine rg ic  denervation  in 
Parkinson's disease (PD).
Methods: Using the  pegboard de x te rity  test, we com pared m o to r perfo rm ance of 
bo th  hands be tw een healthy subjects (n=48), PD patien ts w ith  predom inan tly  
righ t-hem ispheric  dopam ine  de p le tion  (PD-RIGHT; n=83) and PD patien ts w ith  
m ore severe le ft-hem ispheric  dopam ine de p le tion  (PD-LEFT; n=103). All subjects 
were right-handed.
Results: A fte r ad justing  fo r  hand-dom inance effects, we fou nd  th a t PD-RIGHT 
patien ts exh ib ited  a 55% larger d ifference betw een r ig h t and le ft de x te rity  scores 
than PD-LEFT patients. This e ffect could be a ttr ib u te d  to  greater m o to r dysfunction  
o f the  m ore-affected hand in PD-RIGHT patients, w h ile  the  less-affected hand 
pe rfo rm ed sim ilarly in bo th  groups.
Conclusions: We conclude th a t the  side o f sym ptom  onset affects m o to r dysfunction  
in PD, and suggest th a t the  no n -d om in an t r ig h t hem isphere may be more 
susceptib le to  dopam ine rg ic  denervation  than the  do m in an t le ft hem isphere.
Key words: Parkinson's disease, asym m etry, dopam ine, m o to r fun c tion .
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Introduction
The hum an brain displays im p o rta n t s tructura l and fu n c tiona l asym m etries. For 
exam ple, in m ost peop le the  le ft hem isphere plays a do m in an t role in m oto r 
fu n c tio n  and language.1 A ltho ug h  the mechanisms underly ing  m o to r la teralization 
rem ain po o rly  understood , it has been hypothesized th a t hem ispheric asym m etries 
in dopam ine con ten t may play a role.2 This idea is based on anim al w o rk  show ing 
h igher levels o f dopam ine in the  le ft than in the  rig h t basal gang lia .3 These find ings 
have later been supported  by hum an nuclear im aging studies.45 If the  rig h t stria tum  
contains low er dopam ine  levels than the  le ft s tria tum , then th is  physio log ica l 
asym m etry could make the  rig h t s tria tum  m ore vu lne rab le  to  pa tho log ica l 
dopam ine rg ic  denervation . Here, we addressed th is poss ib ility  by focusing  on 
patien ts w ith  Parkinson's disease (PD), a neurodegenera tive d isorder th a t is 
characterized by asym m etric dopam ine de p le tion  in the  le ft or r ig h t s tria tum ,6 
w h ich  leads to  asym m etric m o to r defic its. The reasons behind the  sym m etric  loss o f 
dopam ine  in PD are unknow n, and the  side o f onset has been a ttr ib u te d  to  pure 
chance.7 Nevertheless, the  asym m etric nature o f PD makes th is d isorder a suitable 
m odel to  com pare the  effects o f a dopam ine rg ic  lesion in the  le ft and the  righ t 
s tria tum .8 We have used th is approach to  test the  hypothesis th a t righ t-handed PD 
patien ts w ith  p redom inan t dopam ine  dep le tion  in the  r ig h t s tria tum  (PD-RIGHT) 
d isplay m ore severe m o to r dysfunction  in the  contra la teral lim b than right-handed 
PD patien ts w ith  p redom inan t dopam ine de p le tion  in the  le ft s tria tum  (PD-LEFT). 
To test this, we used the  pegboard d e x te rity  test,9 a va lida ted measure of 
Parkinsonian m o to r dysfunction , to  com pare le ft and r ig h t hand m o to r perfo rm ance 
be tw een PD-RIGHT patients, PD-LEFT patien ts and healthy contro ls.
Experim ental procedures
Subjects
The s tudy po pu la tion  was selected from  a previously described lo ng itud ina lly  
observed coh ort o f consecutive PD patien ts w h o  vis ited the  M ovem ent Disorders 
o u tp a tie n t clin ic o f the  Radboud University N ijm egen M edical Centre between 
1990 and 2004.10 There were fo u r inclusion criteria: (1) a clinical diagnosis of 
id iopa th ic  PD according to  the  UK PD Society Brain Bank criteria,11 (2) clearly 
asym m etric sym ptom s, based on the  clinical assessment (see below), (3) no use o f
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dopam ine rg ic  m ed ica tion  yet, to  avoid in terfe rence o f m ed ica tion  or m ed ica tion - 
re la ted side e ffec ts  (e.g. dyskinesias) w ith  the  task, and (4) consis ten t righ t- 
handedness. Patients w ith  a disease du ra tion  beyond 7  years (based on sym ptom  
onset) were excluded to  ob ta in  a coherent cohort w ith o u t ou tlie rs (a few  patien ts 
had no t started dopam ine rg ic  m ed ica tion  a fte r 7  years o f disease duration). This 
y ie lded  186 patien ts (59% men, mean age 53.7 years). These patien ts were d iv ided 
in to  tw o  groups, based on the  side o f sym ptom  onset: right-s ide onset (corresponding 
to  le ft n ig rostria ta l dysfunction : PD-LEFT; n=103) and le ft-s ide onset (right 
n ig rostria ta l dysfunction : PD-RIGHT; n=83). We also recru ited 48 healthy, 
r igh t-handed, age-m atched contro ls (58% men, mean age 50.0 years). Subject char­
acteristics are sum m arized in tab le  1.
Table 2 Subject characteristics.
Subject characteristics PD-LEFT PD-RIGHT CS
Number of patients (% men) 103 (63%) 83 (53%) 48 (42%)
Age at assessment (years) 54.0 54.5 50.0
Number of assessments per subject 3.5 3.3 1
Age at onset (years) 51.1 51.7 -
Disease duration at assessment (years) 2.9 2.7 -
sUPDRS-III (sum of items, max. score = 33) 9.5 10.7 -
PD-LEFT: PD patien ts w ith  p redom inan t le f t  n ig rostria ta l dys function . PD-RIGHT: PD patien ts  w ith  
p redom inan t r ig h t n ig rostria ta l dys function . CS: hea lthy contro ls. sUPDRS-III: se lection o f UPDRS-III 
items.
Timed motor assessments
All subjects were assessed by the  same neuro log is t (MH) w ith  the  pegboard 
d e x te rity  test, a prev iously va lida ted tim ed  m o to r test (TMT) th a t requires ind iv idual 
fing e r m ovem ents to  tu rn  e igh t round w ooden pegs tw ice  each, as fast as possible, 
using one hand [fo r details, see Haaxma et al., 20089]. Briefly, perform ance on this 
test was quan tified  using the  to ta l tim e  to  tu rn  all the  pegs, fo r each hand and fo r 
each sub ject separately.
84
Side o f sym ptom  onset affects m otor dysfunction  in Parkinson's disease
Clinical assessments
Patients were assessed w ith  the  sUPDRS-III (selected UPDRS-III item s [Unified 
Parkinson's Disease Rating Scale m o to  part]): speech, facial expression, tre m o r at 
rest r/l, r ig id ity  r/l, rapid a lte rna ting  hand m ovem ents r/l, arm sw ing r/l, posture, and 
body  bradykinesia. This selection represents the  W ebster Scale, the  predecessor of 
the  UPDRS-III, w h ich  was used before the  UPDRS-III became w ide ly  accepted and 
correlates h igh ly  w ith  the  UPDRS-III.12 The sUPDRS-III results were used to  select 
pa tien ts w ith  clear sym ptom  asym m etry, w h ich  was defined as a m in im al d ifference 
o f tw o  po in ts  be tw een the  to ta l scores o f the  le ft- and righ t-la te ra lized sUPDRS-III 
item s "trem or", "r ig id ity ", "arm sw ing" and "rap id a lte rna ting  hand m ovem ents." We 
fo llow e d  the  patien ts over the  course o f the ir disease, assessing them  every 3 to  6 
m onths (on average 3.4 times). All healthy subjects were measured once. Patient 
assessments were part o f the  standard PD care program .
Statistical analyses
The main goal o f th is s tudy was to  test the  hypothesis th a t PD-RIGHT patien ts have 
m ore severe m o to r dys func tion  in the  contra la teral lim b than PD-LEFT patients. 
However, since all subjects were righ t-handed, greater asym m etry may be found  in 
PDRIGHT patien ts due to  be tte r m o to r perfo rm ance o f the  do m in an t r ig h t hand. We 
the re fo re  used the  results in the  con tro l g roup  to  ad just fo r  hand dom inance. First, 
we de term ined the  d iffe rence (d) be tw een le ft and rig h t hand m o to r perform ance 
fo r all subjects. Then we sta tis tica lly  tested w he the r the  d ifference between 
PD-RIGHT and PD-LEFT patien ts was larger than exp la ined by hand dom inance 
alone (as de te rm ined  in the  controls). Specifically, w hen in healthy righ t-handed 
subjects le ft hand scores are on average X  h igher (=worse) than rig h t hand scores, 
the  mean d iffe rence (dC) be tw een the  le ft and r ig h t hand scores is X. However, 
w hen the  dopam ine -dep le ted  rig h t hem isphere produces le ft hand scores tha t are 
on average r h igher in ad d ition  to  X, the  expected d ifference (dR) be tw een le ft and 
rig h t hand scores fo r PD-RIGHT patien ts is X+r. Sim ilarly, fo r PD-LEFT patients, the 
d iffe rence (dL) is expected to  be X-l.The d ifference in hand-asym m etry o f PD-RIGHT 
versus PD-LEFT patien ts is r-l, w h ich  is equal to  dR + dL -2x dC. To estim ate this 
contrast, we used a m ixed linear m odel w ith  d  as the  dependen t variab le, sub ject as 
random  factor, and affected side and pa tien t v is it as fixed factors. To correct fo r  the 
possible in fluence o f age at assessment and gender, we included these variables as 
covariates in the  analyses, and we pe rfo rm ed separate analyses fo r men and w om en. 
Statistical analysis was carried o u t using SPSS version 16 and SAS.
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Fig. 1 M otor perform ance across PD patients and healthy subjects. Pegboard 
dex te rity  test scores (Y-axis, m ean+error bars, in seconds) are shown fo r 
healthy contro ls (CS), PD patients w ith  p redom inant le ft nigrostriatal 
dysfunction (PD-LEFT) and PD patients w ith predom inant right nigrostriatal 
dysfunction (PD-RIGHT; X-axis). H igher scores indicate worse perform ance. 
Dark grey bars represent the  dom inant (right) hand, ligh t grey bars 
represent the non-dom inan t (left) hand. PD-RIGHT patients display a 
s ign ificantly greater difference between the dom inant and the  non­
dom inan t hand than PD-LEFT patients (difference A =55%, P=0.008), due 
to  worse m otor perform ance o f the ir m ore-affected hand (P<0.001) rather 
than to  be tte r perform ance o f the  less-affected hand (P=0.33). The bars 
show raw scores w ith o u t correcting fo r the  physio logical difference in 
handedness (which is shown by the m ost left-placed bars). Im portantly, 
the difference in between-hand asymmetry across PD groups was larger 
than the between-hand asymmetry explained by hand dominance (see CS).
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Results
Fig. 1 shows average task perform ance fo r the  healthy subjects, PD-LEFT patients 
and PD-RIGHT patients, arranged by hand dom inance. H igher scores indica te worse 
perfo rm ance. As expected, the  healthy subjects were faster w ith  th e ir dom inan t 
r ig h t hand than w ith  th e ir no nd om in an t le ft hand (P=0.003). Both PD groups were 
slower fo r th e ir m ore-affected hand than fo r th e ir less affected hand, irrespective of 
hand-dom inance. Im portan tly , hand asym m etry (i.e. the  d ifference be tw een the 
m ore- and less-affected hand) was 55% larger in PDRIGHT than in PD-LEFT patients 
(P=0.008), m uch m ore than w ou ld  be expected based on hand dom inance alone. 
There was an add itiona l, independen t e ffect o f age at assessment on hand 
asym m etry (P=0.03), b u t no e ffect o f gender (P=0.81). To test w he the r the  greater 
hand asym m etry in PD-RIGHT patien ts was caused by the  m ore-affected hand (PD- 
RIGHT>PD-LEFT), the  less-affected hand (PD-LEFT>PD-RIGHT), or bo th, we d irec tly  
com pared task perfo rm ance o f PD-RIGHT and PD-LEFT groups separately fo r each 
hand. This revealed worse perfo rm ance o f the  m ore-affected hand in PD-RIGHT 
than PD-LEFT patien ts (P<0.001), w h ile  bo th  groups pe rfo rm ed sim ilarly w ith  the 
less-affected hand (P=0.33).
Discussion
We have shown th a t m o to r asym m etry in PD is larger in patien ts w ith  p redom inan t 
dopam ine  dep le tion  o f the  rig h t (PD-RIGHT) than the  le ft (PD-LEFT) n igrostria ta l 
system. This fun c tiona l asym m etry was a ttr ib u ta b le  to  a 55% greater m otor 
dys func tion  o f the  m ore-affected le ft hand in the  PD-RIGHT group, w h ich  clearly 
exceeded hand dom inance effects, even if those effects could no t be excluded 
entire ly. Assum ing a positive corre la tion  be tw een striatal dopam ine  levels and 
m o to r fun c tio n , these results f i t  w ith  previous find ings  o f a h igher dopam ine 
con ten t in the  le ft than in the  r ig h t s tria tum  o f healthy brains.34 We propose tha t 
th is  physio log ica l dopam ine rg ic  asym m etry could make the r ig h t s tria tum  more 
vu lne rab le  to  dopam ine rg ic  degenera tion  as occurring in PD, and the reby  increase 
m o to r asym m etry.
Theoretica lly, an increased vu ln e ra b ility  o f the  rig h t s tria tum  due to  a pre-existent 
low er dopam ine  con ten t could lead to  an earlier age at onset, a faster func tiona l 
decline, or bo th, in the  PD-RIGHT group (see also D ja lde tti et al., 2006),7 and possibly
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to  a h igher prevalence o f pa tien ts w ith  le ft-s ided sym ptom  onset. In th is study, we 
observed a s im ilar age at onset across bo th  (righ t-handed) PD groups and s ligh tly  
m ore (righ t-handed) patien ts w ith  right-s ided sym ptom  onset (=PD-LEFT group), 
w h ich  is in line w ith  some previous studies.1314 However, others could no t con firm  a 
re la tionship betw een handedness and the side o f sym ptom  onset.15 M oreover, this 
typ e  o f in fo rm a tion  as derived from  our s tudy should be in te rp re ted  w ith  caution. 
First, the  current s tudy was no t designed as a popu la tion-based prevalence study, 
a lthough  the  pa tien t sample was derived from  consecutive patients. Secondly, the 
age at onset was based on sub jective reports  th a t may no t have been en tire ly  
com parable across groups. For instance, la ter n ig rostria ta l dys func tion  in the 
PD-LEFT group  may have been masked by earlier sym ptom  awareness, since the  
m ore-affected side is also the  do m in an t hand in th is group. Thus, a lthough  both 
groups had a s im ilar age o f sym ptom  awareness, the  PD-RIGHT g roup  may have 
been at a pa thophys io log ica lly  m ore advanced stage. This seems consistent w ith  
the  s ligh tly  worse UPDRS-III scores fou nd  in th is g roup, a lthough  one w ou ld  expect 
worse perform ance fo r bo th  sides w h ile  we observed a d ifference on ly  fo r the 
m ore-affected side. Reversely, assuming sim ilar disease du ra tion  at sym ptom  
awareness in bo th  groups, PD-RIGHT patien ts w ou ld  be consisten tly younger than 
PD-LEFT patients, w h ich  is no t reflected in our po pu la tion . Moreover, the  d ifference 
be tw een PD-RIGHT and PD-LEFT patien ts was s ign ifican t even w hen con tro lling  fo r 
age at testing . It also rem ained present du ring  fo llo w -u p  (up to  6 years), in o ther 
words m o to r fu n c tio n in g  de te rio ra ted  at the  same rate fo r  bo th  hands. Com bined 
w ith  s im ilar previous find ings  o f sustained stab le sym ptom  asym m etry,16 th is argues 
against a faster progression in the  PD-RIGHT group, at least a fte r sym ptom  onset. 
Together, based on the  present results, we are cautious to  a ttr ib u te  increased m otor 
dys func tion  in PD-RIGHT patien ts to  e ither earlier onset or m ore rapid disease 
progression. A no ther issue relates to  the  causal re la tionship be tw een m otor 
fu n c tio n  and the  dopam ine con ten t in the  basal ganglia. W hile it seems plausible 
th a t h igher s triatal dopam ine levels enhance contra la teral m o to r perfo rm ance,2 the 
reverse may also be true. For instance, roden t studies showed th a t forced nonuse of 
one lim b du ring  the  period o f n ig rostria ta l degenera tion  may act to  po ten tia te  
contra la teral degenera tion .1718 If th is were true, perhaps physical in a c tiv ity  may 
then  expla in our fin d in g  o f worse m o to r perfo rm ance o f the  m ore-affected hand in 
the  PD-RIGHT group. To fu lly  address th is  possib ility , fu tu re  s im ilar studies w ou ld  
also need to  include data o f standard ized qu an tita tive  measures on physical ac tiv ity  
fo r  each hand and group. However, g iven th a t all pa tien ts in th is s tudy were
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righ t-handed, the  m ore-affected hand in the  PD-RIGHT group was also the ir 
no n -d om in an t hand. Therefore it appears like ly tha t PD-LEFT patien ts were more 
inc lined to  con tinue using the ir m ore-affected (dom inan t right) hand than PD-RIGHT 
patients. From th is p o in t o f v iew , it w ou ld  be in te resting  and c lin ica lly  relevant to 
investigate w h e the r PD patien ts w h o  tra in  th e ir a ffected hand, longer preserve 
m o to r fun c tio n . In animals, forced use o f one fo re lim b  p ro tected  against contra lateral 
n ig rostria ta l degenera tion ,1920 w h ile  general physical a c tiv ity  im proved m otor 
fu n c tio n  bo th  in PD patien ts and anim als.21-24
To conclude, the  current s tudy indicates th a t the  side o f PD onset is d iffe ren tia lly  
associated w ith  m o to r asym m etry. W hile pre lim inary, our results sup po rt the 
hypothesis th a t the  no n -d om in an t hem isphere is m ore vu lne rab le  to  dopam inerg ic  
denerva tion  than the  do m in an t hem isphere. This may encourage fu r th e r research 
in to  bo th  physio log ica l and pa tho log ica l dopam ine rg ic  processes underly ing  
lateralized brain fun c tion .
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Abstract
Introduction: Striatal postsynap tic  D2 receptors in Parkinson's disease (PD) are 
th o u g h t to  be upregu la ted in the  firs t years o f the  disease, especially contra lateral 
to  the  c lin ica lly  m ost affected side. The aim o f th is study was to  evaluate w hethe r 
the  h ighest striatal D2 b ind ing  is fou nd  contra la teral to  the  m ost affected side in PD, 
and w h e the r th is up regu la tion  can be used as a d iagnostic  too l.
Methods: Cross-sectional survey was undertaken o f 81 patien ts w ith  clin ica lly 
asym m etric PD, w ith o u t an tipa rk insonian drugs and w ith  a disease du ra tion  o f <5 
years and 26 age-m atched contro ls. Striatal D2 b ind ing  was assessed w ith  [123I] IBZM 
SPECT, and severity o f the  presynaptic dopam ine rg ic  lesion w ith  [123I] FP-CIT SPECT. 
Results: The mean s tria to -occ ip ita l ra tio  o f [123I] IBZM b ind ing  was s ign ificantly  
h igher in PD patien ts (1.56±0.09) than in contro ls  (1.53±0.06). In PD patients, higher 
values were found  contra la teral to  the  c lin ica lly  m ost a ffected side (1.57±0.09 vs 
1.55±0.10 ipsilaterally), suggesting D2 receptor up regu la tion , and the  reverse was 
seen using [123I] FP-CIT SPECT. However, on an ind iv idua l basis on ly  56% o f PD 
patien ts showed th is up regu la tion .
Conclusion: Our s tudy confirm s asym m etric D2 receptor up regu la tion  in PD. 
However, the  sens itiv ity  o f contra la teral h igher striatal [123I] IBZM b ind ing  is on ly 
56%. Therefore, the  presence o f contra la teral h igher striata l IBZM b ind ing  has 
insuffic ien t d iagnostic  accuracy fo r PD, and PD cannot be excluded in pa tien ts w ith  
parkinsonism  and no contra la teral up regu la tion  o f D2 receptors, 
assessed w ith  [123I] IBZM SPECT.
Keywords: Parkinson's disease, [123I] IBZM SPECT, [123I] FP-CIT SPECT, upregu la tion .
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Introduction
Parkinson's disease (PD) is characterised by asym m etric degeneration o f presynaptic 
n igrostria ta l dopam ine neurons, especially those p ro jecting  to  the  putam en. This 
leads to  dopam ine deficiency and the deve lopm ent o f parkinsonism, in itia lly  w ith  a 
unilateral onset and progressing over the years to  a bilateral bu t persistently 
asym m etric involvem ent.1 Dopam ine binds m ainly to  the postsynaptic striatal D2 
receptors and the  b ind ing  capacity o f these receptors can be measured by 
s ing le -photon emission com puted tom ography (SPECT) using the  D2 radiotracer [123I] 
IBZM.2 The reduction o f striatal dopam inerg ic term inals is presum ably compensated 
by an increase in postsynaptic dopam inerg ic receptors, as observed bo th  in animal 
studies3, 4 and in patients w ith  PD, at least in the early stage o f PD.5-9 This D2 receptor 
upregula tion is m ost ev ident contralateral to  the  c lin ica lly m ost affected side,6, 7' 10, 11 
w h ich is usually the  side o f onset in PD. Upregulation disappears in more advanced 
stages o f the disease.7,12 It has been suggested, however, tha t this increase in 
postsynaptic D2 receptor b ind ing could also be due to  loss o f endogenous dopam ine, 
resulting in decreased receptor occupancy by endogenous dopam ine and accordingly 
increased receptor occupancy by the  tracer.13 Studies thus far have investigated D2 
receptor upregula tion fo r the w ho le  group o f PD patients. In the present study we 
analysed the  diagnostic accuracy o f asym m etric D2 receptor b ind ing  in individual 
patients w ith  PD, using [123I] IBZM SPECT. The question o f w hethe r the increase in 
striatal postsynaptic D2 b ind ing is related to  the  degree o f presynaptic nigral cell loss 
is addressed using [123I] FP-CIT SPECT and pegboard testing.
M aterials and m ethods
Patients
In this cross-sectional survey we selected 86 patients w ith  PD, w ho underw ent [123I] 
IBZM SPECT scanning fo r various reasons between 1994 and 2003. We included 
patients w ith  a disease dura tion  o f m axim ally five years, because upregula tion is 
expected on ly  in the early stages o f PD. Patients w ith  dem entia or o ther m ajor neuro­
psychiatric disorders were excluded, as were patients w ith  clinical bilateral and 
sym m etric parkinsonism. In m ost patients, [123I] IBZM and [123I] FP-CIT SPECT were 
rou tine ly  perfo rm ed during diagnostic work-up. It m ust be noted tha t in the  years 
prio r to  [123I] FP-CIT SPECT, we also used [123I] IBZM SPECT, assuming tha t the  d irection
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o f D2 b ind ing asym m etry could yie ld  diagnostic clues fo r PD, i.e. upregula tion 
contralateral to  the m ost affected body side w ou ld  favour PD [14]. A m ino rity  of 
patients underw ent SPECT as part o f research studies. Twenty-six age-m atched 
individuals served as [123I] IBZM SPECT controls. Controls were retrospective ly selected 
from  healthy persons and from  patients w ith o u t striatal disease pa rtic ipa ting  in 
previous research studies. A t the  tim e, in form ed consent had been obta ined from  all 
subjects taking part in research studies, and studies were approved by the  institu tional 
review board. Diagnosis o f PD was made according to  UK Parkinson's Disease Brain 
Bank clinical diagnostic criteria.15 Patients were included on ly  w hen com puted 
tom ography (CT) or m agnetic resonance im aging (MRI) were normal.
No patients showed sym ptom s suggesting o ther causes o f parkinsonism during the 
fo llo w in g  tw o  or m ore years. Patients had never been trea ted w ith  antiparkinsonian 
drugs, or the rapy had been w ith d ra w n  at least 1 m on th  before [123I] IBZM or [123I] 
FP-CIT SPECT. Patients d id  no t take any drugs know n to  in te rfe re  w ith  e ither SPECT 
study. Patients w ho  had received bo th  SPECT studies were included on ly  if the 
in terva l was shorte r than 6 m onths (mean 2.4±2.3 months).
Clinical exam ination was pe rfo rm ed before the  [123I] IBZM SPECT. Bradykinesia, 
w h ich  correlates best w ith  n ig rostria ta l dopam ine rg ic  status,16,17 was used to 
evaluate w h ich  side was c lin ica lly  m ost affected. Bradykinesia is rou tine ly  assessed 
in all ou r patien ts w ith  a pegboard test, in w h ich  patien ts have to  tu rn  pegs upside 
dow n , m easuring fing e r dexterity .18
SPECT imaging
N inety m inutes a fte r i.v. in jec tion  o f 185 MBq 123I-iodobenzam ide (IBZM, 
GE-Amersham, E indhoven, The Netherlands) or 3 hours a fte r i.v. in jec tion  o f 200 
MBq 123I-FP-CIT (DaTSCAN, GE-Amersham, E indhoven, The Netherlands), SPECT 
was pe rfo rm ed w ith  a M u ltiS pect 2 dual-headed gam m a camera, connected to  an 
ICON com pu te r (Siemens, Hoffm an Estates, IL, USA). The d ig ita l images (128x128 
m atrix, 64 angles) were corrected w ith  Chang's a lgo rithm  fo r a ttenua tion  (IBZM 
only), reconstructed using a B u tte rw o rth  f ilte r (0.6 Nyquist, o rder 7) and reoriented 
in the  canthus-m eatus plane. The th ree consecutive slices w ith  the  highest striatal 
uptake (tota l thickness 14.6 mm) were selected fo r quan tita tive  analysis. Fixed size 
regions o f in te rest (derived from  an anatom ical brain atlas) were b ila te ra lly  drawn 
over the  stria tum  and the  occip ita l cortex (serving as the  reference region). For 
IBZM, stria to -occ ip ita l ratios were calcula ted.19 For FP-CIT, s tria to -occ ip ita l ratios 
were calculated and norm alised to  A lderson's phantom .
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Statistical analysis
Statistical analyses w ere carried o u t using SPSS 12.1 (Chicago, IL, USA. The analyst of 
data (CV) was b linded  to  the  clinical status o f the  subjects. One-sam ple Kolm ogorov- 
Sm irnov tests fo r no rm a lity  showed norm al d is tribu tions  o f the  variables; therefore, 
param etric tests fo r fu rth e r analysis were applied . Two-ta iled Student's t  tests fo r 
unpa ired samples were pe rfo rm ed to  com pare the  means o f [123I] IBZM b ind ing  and 
dem ograph ic  and clin ical data be tw een patien ts and contro ls  and betw een groups 
o f patients. Two-ta iled Student's t  tests fo r  paired samples were pe rfo rm ed to 
com pare the  means o f SPECT data w ith in  subjects, i.e. be tw een the le ft and righ t 
and be tw een the  con tra - and ipsilateral sides. The paired t  test excludes betw een- 
sub ject va ria tion  and was appropria te  in our patien ts to  analyse w ith in -su b jec t 
s ide-to-side differences. The percentages o f pa tien ts w ith  up regu la tion  in le ft- or 
righ t-s ided p redom inan t parkinsonism  was com pared w ith  the  chi-square test. The 
re la tion be tw een [123I] IBZM b ind ing  and du ra tion  o f PD was exam ined w ith  one-way 
ANOVA and the  post-hoc LSD (least significance difference) test. For th is purpose, 
disease du ra tion  was stra tified  in to  five  consecutive years. Furtherm ore, using 
Pearson linear corre la tion, the  re la tion be tw een [123I] IBZM b ind ing  and disease 
du ra tion , age and pegboard score, as well as the  re la tion be tw een [123I] FP-CIT 
b ind ing  and pegboard  score, was investigated in PD. In contro ls, Pearson linear 
corre la tion  was used to  analyse the  re la tion be tw een [123I] IBZM b ind ing  and age. 
The question o f w he the r postsynap tic  up regu la tion  o f striatal D2 receptors depends 
on presynaptic cell loss was stud ied using regression analysis, w ith  postsynaptic 
[123I] IBZM b ind ing  serving as a dependent variable.
Results
Patient characteristics and results are sum m arised in Table 1. E ighty-one patients 
w ith  PD fu lf ille d  the  inclusion criteria. Tw enty patien ts had also received [123I] FP-CIT 
SPECT. Five patien ts w ith  b ilateral and sym m etric  parkinsonism  were excluded 
(table 1). Patients w ith  PD showed a s ign ifican tly  h igher overall b ila teral mean [123I] 
IBZM b ind ing  than contro ls. In PD, contra la teral [123I] IBZM b ind ing  was sign ificantly  
h igher than ipsilateral b ind ing , whereas the  reverse was seen w ith  [123I] FP-CIT 
b ind ing  (table 1). There was no corre la tion  be tw een [123I] FP-CIT and [123I] IBZM 
b ind ing . However, regression analysis o f the  rig h t m inus le ft paired d ifference 
scores o f each tracer showed th a t the  am oun t o f [123I] IBZM b ind ing  asym m etry in
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Table 1 Patient characteristics and results.
Patients (n=81) Controls (n=26)
Age (years) 53.2 ± 11 51.3 ± 6.6a
Disease duration (years) 2.2 ± 1.2
Clinically worst side (no.) Right: 39 Left: 42a
Pegboard right+left (sec) 15.6 ± 9.3 9.86 ± 1.30***
D2 striatum right+left 1.56 ± 0.09 1.53 ± 0.06*
DaT striatum right+left 3.56 ± 1.14
Pegboard right vs. left (sec) 15.4 ± 9.4 15.9 ± 9.2a 9.77 ± 1.28 9.95 ± 1.31a
D2 striatum right vs. left 1.59 ± 0.10 1.54 ± 0.09*** 1.55 ± 0.06 1.50 ± 0.07***
DaT striatum right vs. left 3.57 ± 1.25 3.54 ± 1.16a
Pegboard contra vs. ipsi (sec) 19.9 ± 10.9 11.4 ± 4.1***
D2 striatum contra vs. ipsi 1.57 ± 0.09 1.55 ± 0.10*
D2corr striatum contra vs. ipsi 1.55 ± 0.09 1.53 ± 0.09*
D2 striatum PDup+ contra vs. ipsi 1.60 ± 0.09 1.52 ± 0.07***
D2 striatum PDup- contra vs. ipsi 1.55 ± 0.10 1.61 ± 0.11***
DaT striatum contra vs. ipsi 3.22 ± 1.12 3.90 ± 1.21***
D2 striatum: D2 striata l/occip ita l [123I] IBZM bind ing; D2 corr: [123I] IBZM bind ing corrected for physiological 
asymmetry; DaTstriatum: DaT striato/occipita l [123I] FP-CIT bind ing; contra: contralateral; ipsi: ipsilateral; 
PDup+: PD upregulation detected; PDup-: PD upregulation no t detected. 
a N ot significant, *p<0.05, **p<0.01, ***p<0.001.
one d irec tion  depended on the  am oun t o f [123I] FP-CIT b ind ing  asym m etry in the 
o ther d irec tion  o f (F=19.11, df=19, be ta= -0 .72 , p<0.001; fig . 1). This shows th a t the 
m ore pronounced the  side-to-side d ifference in presynaptic n ig rostria ta l loss, the 
greater the  side-to-side d ifference in postsynap tic  D2 b ind ing . The h ighest surplus 
value o f bo th  sides' [123I] IBZM -b ind ing is, the re fore, connected to  the  greatest 
de fic it in [123I] FP-CIT b ind ing  o f bo th  sides, re flec ting  up regu la tion  contra la teral to 
the  m ost a ffected body side. In six patients, w ho  showed a large asym m etry in [123I] 
IBZM b ind ing , and w ith  a h igher b ind ing  ips ila te ra lly  instead o f contra la terally, [18F] 
fluo rodeoxyg lucose  positron  em ission tom og rap hy  (PET) showed norm al and 
sym m etric  striatal uptake, exclud ing Parkinson-plus syndrom es w ith  striatal 
degenera tion  (data no t shown).
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Fig. 1 Regression analysis o f r ig h t m inus le ft striata l [123I] IBZM b ind ing  and 
rig h t m inus le ft striata l [123I] FP-CIT b ind ing . A rrow ed line discloses 
physio log ica l asym m etry o f [123I] IBZM b ind ing  (see text).
O ne-way ANOVA showed a s ign ificant d iffe rence (p=0.018) in [123I] IBZM b ind ing  
contra la tera l to  the  m ost affected side th ro u g h o u t the  firs t five years o f PD: 
contra la tera l [123I] IBZM b ind ing  was s ign ifican tly  increased in the  th ird  (p=0.009) 
and fo u rth  (p=0.05) year com pared w ith  the  firs t year o f PD (fig. 2). Furtherm ore, in 
bo th  PD and contro ls [123I] IBZM b ind ing  in the  rig h t s tria tum  was s ign ifican tly  h igher 
than in the  le ft stria tum  (table 1), w h ile  there  was no diffe rence betw een le ft and 
rig h t [123I] FP-CIT b ind ing  or m o to r perform ance using the  pegboard test in PD. This 
suggests a pre- existing asym m etry o f postsynaptic D2 receptors, w ith  h igher [123I] 
IBZM b ind ing  in the  righ t than in the  le ft s tria tum . This pre -ex is ting  d ifference 
betw een rig h t and le ft was on average 0.05 in contro ls. A fte r sub tracting  this 0.05 
diffe rence from  the rig h t s tria tum  in contro ls, the re  rem ained a random  asym m etry 
be tw een [123I] IBZM b ind ing  in the  righ t and in the  le ft s tria tum , w ith  absolute 
values o f mean=0.06, SD=0.04, min.=0.01 and max.=0.17. A fte r sub tracting  the 
above -m entioned  pre -exis ting 0.05 diffe rence in [123I] IBZM b ind ing  in favour o f the 
rig h t s tria tum  from  the  rig h t [123I] IBZM b ind ing  value in PD patients, the  mean [123I]
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Fig. 1 D2 receptor [123I] IBZM b ind ing  (contra la teral and ipsilateral) in PD as a 
fu n c tio n  o f disease du ra tion  (cross-sectional survey). H orizontal dashed 
line: D2 receptor [123I] IBZM b ind ing  in healthy subjects.
IBZM bind ing on the  contra la teral side rem ained s ign ifican tly  h igher than th a t on 
the  ipsilateral side (table 1). This pre -ex is ting  asym m etry o f D2 b ind ing  can also be 
iden tified  in fig . 1 (if the re  is no d iffe rence be tw een rig h t and le ft [123I] FP-CIT b ind ing 
on the  x-axis, the  arrowed line indicates an approx im ate ly  0.05 h igher [123I] IBZM 
b ind ing  in the  rig h t s tria tum  as com pared w ith  the  le ft (y-axis). Forty-five PD 
patien ts (sensitiv ity  56%) had h igher [123I] IBZM b ind ing  on the  contra la teral side, 
consistent w ith  up regu la tion , w ith  a d ifference be tw een the  tw o  sides o f 0.08±0.06. 
T h irty -s ix  patien ts (44%) had h igher b ind ing  on the  ipsilateral side, w ith  a d ifference 
be tw een the  tw o  sides o f 0.06±0.06 (fig. 3). The sens itiv ity  regard ing up regu la tion  
increased to  80% w hen analyzing patien ts w ith  a disease du ra tion  o f 3 and 4 years 
on ly  (n=30). The num ber o f pa tien ts w ith  p redom inan t le ft-s ided parkinsonism  was 
no t s ign ifican tly  d iffe re n t from  the num ber w ith  righ t-s ided parkinsonism  (table 1). 
However, the  percentage o f pa tien ts w ith  le ft-s ided parkinsonism  show ing con tra ­
lateral h igher [123I] IBZM b ind ing  was s ign ifican tly  greater (76%) than the  percentage 
o f pa tien ts w ith  right-s ided parkinsonism  (33%, x2<0.0001). This side-re lated bias in
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Fig. 3 Boxplots show ing m edian, 0.25 and 0.75 quartiles, and extrem e values 
o f side-specific striatal [123I] IBZM b ind ing  in PD and contro ls. All all 
patients, up+  h ighest b ind ing  contra la teral to  m ost affected body  side, 
u p -  lowest b ind ing  contra la teral to  m ost a ffected body  side, R= rig h t 
s tria tum , L= le ft s tria tum , C= contra la teral s tria tum , I= ipsilateral 
s tria tum , CS= contro ls. Num bers o f pa tien ts fo r  each g roup  are shown in 
parentheses.
the  percentage o f pa tien ts w ith  contra la teral up regu la tion  fu lly  disappeared after 
sub trac ting  0.05 from  the  right-s ided [123I] IBZM b ind ing  to  correct fo r pre-existing 
asym m etry: contra la teral h igher [123I] IBZM b ind ing  (upregu la tion ) was then found 
in 55% o f pa tien ts  w ith  le ft-s id ed  park inson ism  and in 56% w ith  righ t-s ided  
pa rk inson ism  (x2=0.88). Age, disease d u ra tio n  and seve rity  o f bradykinesia  were 
n o t re la ted to  [123I] IBZM b in d in g , w h e th e r con tra la te ra l o r ips ila te ra l, in PD. 
Furtherm ore, age did  no t a ffect [123I] IBZM uptake in contro ls. Regression analysis 
con firm e d  th a t bradykinesia , scored using a pegboa rd  test, depended  on the  
am oun t o f n igrostria ta l degenera tion  as assessed w ith  [123I] FP-CIT b ind ing  (df=38; 




In th is cross-sectional study, we observed striatal D2 receptor up regu la tion  in early 
and untreated PD patien ts com pared w ith  contro ls. The am oun t o f up regu la tion  
depended on the  degree o f degenera tion  in the  n igrostria ta l system and on the 
du ra tion  o f PD, w h ich  is in accordance w ith  the  results o f previous studies.6, 7' 10 11 
U pregu la tion  was m axim al fo r  pa tien ts w ith  a disease du ra tion  o f 3 or 4 years. The 
du ra tion  o f D2 receptor up regu la tion  in PD varied in o ther studies be tw een 1.5 and 
3 years.10, 20 In animal experim ents, up regu la tion  starts w ith in  days or weeks after 
resynaptic les ion ing.4' 13, 21 However, conclusions from  animal studies rely on acute 
experim ents, whereas PD in humans typ ica lly  represents a s low ly progressive 
degenera tion  o f the  n ig rostria ta l system. Therefore, the  d iffe rence in the  tim e  
course o f up regu la tion  be tw een acute animal experim ents and patien ts is p robab ly  
caused by the  d iffe re n t rates o f progression o f n ig rostria ta l cell loss. A ltho ug h  the 
cross-sectional nature o f our survey p ro h ib its  de fin itive  conclusions abou t the 
am oun t o f up regu la tion  over tim e, our results f i t  very  w ell w ith  o the r im aging 
studies o f dopam ine  receptors in PD.10 Secondly, in bo th  PD and contro ls we found 
h igher [123I] IBZM b ind ing  in the  r ig h t s tria tum  com pared w ith  the  le ft side. Such 
asym m etry has already been described in healthy subjects by Larisch et al., w ho 
also reported s ign ifican tly  h igher b ind ing  in the  r ig h t s tria tum  com pared w ith  the 
le ft.22 We agree w ith  Larisch et al. th a t th is  asym m etry is re la tive ly  small, so it w ill 
p robab ly  on ly  be de tected in large case series. We assume th a t th is asym m etry is a 
physio log ica l phenom enon, and, there fore, p re -ex is tent in patien ts w ith  PD as well. 
The relevance o f th is asym m etry, however, needs to  be elucidated. It m ig h t be 
caused by an anatom ical asym m etry, as the  vo lum es o f the  caudate nucleus and 
pu tam en are s ligh tly  greater in the  rig h t hem isphere.23, 24 A lte rna tive  explanations 
seem less plausible. Theoretica lly, there could be a s ligh t system atic s ide-related 
bias o f m easurem ent w ith  our SPECT system. However, in th a t case th is  system atic 
bias w ou ld  also have been observed in [123I] FP-CIT b ind ing , w h ich  was no t the  case. 
The righ tw a rd  asym m etric [123I] IBZM b ind ing  in contro ls  is p robab ly  no t caused by 
an asym m etric age-re lated loss o f [123I] FP-CIT b ind ing  e ither.25 Can the  presence of 
up regu la tion  be used as a d iagnostic  too l fo r  PD? Our data indica te th a t iden tifica tion  
o f up regu la tion  based on analysis o f absolute [123I] FP-CIT and [123I] IBZM b ind ing  is 
no t possible. In our pa tien t g roup  w ith  asym m etric PD there was a sign ificant 
asym m etry in mean D2 receptor b ind ing , w ith  h igher [123I] IBZM b ind ing  contra lateral 
to  the  m ost affected body  side, consistent w ith  up regu la tion . However, when
102
Diagnostic value o f asym m etric striatal D2 receptor upregu la tion  in Parkinson's disease
look ing  at the  ind iv idua l patients, the  sens itiv ity  o f th is contra la teral h igher [123I] 
IBZM b ind ing  was on ly  56%. This percentage increased to  80% in the  th ird  and 
fo u rth  years o f PD, th is  be ing the  period o f m axim al up regu la tion . Patients w ith  
h igher [123I] IBZM b ind ing  ips ila te ra lly  had no clin ical signs suggestive of 
parkinson-p lus syndrom es, e.g. m u ltip le  system a trophy and progressive 
supranuclear palsy, w h ich  was also con firm ed by a subsequent analysis using [18F] 
fluo rodeoxyg lucose  PET. Disease du ra tion  in our patien ts was on average 2.2 years, 
and did  no t d iffe r be tw een patien ts w ith  h ighest contra la teral [123I] IBZM b ind ing  
and those w ith  h ighest ipsilateral b ind ing . Therefore, a later up regu la tion  o f the 
ipsilateral s tria tum  du ring  the  course o f PD is un like ly  to  expla in the  low  sensitiv ity  
o f contra la teral up regu la tion . Furtherm ore, fig . 2 shows th a t bo th  sides o f the 
stria tum  have a m ore or less s im ilar course o f [123I] IBZM b ind ing  over 5 years. The 
fin d in g  o f ipsilateral h igher IBZM b ind ing  is pa rtly  caused by the  pre-existing 
physio log ica l asym m etry in IBZM b ind ing  in favour o f the  r ig h t side, on to p  of 
pre -exis ting  random  asym m etries in IBZM b ind ing . This pre -ex is ting  asym m etry 
conceals up regu la tion . The fac to r tim e  also plays an im p o rta n t role: the  am oun t o f 
up regu la tion  is greatest in the  th ird  or fo u rth  year a fte r m o to r sym ptom  onset, bu t 
m uch less in o the r stages o f PD.
In th is s tudy we con firm ed the  existence o f D2 receptor up regu la tion  as assessed 
w ith  [123I] IBZM and [123I] FP-CIT b ind ing  in PD. U pregu la tion  is m axim al in the  th ird  
and fo u rth  year o f PD and is m ost obvious contra la teral to  the  c lin ica lly  most 
a ffected side in patien ts w ith  PD. However, because o f its low  sensitiv ity, [123I] IBZM 
SPECT cannot be used as an early d iagnostic  too l in clinical practice fo r  the  ind iv idua l 
pa tien t. In add ition , contra la teral low er [123I] IBZM b ind ing  does no t exclude PD or 
represent the  very earliest sign o f a parkinsonism -plus syndrom e.
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Chapter 5
Ter vervanging van de paragrafen "Statistical methods" en "Results" evenals de 
legenda bij Figure 1.
Statistical methods
One hundred seventy-four questionnaires (PD: n=57/750; controls: n=117/1300) 
were not completed adequately and therefore excluded from the analyses. We next 
evaluated whether both databases (PD and healthy controls) were comparable in 
terms of basic characteristics, such as age at time of questionnaire and educational 
level. We had two primary hypotheses: 1) a low PD risk for artistic occupations and 2) 
a high PD risk for conventional occupations. Logistic regression analyses were 
performed on the very first occupation and on the most recent occupation, which, in 
case of the patients, was the last occupation prior to the self-reported symptom 
onset. The primary analysis included the factors 'artistic occupation (A; yes/no)', 
'conventional occupation (C; yes/no)' and 'age'. Because we evaluated two 
hypotheses in the primary analysis, we used a Bonferroni correction and considered 
p<0.025 as statistically significant. In a secondary analysis, we investigated the role of 
educational level by including this as an additional factor in the logistic regression.
We estimated odds ratios (ORs) for the artistic (A) occupations versus each of the 
remaining five occupational categories (R, I, S, E, C) with respect to their association 
with PD. Since previous reports had identified farming as a risk factor for PD, we also 
calculated the odds ratio of farming versus all other occupations. To examine 
whether farming had influenced the outcome of the primary analysis, we repeated 
this analysis with 'farming' as additional factor. We also repeated the analyses 
restricted to subjects from the Nijmegen area to verify whether this specific 
geographical area would yield different results from the group in total.
Demographic characteristics did not differ between both databases, except for a 
higher age at the moment of completing the questionnaire in the PD group (69.4 
versus 51.2 years; table 2). The distribution of the subjects across all occupations 
showed that artists represented a minority in both populations (between 1% and 4%, 
table 2). Analyses on these data revealed a reduced risk of subsequent PD for men 
with an artistic occupation late in life, compared to all other job categories (OR 0.14, 
CI 0.04-0.53, p=0.004, figure 1). In contrast to our hypothesis, conventional 
occupations late in life showed no increased risk of subsequent PD (OR 1.07, CI 0.70­
1.64, p=0.76, figure 1). Table 3 displays the odds ratios for artistic occupations in 
comparison to the other five RIASEC categories separately, which were all quite 
similar (OR 0.11-0.19). None of the first occupations showed an increased or 
decreased risk of PD, especially not the artistic (OR 0.72, CI 0.32-1.59, p=0.41) and 
conventional categories (OR 1.14, CI 0.77-1.71, p=0.51). In support of previous 
research,15 an increased risk of PD was found for farming , which belongs to the R 
category (last: OR 2.6, CI 1.4-4.6; first: OR 2.7, CI 1.6-4.5).




Percentage of artistic (Fig. 1A) and conventional (Fig. 1B) occupations within all first 
as well as all last (=most recent) occupations. PD patients are less likely than controls 
to have had an artistic occupation as their last occupation (*P=0.004). For the 




Background: In Parkinson's disease (PD), a p rem oto r phase precedes the 
deve lopm en t o f m o to r signs. We hypothesized th a t in p rem oto r subjects a m ild 
hypo -dopam ine rg ic  state m ig h t affect th e ir jo b  preference, leading to  overrepre­
sentation in s truc tu red  and p red ic tab le  occupations, or underrepresen ta tion  in 
a rtis tic  occupations.
Methods: In a case-contro l study, 750 men w ith  PD (age at onset 40 years) and 1300 
healthy men com ple ted a va lida ted questionnaire  abou t th e ir life tim e occupational 
status. A ccord ing to  the  R-I-A-S-E-C m odel, occupations w ere classified in to  6 m ajor 
categories, based on specific pe rsona lity  tra its. Odds ratio 's (OR) were calculated fo r 
conven tional and artis tic  categories, bo th  fo r the  m ost recent occupa tion  before 
sym ptom  onset, and fo r the  ve ry  firs t occupation . Because fa rm ing  is associated 
w ith  deve lop ing  PD, we also calculated OR's fo r farm ers separately.
Results: For the  m ost recent occupa tion , men w ith  a rtis tic  jobs  had a low er risk of 
deve lop ing  PD com pared to  all o ther categories (OR 0.14, 95% CI 0.04-0.53). An 
a rtis tic  f irs t occupa tion  did  no t p red ic t subsequent PD (OR 0.72, CI 0.32-1.59). The 
risk o f deve lop ing  PD was no t associated w ith  conven tional occupations (most 
recent occupation : OR 1.07, CI 0.70-1.64; firs t occupation : OR 1.14, CI 0.77-1.71). In 
concordance w ith  previous reports, fa rm ing  was associated w ith  an increased risk 
o f deve lop ing PD (m ost recent occupation : OR 2.6, CI 1.4-4.6; f irs t occupation : OR 
2.7, CI 1.6-4.5).
Interpretation: Having an a rtis tic  occupa tion  late in life is associated w ith  a reduced 
risk o f deve lop ing  PD, perhaps because th is reflects a be tte r preserved dopam inerg ic 
state. No o the r in itia l occupa tion  pred ic ted PD, suggesting tha t the  p rem oto r phase 
starts later in life.
Key words: Parkinson's disease, prem otor, occupations, jobs, a rtistic, RIASEC.
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Introduction
It is increasing ly recognized th a t Parkinson's disease (PD) is preceded by a p rem otor 
phase. P rem otor sym ptom s include, am ong others, REM sleep behaviour disorder, 
hyposm ia and depression.1,2 Some o f these sym ptom s are related to  a m ild  hypo- 
dopam ine rg ic  state, w h ich  does no t ye t cause m o to r signs. The leng th  o f the 
p rem oto r phase remains unknow n.
Here, we use a new approach to  probe the existence o f the  p rem oto r phase, and to 
evaluate its possible presence in early adu lthood . Specifically, w e aim ed to  evaluate 
w h e the r a m ild  hypo-dopam ine rg ic  state in p rem oto r subjects m ig h t a ffect the ir 
occupational status du ring  the  years prio r to  the  diagnosis o f PD. Several occupations 
have been linked w ith  an increased risk o f deve lop ing  PD.3,4 Some o f these, such as 
fa rm ing , have been stud ied in the  con tex t o f exposure to  environm enta l tox ins.5 
For others, such as teaching or ICT w ork, the  re la tionship w ith  PD is unkow n. We 
hypothesize th a t specific occupa tional preferences could re flect p rem oto r cogn itive  
and behavioral changes due to  a d im in ish ing  dopam ine rg ic  state. Indeed, low 
dopam ine  levels and low  D2-recep to r b ind ing  are associated w ith  a lack o f nove lty  
seeking in healthy peop le  and PD pa tien ts.6 In tu rn , low  nove lty  seeking scores in 
PD are corre lated w ith  a reflective, rig id , loyal, stoic, fruga l, o rderly  and persistent 
personality.7 Conversely, de novo artis tic  skills have been reported  in PD patients 
fo llo w in g  dopam ine rg ic  trea tm e n t.8 From th is perspective, subjects in the  p rem otor 
phase o f PD may be m ost com fo rtab le  in jobs  tha t do  no t require high dopam ine 
levels, leading to  an overrepresen ta tion in s tructured and p red ic tab le  occupations, 
an underrepresen ta tion  in a rtis tic  occupations, or both.
To investigate this, we used the RIASEC m odel,9 a va lida ted m ethod  to  classify 
occupations in to  six m ajor categories, linked to  pe rsona lity  characteristics: realistic 
(R), investigative (I), artis tic  (A), social (S), en terpris ing  (E) and conventional (C). This 
approach is supported  by evidence o f a re la tionship betw een a rtis tic  jobs  and the 
pe rsona lity  tra it 'openness to  new experience'.10 Openness, in tu rn , has been 
associated w ith  increased levels o f centra l dopam ine.11 Here, we focused on the 
tw o  m ost con trasting  occupational categories, i.e. artis tic  jobs  - characterized by 
creativeness, expressiveness and a d isorderly  w o rk  pa tte rn  - versus conventional 





In a case-contro l design, 750 PD patien ts (UK Brain Bank Criteria12), w ith  an onset of 
m o to r sym ptom s at age 40 or above, were recru ited from  the  Radboud University 
N ijm egen M edical Centre as well as from  15 com m u n ity  hospita ls in a w ide  area 
surround ing  N ijm egen. The patien ts were selected upon review  o f m edical charts, 
exc lud ing subjects w ith  cogn itive  decline (MMSE <27) or w ith  physical or psychiatric 
illnesses th a t could have in fluenced the ir jo b  op po rtu n itie s . 1300 healthy 
age-m atched contro ls were derived from  the  N ijm egen B iom edical Study, a large 
popu la tion-based cross-sectional survey in and around N ijm egen.13 We included 
on ly  men, to  prevent sex-related differences in jo b  op po rtu n itie s  in the  e lderly 
po pupa tion . A ll pa rtic ipan ts  gave in fo rm ed consent, as approved by the  local ethics 
com m ittee .
Data acquisition
Patients and contro ls com p le ted a structu red  questionna ire  abou t the ir life tim e 
occupa tional status, years and level o f education , and com orb id ity . Patients also 
reported  the  sub jective onset o f th e ir m o to r sym ptom s. The ob lig a to ry  m ilita ry  
service (abolished in 1997) was no t inc luded as occupation . A research assistant 
w h o  was b linded  to  the  study aims classified each occupa tion  according to  the 
RIASEC system (table 1). This produces a 3 -le tte r code related to  the  main persona lity  
characteristics associated w ith  the  occupation , e.g. ERS, RIA, and so on. For this 
study, we focused on the  f irs t (and m ost im p ortan t) le tte r o f th is code.
Statistical methods
Fifty-seven questionnaires o f pa tien ts were no t com p le ted adequate ly  and 
the re fo re  excluded from  the analyses. Logistic regression analyses were perform ed 
on the  ve ry  f irs t occupa tion  and on the  m ost recent occupa tion , w h ich , in case of 
the  patients, was the  last occupa tion  p rio r to  the  se lf-reported  sym ptom  onset. The 
regression analyses included a rtis tic  profession (yes/no), conventional profession 
(yes/no) and age as factors. Because we evaluated tw o  hypotheses in the  prim ary 
analysis, we used a Bonferron i co rrection , and considered p<0.025 as statistica lly 
sign ificant. In a secondary analysis, we investigated the  role o f educational level by 
inc lud ing  th is as an add itiona l fac to r in the  log istic  regression. Because previous 
reports  iden tified  fa rm ing  as a risk fac to r fo r  PD, we also calculated the  odds ratio
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Table 1 The RIASEC m odel. 9
R: Realistic • Auto mechanic, aircraft controller, surveyor, electrician, farmer, etc.
• Have mechanical and athletic abilities.
• Like to work outdoors and with tools and machines.
• Generally like working with things more than with people.
• Honest, humble, natural, persistent, practical, shy, and thrifty.
I: Investigative • Biologist, chemist, geologist, laboratory assistant, medical technician, 
etc.
• Have math and science abilities.
• Like to work alone and to solve problems.
• Like to explore and understand things, rather than persuade others or 
sell things.
• Curious, independent, modest, precise, rational, reserved, and smart.
A: Artistic • Musician, stage director, dancer, decorator, actor, writer, etc.
• Have artistic skills, enjoy creating original work, have good 
imagination.
• Like working with creative ideas and self-expression more than 
routines and rules.
• Disorderly, expressive, idealistic, impractical, independent, open, and 
original.
S: Social • Teacher, speech therapist, religious worker, counsellor, nurse etc.
• Like to be around other people, are interested in how people get 
along, like to help other people with their problems.
• Like helping and teaching people more than doing mechanical or 
technical activities.
• Convincing, friendly, generous, helpful, idealistic, kind, patient, tactful, 
warm.
E: Enterprising • Sports promoter, TV producer, business executive, salesperson, 
manager, etc.
• Have leadership and public speaking abilities, are interested in money 
and politics, like to influence people.
• Like persuading or directing others, more than working on scientific or 
complicated topics.
• Agreeable, ambitious, dominant, energetic, outgoing, pleasure- 
seeking, popular, and self-confident.
C: Conventional • Bookkeeper, financial analyst, banker, tax expert, secretary, etc.
• Have clerical and math abilities.
• Like to work indoors and to organize things.
• Like to follow orderly routines and meet clear standards, avoiding work 
that does not have clear directions.
• Careful, efficient, orderly, persistent, practical, and thrifty.
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(OR) o f fa rm ing  versus o the r occupations. Finally, as fa rm ing  may had in fluenced the 
ou tcom e o f the  prim ary  analysis, we repeated th is w ith  farm ers as add itiona l factor. 
As the  PD database was derived from  a w ide  geograph ica l area w h ile  the  healthy 
po pu la tio n  came from  in and around N ijm egen, we evaluated w he the r bo th 
databases were com parable in term s o f basic characteristics. We also repeated the 
analyses restricted to  subjects from  the  N ijm egen area.
Results
D em ograph ic characteristics d id  no t d iffe r be tw een bo th  databases, except fo r  a 
h igher age at the  m om en t o f com p le ting  the  questionnaire in the  PD group (69.4 
versus 51.2 years; tab le  2). We found  a reduced risk o f subsequent PD fo r men w ith  
an a rtis tic  occupa tion  late in life, com pared to  all o the r jo b  categories (OR 0.14, CI 
0.04-0.53, p=0.004). However, conventional occupations late in life showed no 
increased risk o f fu tu re  PD (OR 1.07, CI 0.70-1.64, p=0.76; tab le  3).
Analysis o f all firs t occupations showed no risk differences between the occupational 
categories (artistic: OR 0.72, CI 0.32-1.59, p=0.41; conventional: OR 1.14, CI 0.77-1.71, 
p=0.51).
In sup po rt o f previous research (Rugbjerg 2011), an increased risk o f PD was found 
fo r  fa rm ing  (recent: OR 2.6, CI 1.4-4.6; firs t: OR 2.7, CI 1.6-4.5), w h ich  be longs to  the 
R category. These find ings  were robust, as all add itiona l analyses produced sim ilar 
results.
112
Early indicators o f non -m otor changes in Parkinson's disease
Table 2 Subject characteristics, and occupations fo r bo th  groups.
PD (n=693) Controls (n==1183)
Age (y) at tim e of questionnaire 69.4± 9.3 (42.0-90.0) 51.2 ±7.4 (40.0-83.0)
RIASEC categories; 
no. of occupations (%) First occ. Last occ. First occ. Last occ.
Realistic (R) 316 (51%) 191 (34%) 337 (31%) 275 (23%)
Investigative (I) 27 (4%) 37 (7%) 113 (16%) 122 (10%)
Artistic (A) 16 (3%) 5 (1%) 40 (4%) 34 (3%)
Social (S) 60 (10%) 63 (11%) 214 (19%) 217 (18%)
Enterprising (E) 102 (17%) 171 (31%) 222 (20%) 355 (30%)
Conventional (C) 97 (16%) 91 (16%) 176 (16%) 180 (15%)
Table 3 Risk o f deve lop ing  PD, displayed fo r a rtis tic  jobs  (A) as com pared to  
all o ther occupa tional groups (R, I, S, E, C). Odds ratio 's (OR) and 95% 
confidence in tervals (CI) a fte r ad justm ent fo r age.
OR (95% CI)
Occupational category First occupation Last occupation
Realistic (R)
- including farming 0.34 (0.21-0.56) 0.11 (0.03-0.43)
- excluding farming 0.38 (0.23-0.64) 0.13 (0.03-0.52)
Investigative (I) 1.00 (0.49-2.03) 0.19 (0.05-0.78)
Social (S) 0.66 (0.36-1.20) 0.18 (0.05-0.71)
Enterprising (E) 0.59 (0.34-1.02) 0.18 (0.04-0.56)




Fig. 1 Percentage o f a rtis tic  and conven tiona l occupations w ith in  all firs t 
occupations (A) and w ith in  the  most recent occupations (B). PD patients 
are less likely than contro ls to  have had an artistic occupation as the ir last 
occupation (*P=0.004). For the  conventional occupations, no substantial 
d ifference between PD and healthy subjects could be found.
A: Artistic B: Conventional
first last first last
Discussion
We found  a reduced risk o f deve lop ing  PD fo r men w ith  an artis tic  jo b  late in life. 
This fin d in g  m ust be in te rp re ted  w ith  caution, because con tra ry to  ou r hypothesis, 
conven tiona l jobs  were no t associated w ith  an increased risk o f PD. Moreover, w h ile  
the  RIASEC classification is a va lida ted approach to  categorize occupations as linked 
to  persona lity  characteristics,9 it is no t an established approach to  probe the 
dopam ine rg ic  state o f subjects. Indeed, behavior is de te rm ined  no t on ly  by 
dopam ine, bu t also by e.g. noradrena line w h ich  is associated w ith  harm avoidance.14 
However, the  observed e ffec t was in keeping w ith  ou r baseline p red ic tion , and 
rem ained present a fte r correction  fo r po ten tia l confounders. M oreover, the  RIASEC 
approach con firm ed the  previously established link  be tw een fa rm ing  and PD, w ith  
a com parable risk (OR 2.6) th a t was found  by others (OR 2.5).15 
One possible in te rp re ta tion  could be th a t a rtis tic  ab ilities are associated w ith  a 
be tte r preserved dopam ine rg ic  state, w h ich  postpones the  deve lopm ent o f
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parkinsonian m o to r signs. This w ou ld  be in line w ith  previous reports  o f a positive 
re la tionship be tw een a rtis tic  p ro d u c tiv ity  and dopam ine rg ic  activ ity .16-18 A rtis tic  
c rea tiv ity  can be enhanced by drugs such as cocaine or am phetam ines, w h ich 
stim ula te  the  m eso lim b ic dopam ine rg ic  system, a ffecting  reward responses and 
add ic tion  behavior.19,20 This could expla in w hy artists have an increased risk of 
deve lop ing  the  dopam ine dysregu lation syndrom e.16 Conversely, a rtis tic  skills can 
be tu rned  o ff by le ft subtha lam ic nucleus s tim u la tio n ,21 w h ile  do pa m ine -dep le ting  
lesions in the  nucleus accum bens or ventra l teg m e n tum  decrease exp lo ra to ry  
behavior.22 Our find ings  may the re fo re  suggest th a t a gradua lly  dec lin ing  dopam ine 
level du ring  the  p rem oto r phase o f PD influences a subject's occupa tional preference 
or ab ilities, reducing the  like lihood o f be ing fou nd  in artis tic  professions in the  years 
before diagnosis. No in itia l occupa tion  pred ic ted PD, suggesting th a t the  p rem otor 
phase starts later in life. Despite the  large num ber o f subjects in our study, the  low 
frequency  o f artis tic  jobs  prevented us from  de te rm in ing  at w h ich  po in t in tim e 
these conveyed to  a low er risk o f deve lop ing  PD. This should be a top ic  o f fu tu re  
research in th is  area.
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Summary, discussion and ou tlook
This chapter discusses the  main find ings  o f the  thesis, in cohesion w ith  each other 
as w e ll as in the  con text o f the  existing literature. The chapter concludes w ith  a set 
o f fu tu re  perspectives. The com m on them e th ro u g h o u t th is thesis has been the 
search fo r a deeper understanding o f the pathophysiological mechanisms underlying 
the  early stages o f PD, and the  techniques app lied  in th is search.
Gender differences in PD
In C h a p te r 2, we found  several ind ica tions o f a m ore neurodegenera tive  process in 
w om en du ring  the  disease stages preced ing ove rt PD. First, w om en were tw o  years 
o lde r than men at sym ptom  onset. Second, they  presented m ore o ften  (67%) w ith  a 
trem or-d om in an t fo rm  o f PD than men (48%), w h ich  in tu rn  was associated w ith  a 
38% slower disease progression. Previous w o rk  by others has also shown a m ilder 
de te rio ra tion  o f m o to r signs and a slower striata l degenera tion  in trem or-dom inan t 
PD,1-3 suggesting it to  be a substantia l find in g . Third, at onset o f the  disease, w om en 
had 16% h igher levels o f striatal dopam ine  b ind ing  than men. However, w om en 
seemed to  have no fu r th e r advantage over men once PD had becom e clin ica lly 
m anifest. This was shown by the  s im ilar rates o f disease progression fo r men and 
w om en as indexed by bo th  clinical scores and m easurem ents o f striata l dopam ine 
b ind ing  du ring  the  f irs t ten years a fte r m o to r sym ptom  onset.
A ltho ug h  differences in disease characteristics be tw een men and w om en w ith  PD 
have been noted previously, the  exact nature o f these differences is unknow n. One 
m ajor fac to r d iffe re n tia lly  in fluencing  the  cerebral deve lopm en t and fu n c tio n  of 
men and w om en is fo rm ed  by the ir d iffe ring  levels o f c ircu la ting  sex horm ones.4 It 
is the  fem ale sex horm one estrogen th a t has been suggested to  play a role in the 
pathogenesis o f PD and in dopam ine m etabolism  in general. In animal models, fo r 
exam ple, estrogens have dem onstra ted a neurop ro tec tive  e ffect on dopam inerg ic  
neurons, b u t on ly  w hen adm in istered prio r to  the  tox ic  insu lt.5-7 Furtherm ore, 
w om en w ith  low  estrogen levels a fte r hysterectom y or ova riec tom y have shown an 
increased risk to  develop PD.89 We hypothesized tha t the  m om ent o f reaching the 
critica l th resho ld  o f dopam ine dep le tion  (associated w ith  m o to r sym ptom  onset) 
may be postponed in w om en due to  a p ro -dopam ine rg ic  e ffect o f estrogens. The 
results presented here sup po rt th is hypothesis. Parity (num ber o f children), age at 
m enopause and du ra tion  o f the  fe rtile  life span - measures o f the  w om en's estrogen 
status - were all pos itive ly  associated w ith  a later age at m o to r sym ptom  onset. In
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other words, the  m ore ch ildren w om en had and the  longer the ir fe rtile  life span, the 
later they  developed m o to r sym ptom s (2.5 years later per child).
In accordance w ith  our fin d in g  o f a van ish ing advantage fo r w om en afte r m oto r 
sym ptom  onset, others have shown th a t w om en do no t experience any beneficial 
effects o f estrogen supp le tion  once the m o to r sym ptom s have em erged.1011 A nother 
corre late o f our fin d in g  relates to  ep idem io log ica l observations o f a low er incidence 
and h igher age at onset in w om en, w h ich  could be exp la ined by a h igher n igrostria ta l 
dopam ine  level in w om en observed in th is thesis. A ltho ug h  th is hypothesis is 
a ttractive , incidence rates o f PD am ong Asian popu la tions do no t show  a male 
preponderance.12,13 Some even found  a m ore aggressive disease course in w om en, 
w h ich  argues against a fundam enta l p ro tective  e ffect o f estrogens. These find ings  
suggest th a t add itiona l gene tic  factors may be invo lved. However, w hen in te rp re ting  
clinic-based coh o rt studies, it is good to  bear in m ind th a t w om en w ith  PD may be 
less like ly than men to  access secondary and te rtia ry  m edical care,14 especially in 
rural or less developed areas. There may, there fore, be s ign ificant geographica l 
d ifferences in gender effects on the  incidence and natural h is to ry  o f PD.
T im e d  m o to r  te s ts  in  e a r ly  PD
The serial assessments o f the  PD patien ts as described in C h a p te r 2 were perfo rm ed 
be tw een 1988 and 2003. This explains w hy we firs t used a selection o f item s derived 
from  the  W ebster Scale, w h ich  is the  predecessor o f the  UPDRS-III and has shown 
good  corre la tion (>0.8) w ith  the  UPDRS-III in all Hoehn and Yahr stages.15 This 
selection (which we named sUPDRS-III in th is thesis) consists o f assessments of 
speech, facial expression, trem or at rest (r ig h t/le ft), r ig id ity  (r ig h t/le ft), rapid 
a lte rna ting  hand m ovem ents (r ig h t/le ft), arm sw ing (r ig h t/le ft), posture and body 
bradykinesia. A d isadvantage o f the  sUPDRS-III, however, is its rather subjective 
scoring system and the relative lack o f sens itiv ity  to  subtle  changes in m oto r 
fu n c tio n , w h ich  are like ly to  take place in recently d iagnosed PD patients. Therefore, 
m eanw hile  we had been deve lop ing  a tim ed  m oto r test (TMT) batte ry, aim ed at 
fin d in g  an easy-to-use and m ore ob jective , m ore re liab le and m ore sensitive too l to 
assess patien ts long itud ina lly , especially in the  early stages o f PD.
In C h a p te r 3.1 we investigated the  va lid ity , re liab ility , responsiveness, and feas ib ility  
o f th is TMT battery. The to ta l b a tte ry  consisted o f e igh t TMTs based on aspects of 
w a lk ing , w ritin g , single and doub le -handed pegboard perform ance, fing e r tapp ing,
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and rapid a lte rna ting  forearm  m ovem ents. The TMT ba tte ry  proved to  be fast - 
com p le ting  the  test to o k  less than five m inutes. It corre lated well w ith  the  sUPDRS-II I 
and disease du ra tion . Two factors exp la ined 61% o f the  TMT variance: the  firs t 
represented m ain ly  upper ex tre m ity  fun c tio n , the  second m ain ly  axial and lower 
e x tre m ity  fun c tio n . Cronbach's a was equal fo r the  TMT and the UPDRS-III (0.8). 
Test-retest re liab ility  of the  TMT sumscore was 0.93 to  0.89 fo r m easurem ents 
separated by 3 up to  24 m onths, whereas UPDRS-III corre la tions were 0.88 to  0.84. 
This means tha t, at group level, a tria l using ''change from  baseline '' as en dpo in t 
w ou ld  require on ly  75% o f the  patien ts needed w hen the  UPDRS-III was used as 
ou tcom e measure, and 57% o f pa tien ts w hen using the  pegboard d e x te rity  test. At 
pa tien t level, TMT and UPDRS-III were equa lly  responsive.
These results show th a t the  TMT battery, representing a con tinuous quan tita tive  
scoring system, is a valid and reliable ins trum en t to  measure m o to r dysfunction  in 
PD. W hile h igh ly  corre lated to  the  sUPDRS-III, it  is m ore ob jective  and m ore sensitive 
to  change. A ltho ug h  no t exp lic itly  investigated here, the  fast and s im ple design of 
the  TMT ba tte ry  - no t requ iring  extensive tra in in g  or the  experience o f a m ovem ent 
d isorders specia list - cou ld offer an add itiona l advantage. Interestingly, the 
pegboard  de x te rity  test surpassed the  qualities o f the  en tire  TMT ba tte ry  as an 
ins trum en t to  m on ito r dopam ine rg ic  m o to r dys func tion  and dopam inerg ic  
trea tm e n t effects in PD. This may be exp la ined by its requirem ents o f precise and 
coo rd ina ted independen t f ing e r m ovem ents w h ich  have previously been shown to 
be im paired in PD.1617 Furtherm ore, these fing e r m ovem ents are accom panied by a 
ro ta ting  a lte rna ting  w ris t m ovem ent w h ich  contains the  e lem ent o f d iadochok ine- 
sis (rapid sw itch ing be tw een m ovem ent d irections). Dysdiadochokinesis is 
considered to  re flect PD's cardinal features, brady- and akinesia.18 The o ther TMTs 
rely on proxim al or axial m ovem ents as well, and the reby provide ways to 
com pensate fo r distal m o to r problem s. The com b ina tion  o f the  above-m entioned 
characteristics suggests th a t the  TMT battery, bu t perhaps even m ore so the  
pegboard  d e x te rity  test as a s ingle test, cou ld be useful fo r bo th  practical and 
scientific  purposes.
C h a p te r 3 .2  describes the  next step in the  characterization o f the  TMT battery, and 
in pa rticu la r the  pegboard  de x te rity  test. Specifically, we exp lored the  a b ility  of 
these tim ed  tests to  d iscrim inate levodopa-na ive PD patien ts w ith  a sym ptom  
du ra tion  o f <2 years from  contro ls, as expressed by ROC curves. We also investigated 
w h e the r the  TMTs could d iscrim inate betw een healthy forearm  fu n c tio n  and the
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fu n c tio n  o f the  c lin ica lly  still unaffected forearm s o f s tr ic tly  hem iparkinson ian 
patients. O f all TMTs, the  pegboard  de x te rity  test had the  best ROC curve regard ing 
bo th  questions. D iscrim inating patien ts from  contro ls was possible w ith  an AUC of 
0.97 (95% sensitiv ity, 89% specific ity). As expected, the  accuracy decreased to  an 
AUC o f 0.73 w hen testing  the  c lin ica lly  unaffected lim b o f hem iparkinson ian 
patien ts versus the  mean o f r ig h t and le ft-hand scores in contro ls. This shows tha t 
the  pegboard  de x te rity  test is a sensitive and inexpensive ins trum en t to  de tect 
m o to r dys func tion  in early PD, a lthough  its accuracy was subop tim a l in the  test of 
the  unaffected forearm s. It may still be w o rth  eva luating th is pa rticu la r test as a too l 
to  assess patien ts w ith  early sym ptom atic  PD in everyday clinical practice, or as part 
o f a m ore e laborate screening ba tte ry  in a de fined po pu la tio n  at risk.
Functional hemispheric asymmetry in early Parkinson's disease
Follow ing the  characterization o f the  TMT ba tte ry  and the  prom is ing results o f the 
pegboard  de x te rity  test, in C h a p te r 4.1 we used the  pegboard de x te rity  test to 
com pare m o to r perform ance o f bo th  hands be tw een healthy subjects, PD patients 
w ith  p re do m ina n tly  righ t-hem ispheric  dopam ine de p le tion  (PD-RIGHT) and PD 
patien ts w ith  m ore severe le ft-hem ispheric  dopam ine  dep le tion  (PD-LEFT). All 
subjects were righ t-handed. A fte r ad justing  fo r hand-dom inance effects, we found 
th a t PD-RIGHT patien ts exh ib ited  a 55% larger d iffe rence be tw een rig h t and le ft 
d e x te rity  scores than PD-LEFT patients. This e ffect could be a ttr ib u te d  to  greater 
m o to r dys func tion  o f the  m ore-affected hand in PD-RIGHT patients, w h ile  the 
less-affected hand pe rfo rm ed sim ilarly in bo th  groups. From these results, we 
concluded tha t the  side o f sym ptom  onset in PD is som ehow  related to  the  in te g rity  
o f la teralized m o to r fun c tio n , and suggested th a t the  no n -d om in an t righ t 
hem isphere may be m ore susceptib le to  dopam ine rg ic  denerva tion  than the 
do m in an t le ft hem isphere.
A no the r aspect o f hem ispheric asym m etry is described in C h a p te r 4 .2 . In a cross­
sectional survey on patien ts w ith  c lin ica lly  asym m etric PD and w ith  a disease 
du ra tion  o f 5 years or under, as w e lll as in age-m atched contro ls, striatal D2 b ind ing  
was assessed w ith  [123I] IBZM SPECT. We also measured the  severity o f the  presynaptic 
dopam ine rg ic  lesion w ith  [123I] FP-CIT SPECT. The mean stria to -occ ip ita l ra tio  o f [123I] 
IBZM b ind ing  was s ign ifican tly  h igher in PD patien ts (1.56±0.09) than in contro ls 
(1.53±0.06). In PD patients, h igher values were fou nd  con tra la te ra lly  to  the  clin ica lly 
m ost affected side (1.57±0.09 vs 1.55±0.10 ipsilaterally), suggesting D2 receptor
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upregu la tion . However, on an ind iv idua l basis, on ly  56% o f the  patien ts showed this 
up regu la tion . The reverse was seen using [123I] FP-CIT SPECT (lower values con tra la t­
erally). The percentage o f pa tients w ith  le ft-s ided parkinsonism  show ing higher 
contra la teral [123I] IBZM b ind ing  was s ign ifican tly  greater (76%) than the percentage 
o f pa tien ts w ith  righ t-s ided parkinsonism  (33%, x2<0.0001). In o ther words, patients 
w ith  p redom inan t r ig h t hem ispheric dopam ine  de p le tion  m ore o ften  showed high 
postsynap tic  IBZM b ind ing  than in le ft hem ispheric disease dom inance. This w ou ld  
f i t  w ith  our find ings  described in C h a p te r 4.1 o f a m ore severely or d iffe ren tly  
affected rig h t hem isphere in le ft-s ided parkinsonism , as com pared to  the  le ft 
hem isphere lesion in right-s ided parkinsonism . However, the  e ffect disappeared 
afte r co rrecting  fo r the  average physio log ica l d ifference as fou nd  in the  healthy 
subjects. Contralateral h igher IBZM b ind ing  was then  found  in 55% o f pa tien ts w ith  
le ft-s ided parkinsonism  and in 56% w ith  right-s ided parkinsonism . Thus, the 
presence o f contra la teral h igher striatal IBZM b ind ing  has insuffic ien t d iagnostic 
accuracy fo r  PD. On the  o ther hand, absence o f contra la teral D2 receptor 
up regu la tion  in pa tien ts w ith  recent onset parkinsonism  does no t exclude PD. 
Therefore, the  fin d in g  o f asym m etric D2 receptor up regu la tion  in early clinical PD 
should no t be used as a d iagnostic  too l, b u t rather seen as a m ore fundam enta l 
co n trib u tio n  to  our unders tand ing o f the  pa thophys io log ica l changes in early PD.
Indicators of non-motor changes preceding the diagnosis of 
Parkinson's disease
Having stud ied the  characteristics o f early PD large ly based on measures o f m oto r 
(dys)function , we w ere also in terested in no n -m o to r changes th a t could offer insight 
in to  the  preclin ica l disease stage (C hap te r 5). For th is purpose, we used Holland's 
RIASEC m odel to  classify occupations in re la tionship w ith  pe rsona lity  characteris­
tics in 750 PD patien ts and 1300 healthy contro ls. We found  a reduced risk o f PD for 
men w ith  an a rtis tic  jo b  later on in life (OR 0.14). This find in g  m ust be in te rpre ted 
w ith  caution, because con tra ry  to  our hypothesis, conventional jobs  could no t be 
related to  an increased risk o f PD. Moreover, w h ile  the  RIASEC classification is a 
va lida ted approach to  categorize occupations as linked to  pe rsona lity  characteris­
tics,19 it is no t an established approach to  probe the  dopam ine rg ic  state o f subjects. 
Indeed, behaviour is de term ined no t on ly  by dopam ine, b u t also by e.g. 
noradrena line w h ich  is associated w ith  harm avoidance.20 However, the  observed 
e ffect was in keeping w ith  our baseline p red ic tion , and rem ained present a fte r 
co rrec tion  fo r po ten tia l confounders. The RIASEC approach con firm ed the  previously
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established link be tw een fa rm ing  and PD, w ith  a com parable risk (OR 2.6) th a t was 
fou nd  by others (OR 2.5),21 w h ich  also validates our database in com parison to 
po pu la tio n  based studies in PD.
Our find ings  are in sup po rt o f the  hypothesis th a t a rtis tic  ab ilities may be associated 
w ith  a be tte r preserved dopam ine rg ic  state, w h ich  in tu rn  could postpone the 
deve lopm en t o f parkinsonian m o to r signs. This w ou ld  be in line w ith  previous 
reports  o f a positive re la tionship betw een a rtis tic  p ro d u c tiv ity  and dopam ine rg ic  
ac tiv ity .22-24 A rtis tic  c rea tiv ity  can be enhanced by drugs such as cocaine or 
am phetam ines, w h ich  stim ulate the  m eso lim b ic dopam ine rg ic  system and thus 
a ffect reward responses and add ic tion  behavior.25,26 This could expla in w hy artists 
have an increased risk o f deve lop ing  the  dopam ine dysregu lation syndrom e.22 
Conversely, artis tic  skills can be tu rned  o ff by le ft subtha lam ic nucleus s tim u la tion ,27 
w h ile  do pa m ine -de p le ting  lesions in the  nucleus accum bens or ventra l tegm entum  
decrease exp lo ra to ry  behavior.28 Therefore, our find ings  may suggest th a t a 
gradua lly  dec lin ing  dopam ine  level du ring  the  p rem oto r stages o f PD could 
in fluence a subject's occupational preference or ab ilities, reducing the  like lihood of 
be ing found  in a rtis tic  professions in the  years before diagnosis. PD was not 
p red ic ted  by any o f the  in itia l occupations (i.e. the  very firs t jo b  in early adu lthood), 
suggesting th a t the  p rem oto r phase starts later in life. Despite the  large num ber of 
subjects in our study, the  low  frequency  o f artis tic  jo bs  prevented us from  
de te rm in ing  at w h ich  p o in t in tim e  these conveyed a low er risk o f deve lop ing  PD. 
This should be a top ic  o f fu tu re  research in th is area.
Outlook
A ltho ug h  a num ber o f questions have been answered in th is thesis, the  w ork 
presented here also y ie lded  several new issues to  be addressed in fu tu re  research. 
Despite our in a b ility  to  con firm  the  exact du ra tion  o f the  preclin ica l period, we 
fou nd  several ind ica tions o f a chang ing dopam ine rg ic  state years before m oto r 
sym ptom  onset, w ith  a d iffe rentia l e ffec t in men and w om en. The role o f estrogens 
in re la tionship w ith  dopam ine m etabolism  and ne u rop ro tec tion  remains to  be 
fu rth e r e lucidated. W ork by Rocca and colleagues is o f special in te rest in this 
con tex t.29 Perhaps, estrogen supp le tion  in w om en can postpone fu ll-b lo w n  PD 
w hen adm in istered in a m uch earlier stage o f PD than w ha t has been tried  so far, 
a lthough  th is may no t be w ith o u t serious side effects. O f course, early adm in is tra tion  
o f a pu ta tive  neuropro tective  agen t necessitates the  deve lopm ent o f a too l to
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id e n tify  PD as early as possible. A ltho ug h  the  pegboard d e x te rity  test showed fa irly  
good  d iscrim inative  properties in the  earliest clinical stage o f PD, it is p robab ly  not 
accurate enough to  de tect fun c tiona l changes in the  supposed ly p rem oto r stage of 
PD. Its a b ility  as a screening too l should be tested on a sam ple o f subjects w ho  are 
at high risk o f deve lop ing  PD, e.g. in gene tic  parkinsonism 3031 or in a coh ort of 
subjects w ith  REM sleep behavior disorder.32
From the  occupations study described in th is thesis, we learned th a t artists have a 
low er risk o f be ing diagnosed w ith  PD later in life. However, th is study was not 
designed to  prove a causal or "dose -dependen t" re la tionship betw een artistic 
ab ilities, striatal dopam ine levels and the po s tponem ent o f pa tho log ica l cerebral 
changes. This w ou ld  require a prospective, lo ng itud ina l study design in w h ich  pre- 
and postsynap tic  dopam ine rg ic  in te g rity  should be measured in re la tionship w ith  
du ra tion  and level o f a rtis tic  skills, no ve lty  seeking behavior, harm  avoidance, and 
perhaps eventua lly  pos tm o rtem  brain exam ination . This w ou ld  also a llow  fo r a 
m ore precise estim ation  o f the  du ra tion  o f the  preclin ica l period, w h ich  is currently  
estim ated at five  to  ten (or perhaps tw en ty ) years.33 Figure 1 (see next page) depicts 
the  several scenario's th a t could represent the  course o f preclin ica l PD, in which 
bo th  the  du ra tion  o f the  p rem oto r phase and the  rate o f degenera tion  (lineair, 
loga rithm ic , biphasic, etc.) are sub ject to  discussion.
Regarding the  app lica tion  o f screening too ls  fo r  preclin ica l PD, the  com b ina tion  of 
several p rem oto r sym ptom s (e.g. cogn itive  and behaviora l changes, sleep 
d isturbances, d im in ished smell) as well as b io log ica l markers (signs o f au tonom ic 
dysfunction , markers in CSF) in to  one parad igm  probab ly  p redicts  the  deve lopm ent 
o f PD best. Further investigations may also be d irected tow ards a be tte r character­
ization o f the  fu n c tiona l hem ispheric changes described in th is  thesis, e.g. by means 
o f fun c tiona l m agnetic  resonance im aging (fMRI) and im aging o f structura l neuronal 
in te g rity  (DTI). Some asym m etries w ill be com pensatory w h ile  others p robab ly 
represent a prim ary  disease characteristic. For exam ple, postsynap tic  D2-receptor 
up regu la tion  du ring  the  early clinical stage o f PD has been reported as a 
com pensatory m echanism .35-37 However, the  hypothesis o f increased righ t 
hem ispheric v u ln e ra b ility  w h ich  we postu la ted in th is  thesis needs to  be confirm ed 
in fu tu re  research. This is o f im portance  to  the  deve lopm en t o f new PD treatm ents, 






















Fig. 1 Time line o f norm al age-related loss o f dopam inerg ic neurons (continuous 
black line) and o f Parkinson's disease progression from  baseline to  
advanced disease (dotted black lines). The do tted  grey line represents the 
critical threshold fo r m oto r sym ptom  developm ent. Various scenario's o f 
PD progression have been postula ted. Scenario A: lower dopam inergic 
starting po in t bu t rate o f degeneration parallel to  healthy aging. Scenario 
B: same starting po in t as in healthy aging bu t faster degeneration from  
the beginn ing. Scenario C (most likely): same starting po in t and rate of 
degeneration as in healthy aging up to  a certain m om ent in tim e, after 
which the degeneration accelerates to  reach the critical threshold fo r 
m otor sym ptom  developm ent. The exact duration o f the  prem otor stage 
is unknown. The results o f the study presented in this m anuscript suggest 
tha t artistic people do no t have an advantage at the  starting po in t, bu t 
either may fo llo w  a d iffe rent rate o f degeneration later in life com pared to  
non-artistic people, or may reach the po in t o f accelerated degeneration 
later.
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In d it hoo fds tuk  w orden de bev ind ingen  van d it p roe fschrift besproken en to t  een 
logische sam enhang gebracht tegen de achtergrond van de bestaande lite ratuur. 
Het s lo t van het hoo fdstuk bespreekt suggesties voo r toekom stig  onderzoek aan de 
hand van de vraagstukken die u it het hu id ige  onderzoek naar voren zijn gekom en. 
De rode draad van d it p roe fsch rift w o rd t gevorm d do o r de zoek toch t naar nieuwe 
inzichten in de pa thofys io log ische m echanism en die ten grondslag liggen aan de 
vroege stadia van de ziekte van Parkinson, en do o r de technieken die in deze 
zoek toch t z ijn  gehanteerd.
G e s la c h ts v e rs c h ille n  in  h e t b e lo o p  v a n  d e  z ie k te  v a n  P a rk in so n
Uit onderzoek is gebleken dat de ziekte van Parkinson 1,5 to t  2x zoveel m annen als 
v rouw en tre ft. Bij m annen beginnen de m otore  verschijnselen (beven, trage en 
kle ine bew egingen, en sp ierstijfhe id ) bovendien gem idde ld  tw ee  jaar eerder dan 
bij vrouw en. D it suggereert da t de pe riode waarin de ziekte zich o n tw ikke lt maar 
nog n ie t m erkbaar is voo r de pa tien t (de zogenaam de "preklin ische fase"), bij 
m annen w e llich t anders v e rlo o p t dan bij v rouw en. O estrogenen (vrouw elijke 
ho rm onen) zouden hierin een rol kunnen spelen. In d ie rm ode llen  bleken 
oestrogenen een bescherm end e ffect op de voo r Parkinson be langrijke hersen­
s tructu ren  te hebben, m its deze w erden toeged iend  voorafgaand aan het 
ziekteproces. Daarnaast is gebleken dat v rouw en m et een lage oestrogeenspiegel 
do o r ve rw ijd e rin g  van eierstokken o f baarm oeder meer risico lopen op het 
on tw ikke len  van de PD. O estrogenen lijken dus een bescherm end e ffect te hebben 
in de preklin ische fase van de PD. Helaas ondervonden vrouw en die eenmaal 
sym ptom en hadden geen verbe te ring  bij he t geb ru ik  van oestrogenen.
In H o o fd s tu k  2 vonden we een aantal aanw ijz ingen voo r een re la tie f gunstiger 
z iekteproces bij v rouw en voorafgaand aan de m otore  verschijnselen van de ziekte 
van Parkinson. Bij 253 nog n ie t m et dopam inerge m edica tie  behandelde Parkinson­
patien ten verzam elden we de vo lgende gegevens: be g in le e ftijd , beg insym ptoom  
en m otore  ziekteverschijnselen (iedere 3-6 maanden gem eten m et de UPDRS-mo- 
torscore). Daarnaast vu lden  de v rouw e lijke  pa tien ten een vragen lijs t in be tre ffende 
hun oestrogeenstatus, een maat voo r de to ta le  hoeveelheid oestrogenen waaraan 
een v ro u w  is b loo tges te ld  gedurende haar leven. De oestrogeenstatus w o rd t o.a. 
bepaald door de le e ftijd  van de eerste en laatste m enstruatie , de duur van de 
v ruch tbare  levensfase en het aantal gebaarde kinderen. We constateerden dat 




kregen. Ten tw eede was bij v rouw en trem or vaak het eerste en be langrijkste 
sym ptoom  (67%), te rw ijl d it slechts voo r 48% van de m annen go ld . D it is van belang 
om da t de trem ord om in an te  pa tiën ten een 38% m inder snelle z iekteprogressie 
doorm aakten op basis van hun UPDRS-motorscore. Eerder onderzoek too nde  ook 
al een tragere  ziekteprogressie b ij trem ord om in an te  pa tiën ten aan. Tenslotte 
bleken vrouw en ook een 16% hogere striata le dopam ine b ind ing  te hebben dan 
m annen, een m oge lijke  ind ica tie  van een hogere fys io log ische dopam ineconcen- 
tra tie  w aardoor vrouw en w e llich t m eer reservecapacite it hebben. W anneer het 
beg insym ptoom  bu iten  beschouw ing werd ge laten, b leek dat vrouw en het 
voordee l dat zij in de periode voorafgaand aan de diagnose hadden, kw ijtraakten  
na de diagnose: zowel hun UPDRS-motorscore d irec t na de diagnose als het tem po  
van vers lech te ring waren verge lijkbaar m et de m annelijke scores. De oestrogeen- 
status b leek d u id e lijk  van invloed op het ontstaan van de Parkinsonsym ptom en. 
Hoe m eer k inderen vrouw en kregen en hoe langer de v ruch tbare  levensfase 
duurde, des te later begonnen de sym ptom en (per kind een u its te l van ru im  2,5 
jaar). Onze bev ind ingen  ondersteunen de hypothese dat de preklin ische fase bij 
mannen en vrouw en versch illend v e rlo o p t en dat oestrogenen hierin m oge lijk  een 
rol spelen. D it zou op popu la tien iveau kunnen verklaren waarom  vrouw en m inder 
vaak de ziekte van Parkinson krijgen en gem idde ld  enkele ja ren ouder zijn als de 
m oto re  sym ptom en ontstaan.
T im e d  m o to r  te s ts  in  d e  v ro e g e  fa se  v a n  d e  z ie k te  v a n  P a rk in so n
Om de m otoriek  bij de z iekte van Parkinson (PD) te beoordelen w o rd t w ere ldw ijd  
geb ru ik  gem aakt van de Unified Parkinson's Disease Rating Scale deel III (UPDRS-III, 
d.w.z. he t onderdee l m otoriek), en sinds kort van de herziene versie MDS-UPDRS-III. 
De UPDRS-III is echter tijd rovend , sub jec tie f en onvo ldoende gevoe lig  voo r kleine 
veranderingen in de m otoriek . Voor het in d it p roe fsch rift beschreven onderzoek 
m aakten w ij aanvankelijk nog geb ru ik  van de voo rlo pe r van de UPDRS-III, do o r ons 
s(selectie)UPDRS-III genoem d. Ook d it systeem is gebaseerd op beoorde ling  van de 
spraak, de m im iek, snelle a lte rnerende po lsbew egingen, arm zwaai en he t al dan 
n ie t aanwezig zijn van een rusttrem or, rig id ite it, houdings- en lichaamsbradykinesie.
Vanwege de genoem de beperk ingen van de sUPDRS-III onderzochten w ij in 
H o o fd s tu k  3.1 als a lte rna tie f een reeks eenvoud ige m otore  testen w aarb ij prestaties 
op het gebied van lopen, schrijven, enkel- en dubbe lhand ige  pegboard 
vaard igheden, v in ge r tappen , en snelle draaiende po lsbew egingen m et een
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stopw atch ge k lo k t werden (X aantal seconden per test, Y aantal bew egingen per 
tijdseenhe id ). Daarom spreken we van tim ed  m o to r tests (TMT's). Het doorlopen  
van de gehele tes tba tte rij kost m inder dan v ijf  m inu ten  en ho e ft n ie t per se door 
een arts te w orden bege le id. We onderzochten 288 vroege, onbehande lde Parkin- 
sonpa tiën ten. Zij werden iedere 3 to t  6 maanden gem eten m et zowel de UPDRS-III 
als de TMT's. De TMT's bleken dezelfde onderdelen van de m o to riek  te m eten als de 
UPDRS-III (Cronbach's a = 0.8). Bovendien reg istreerde de TMT ba tte rij m instens zo 
goed als de UPDRS-III de vers lech te ring van de m otoriek  m et he t vorderen van de 
ziekte. Ten opzich te van de UPDRS-III was de TMT ba tte rij ook m instens zo 
be trouw baar b ij opeenvo lgende m etingen, maar du id e lijk  gevoe liger en ob jectiever. 
Van alle TMT's b leek de pegboard de x te rity  test de beste kw a lite iten  te hebben, 
deze zou daarom  zelfs de gehele TMT b a tte rij kunnen vervangen. Deze goede 
prestatie kan m oge lijk  w orden verklaard door de u ite rs t gecoörd ineerde ind iv idue le  
v inge rbew eg ingen  die een vereiste vorm en om te test adequaat te kunnen 
u itvoeren. Juist deze fijne  m oto riek  is gestoord bij PD.
W anneer de pegboard de x te rity  test in tria lverband w o rd t ge b ru ik t in plaats van de 
UPDRS-III, is nog slechts 57% van het aantal pa tiën ten benod igd  om  een in terven- 
t ie -e ffe c t ten opzich te van het s ta rtpu n t aan te tonen . Door deze gunstige 
eigenschappen in com b ina tie  m et zijn eenvoud ige toepasbaarheid zou de 
pegboard  d e x te rity  test zowel in de spreekkam er als in w e tenschappe lijk  onderzoek 
g e b ru ik t kunnen w orden om  subtie le  veranderingen in de m oto riek  te meten 
(enerzijds in he t kader van ziekteprogressie , anderszijds te r beoorde ling  van het 
e ffect van medicatie).
In H o o fd s tu k  3.2 w o rd t de vo lgende stap in de karakterisering van de TMT ba tte rij 
- en de pegboard  d e x te rity  test in het b ijzonder -  beschreven. H ierbij onderzochten 
we o f de TMT's in staat waren een onderscheid te maken tussen enerzijds Parkin­
sonpatien ten m et een z iek teduur van m aximaal 2 jaar die nog n ie t m et dopam inerge 
m edicatie  gestart waren, en anderzijds gezonde personen (deel 1). D it verm ogen 
werd u itg e d ru k t in receiver opera ting  characteristics (ROC) curves m et een area 
under the  curve (AUC). Hoe hoger de AUC, des te beter is het onderscheidend 
verm ogen van de test. Op deze m anier onderzochten we ook o f de TMT's 
onderscheid konden maken tussen de onderarm - en hand functie  van gezonde 
personen ten opzich te van deze fun c tie  aan de klinisch nog onaangedane 
lichaam shelft van unilateraal aangedane Parkinsonpatienten (deel 2). Van alle TMT's 




In deel 1 was de AUC 0.97 (95% sensitiv ite it, 89% specific ite it), in deel 2 nam - zoals 
te verw ach ten was - de accuraatheid af to t  een toch nog redelijke AUC van 0.73. 
H ierm ee bleek de pegboard de x te rity  een gevoe lig  en be ho o rlijk  accuraat 
ins trum en t om  m otore  dysfunctie  in de vroege fase van de ziekte van Parkinson te 
de tecteren. M ede gezien de eenvoud ige toepasbaarheid zou het daarom  de 
m oe ite  waard kunnen zijn om  de prestaties van deze test verder te onderzoeken 
voo r dagelijks gebru ik  in de spreekkam er o f als onderdee l van een u itgebre idere  
screeningsm ethode in een popu la tie  m et een verhoogd  risico op het on tw ikke len  
van Parkinson, zoals mensen m et een genetische aanleg o f m et REM sleep behavior 
disorder.
Asymmetrische cerebrale (dys)functie in de vroege fase van de ziekte 
van Parkinson
Nadat de pegboard de x te rity  test was aangem erkt als meest sensitieve en 
be trouw bare  test voo r het m eten van subtie le  m oto re  dysfunctie , werd deze voor 
een vo lgend  vraagstuk ingezet (H o o fd s tu k  4.1). H ierbij werd de m otore  hand- en 
onde ra rm func tie  be iderzijds gem eten bij gezonde proefpersonen, Parkinson- 
pa tiën ten m et een overw egend rechts hemisferaal dopam ine rg  de fect (PD-R) en 
pa tiën ten m et een overw egend links hem isferaal dopam inerg  de fect (PD-L). 
A lle proefpersonen waren rechtshandig. Na correctie  voo r het e ffect van hand- 
dom inan tie  vonden we dat PD-R pa tiën ten een 55% gro te r verschil tussen hun 
links- en rechtszijd ige de x te rity  scores dan PD-L patiën ten. D it e ffect kon worden 
toegeschreven aan ernstige r m otorische dysfunctie  van de meest aangedane hand 
bij PD-R patiën ten (d.w.z. de linkerhand) ten opzich te de m eest aangedane hand bij 
PD-L pa tiën ten (d.w.z. de rechterhand), te rw ijl het voordee l van rechtshand ighe id  al 
was u itgeslo ten . De scores van de m inst aangedane hand waren verge lijkbaar voor 
be ide groepen. H ieru it concludeerden we dat de rechter hem isfeer bij de z iekte van 
Parkinson m oge lijk  op een andere m anier is aangedaan dan de linker hem isfeer. We 
postu leerden dat de n ie t-dom inan te  rechter hem isfeer w e llich t kwetsbaarder is 
voo r dopam ine rge denervatie  dan de dom inan te  linker hemisfeer.
Een andere u iting  van fun c tione le  hem isferale asym m etrie b ij de z iekte van 
Parkinson w o rd t beschreven in H o o fd s tu k  4 .2 . In een cross-sectionele stud ie  bij 
pa tiën ten m et klinisch du id e lijk  asym m etrische ziekteverschijnselen en m et een 
z iek teduur van m aximaal 5 jaar, evenals in lee ftijdsgem atch te  gezonde personen, 
werd de striata le postsynaptische D2-b in d in g  gem eten m et [123I] IBZM SPECT scans.
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Ook werd de ernst van de presynaptische dopam ine rge laesie gem eten m et [123I] 
FP-CIT SPECT scans. De IBZM-SPECT-binding was s ign ifican t hoger b ij de patiën ten 
(1,56 ±  0,09) dan bij de con tro legroep  (1,53 ±  0,06). Bij de pa tiën ten werden hogere 
waarden gevonden contra lateraal van de klinisch meest aangedane zijde (1,57 ± 
0,09 vs 1,55 ±  0,10 ipsilateraal), hetgeen D2-recep to r up regu la tie  suggereert. Echter, 
op ind iv idue le  basis too nde  slechts 56% van de pa tiën ten deze upregulatie. 
O m gekeerd vonden we lagere [123I] FP-CIT SPECT waarden contra la teraa l van de 
klinisch meest aangedane zijde. Het percentage pa tiën ten m et contra lateraal 
hogere D2-recep to r b ind ing  was s ign ificant hoger in de groep van links-dom inan t 
parkinsonism e (76%) dan in de groep m et rech ts-dom inan te  sym ptom en (33%, x2 
<0,0001). M et andere w oorden, pa tiën ten m et een voo rnam e lijk  rechts-hem isferaal 
dopam ine rg  de fect ve rtoonden  vaker een verhoogde postsynaptische IBZM -bind ing 
dan pa tien ten m et links-hem isfera le z iek tedom inan tie . D it zou aansluiten b ij de 
bev ind ingen  beschreven in H o o fd s tu k  4.1 van een ernstiger aangedane rechter 
hem isfeer in links-dom inan t parkinsonism e ten opzich te van de linker hem isfeer in 
rech ts-dom inan t parkinsonism e. Echter, het e ffect in de IBZM scores verdw een na 
correctie  voo r het fys io log ische verschil zoals da t werd gevonden in de gezonde 
personen. Contralateraal hogere IBZM b ind ing  werd dan gevonden in 55% van de 
patiën ten m et linksdom inan t parkinsonism e en bij 56% m et rechtsdom inante 
sym ptom en. De aanw ezigheid van contra la teraa l hogere striata le IBZM b ind ing  
hee ft dus onvo ldoende pos itie f voorspe llende waarde. Anderzijds s lu it het 
on tbreken hiervan bij pa tiën ten m et recent ontstaan parkinsonism e de ziekte van 
Parkinson n ie t u it. Daarom m oe t de vastste lling van asym m etrische D2-receptor 
up regu la tie  in de vroege fase van Parkinson n ie t w orden g e b ru ik t als een 
d iagnostisch ins trum en t, maar veeleer w orden gezien als een meer fundam ente le  
b ijd rage aan ons begrip  van de pa thofys io log ische veranderingen in het begin van 
de ziekte.
In d ic a to re n  v a n  n ie t-m o to re  v e ra n d e r in g e n  v o o ra fg a a n d  aan  d e  d ia g n o s e
In de vorige  hoofdstukken werden versch illende aspecten van de m otorische (dys) 
fu n c tie  bij Parkinsonpatienten beschreven. Parkinson is echter n ie t a lleen een ziekte 
van de m otoriek . Diverse onderzoeken hebben reeds aangetoond dat n ie t-m oto re  
versch ijnselen ja ren voorafgaand aan de p rem otore  fase van de ziekte aanwezig 
kunnen zijn. In d it  p roe fsch rift is daarom  een be langrijk  hoo fdstuk (H o o fd s tu k  5) 
hieraan besteed, al is de invalshoek anders dan to t nu toe  ge b ru ike lijk  was. We 




van dopam ine rge in te g rite it, d ie le id t to t  een voo rkeu r en geschikthe id  voor 
specifieke w erkzaam heden. We w isten da t Parkinsonpatienten vaker dan gezonde 
mensen een pe rsoon lijkhe idspro fie l hebben da t gekenm erkt w o rd t door 
con tro ledrang , voo rz ich tighe id , geordendhe id , ve rlegenhe id  en een gebrek aan 
"n ove lty  seeking". O f deze kenm erken zich al in de p rem otore  fase van de ziekte 
on tw ikke len  was echter n ie t bekend. Beroepen waren alleen in kaart gebracht als 
po ten tië le  ris icofactoren voo r het ontstaan van de ziekte van Parkinson in de 
con tex t van b loo ts te llin g  aan toxines. De benadering van beroepen als u iting  van 
een zich on tw ikke lende  z iekte is nieuw. M et behu lp  van Holland 's RIASEC model 
vonden we dat m annen m et een a rtis tiek  beroep een veel lager dan gem idde ld  
risico hadden op het on tw ikke len  van de ziekte van Parkinson, maar u its lu itend  op 
basis van hun meest recente beroep (OR 0,14). In tegenste lling  to t  onze hypothese 
kon voo r de conven tione le  beroepen geen verhoogd  risico op Parkinson worden 
aangetoond. H ierbij is he t be langrijk  te beseffen dat het RIASEC m odel weliswaar 
een gevalideerde m ethode  is voo r het categoriseren van beroepen op basis van 
persoonlijkhe idskenm erken, maar geen algem een erkende m ethode  te r bepaling 
van de dopam ine rge in te g rite it. Bovendien w o rd t ons gedrag n ie t alleen bepaald 
do o r dopam ine, maar b ijvoo rbee ld  ook do or noradrenaline, een neuro transm itte r 
die w o rd t geassocieerd m et verm ijd ingsgedrag . Het in deze stud ie waargenom en 
e ffec t kom t echter overeen m et onze baseline voo rspe lling  en b lee f aanwezig na 
correctie  voo r po ten tië le  confounders. De RIASEC benadering bevestigde ook het 
eerder ge rapporteerde  verhoogde risico op Parkinson voo r boeren (OR 2,6 in de 
hu id ige  studie; OR 2,5 in voorgaand onderzoek). Ind irect is d it een va lida tie  van 
onze database ten opzich te van de veel gro te re  popu la tiestud ies ge rich t op het be- 
roepsgerelateerde voo rkom en van ziektes. Onze bev ind ingen ondersteunen de 
hypothese da t artistieke ta len ten  m oge lijk  een u iting  zijn van een p rodopam ine rge 
status, die op zijn be u rt de on tw ikke lin g  van de m otorische sym ptom en van 
Parkinson u its te lt o f voo rkom t. U it recente andere studies vo lgde  een pos itie f 
verband tussen artistieke p ro d u c tiv ite it en dopam ine rge ac tiv ite it. A rtis tieke 
c rea tiv ite it kan w orden vers te rk t do o r drugs zoals cocaïne o f am fetam ine, die het 
m esolim bische dopam ine rge systeem stim uleren en daarm ee van invloed zijn op 
be loningsreacties en verslavingsgedrag. D it zou kunnen verklaren waarom  
kunstenaars een verhoogd risico hebben op het on tw ikke len  van het dopam ine 
dysregu latie  syndroom . O m gekeerd kunnen artistieke vaard igheden w orden 
uitgeschakeld door s tim u la tie  van de linker nucleus subthalam icus, te rw ijl dopa- 
m inedep le te rende  laesies in de nucleus accum bens o f he t ven tra le  tegm entum
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leiden to t afgenomen nieuwsgierigheid en onderzoekend gedrag. Onze bevindingen 
suggereren dat een ge le ide lijk  dalend dopam ineniveau tijdens de p rem otore  fase 
van Parkinson to t  een beroepsm atige voo rkeu r o f geschikthe id kan le iden, w aardoor 
de kans om  in een a rtis tiek  beroep werkzaam  te zijn in de ja ren voorafgaand aan de 
diagnose kle in is. Het fe it  dat w e in de hu id ige stud ie  geen associatie vonden tussen 
het eerste beroep en het risico op Parkinson suggereert dat de prem otore  fase later 
beg in t. Ondanks het g ro te  aantal p roefpersonen in onze stud ie  was de frequen tie  
van artistieke beroepen nog te laag om  te kunnen bepalen op w e lk t ijd s tip  d it 
om slagpun t op tre ed t. Toekom stig onderzoek zou zich h ierop kunnen richten.
Toekomstvisie
Hoewel een aantal vragen in d it  p roe fsch rift z ijn  bean tw oord , heeft het onderzoek 
ook diverse nieuwe vragen gegenereerd voo r toekom stig  onderzoek. We konden 
de exacte duur van de preklin ische periode w eliswaar n ie t vastste llen, maar vonden 
wel aanw ijz ingen voo r een veranderend dopam inerg  systeem in de jaren 
voorafgaand aan de eerste m oto re  verschijnselen. Deze veranderingen vo lgden 
een versch illend pa troon voo r m annen en vrouw en. In da t kader m oe t de precieze 
rol van oestrogenen in het dopam inem etabo lism e en in neurop ro tec tie  verder 
worden opgehelderd. Rocca en collega's (Mayo Clinic, Rochester, VS) zijn mom enteel 
ac tie f in de rge lijk  onderzoek. W ellich t kan oestrogeensupp le tie  b ij v rouw en de 
ziekte van Parkinson toch u its te llen , m its deze maar in een zo vroeg m oge lijk  (voor) 
stad ium  w o rd t gestart. U iteraard is vroeg starten voo r ieder po ten tiee l rem m end of 
genezend m edicijn  (zoals we da t in de toekom st verw achten) van em inen t belang. 
Dat v raagt echter wel om  de on tw ikke lin g  van instrum enten die preklin ische ziekte 
kunnen detecteren. De pegboard de x te rity  test zal h ie rvoor helaas onvo ldoende 
bru ikbaar zijn.
U it de beroepenstud ie  kwam  naar voren dat artiesten een verlaagd risico op het 
on tw ikke len  van Parkinson hebben. Deze stud ie  is echter n ie t bew ijzend voo r een 
causaal verband tussen artistieke kw a lite iten , striata le dopam ineconcen tra ties en 
u its te l van n ig rostria ta le  degenera tie. H iervoor is een prospectieve, long itud ina le  
stud ie  aangewezen, w aarb ij pre- en postsynaptische dopam ine rge  in te g rite it w o rd t 
gem eten in sam enhang m et de duur van u itoe fen ing  en de mate van artistieke 
vaard igheden, "n ove lty  seeking" gedrag, gevaar ve rm ijd ing , en w e llich t zelfs post­
m ortem  hersenonderzoek. Derge lijk  onderzoek zou ook meer in fo rm atie  kunnen 























5 en 10 (soms zelfs 20) jaar w o rd t geschat. Zie figuur 1 voor een schematische weergave 
van de versch illende scenario's die be trekk ing hebben op de preklin ische periode.
Fig. 1 Time line o f norm al age-related loss o f dopam inerg ic neurons (continuous 
black line) and o f Parkinson's disease progression from  baseline to  
advanced disease (dotted black lines). The do tted  grey line represents the 
critical threshold fo r m oto r sym ptom  developm ent. Various scenario's o f 
PD progression have been postula ted. Scenario A: lower dopam inergic 
starting po in t bu t rate o f degeneration parallel to  healthy aging. Scenario 
B: same starting po in t as in healthy aging bu t faster degeneration from  
the beginn ing. Scenario C (most likely): same starting po in t and rate of 
degeneration as in healthy aging up to  a certain m om ent in tim e, after 
which the degeneration accelerates to  reach the critical threshold fo r 
m otor sym ptom  developm ent. The exact duration o f the  prem otor stage 
is unknown. The results o f the study presented in this m anuscript suggest 
tha t artistic people do no t have an advantage at the  starting po in t, bu t 
either may fo llo w  a d iffe rent rate o f degeneration later in life com pared to  




W at b e tre ft de toepassing van screeningsinstrum enten voo r p reklin ische Parkinson, 
zal w aarsch ijn lijk  het beste resultaat behaald w orden m et een com b ina tie  van 
testen die zich enerzijds richten op klin ische sym ptom en (bv. cogn itieve  en ge ­
dragsveranderingen, o f reukstoornissen) en anderzijds op laboratorium m arkers 
(bv. hersenspecifieke e iw itten  in liquor). Toekom stig onderzoek zou zich daarnaast 
kunnen richten op het doorg ronden van de asym m etrische hem isferale 
veranderingen in zowel s truc tuu r als func tie , bij voo rbee ld  door m idde l van fMRI of 
DTI scans. Som m ige veranderingen zijn w aarsch ijn lijk  com pensatoir, zoals post­
synaptische D2-recep to r upregula tie , te rw ijl andere een in trinsieke u iting  zijn de 
ziekte. Een beter begrip  van deze processen is van g ro o t be lang voo r het on tw ikke len  
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1 m aart 2011. Als neuro loog  in op le id ing  was zij ac tie f in diverse op le id ingsgere la- 
teerde commissies, en als bestuurslid van de A(N)IOS veren ig ing  van het UMC St 
Radboud. Daarnaast is zij als docen t jaarlijks  be trokken bij de Parkinsonscholing van 
verp leegkund igen  en param edici van u it het Parkinson Centrum  N ijm egen. Sinds 





Het is nog steeds onw erke lijk  te beseffen da t degene die aan de w ieg van d it 
p roe fsch rift hee ft gestaan, de a frond ing  ervan n ie t heeft m ogen meemaken. Beste 
M artin , ik draag d it p roe fsch rift op aan jo u . Dank voo r je  op tim ism e en onw rikbare  
ove rtu ig ing  dat we er samen iets m oois van zouden maken, ook al waren we het 
soms g rond ig  oneens. W at heb je  o n ge loo flijk  veel data verzam eld, en da t vaak 
'gewoon' tijdens je  spreekuur. Je deed d it n iet alleen om er zelf w ijzer van te worden, 
de patiënten waren je  dankbaar dat je  hen concrete feedback over hun functioneren 
kon geven. Zo vonden ze in de door jo u  o n tw o rp en  m otore  tes tba tte rij vaak een 
bevestig ing van hun eigen inscha tting over het e ffect van m edica tie  o f over hun 
ziekteprogressie, hoe subtie l ook. W anneer ik de pa tiën ten die na je  pensioen op 
m ijn  spreekuur te rech t kwam en verte lde  dat w ij nog vo lop  samen aan het schrijven 
waren, werd ik niet alleen zonder enig protest als opvolger ontvangen, maar ook 
u itgeb re id  dee lgenoo t van hun dankbaarheid voo r je  bekwaam heid en het 
ve rtrouw en  dat ze in je  hadden. Ik koester de he rinnering  aan onze laatste 
on tm o e tin g , tijdens een congres in Parijs, onder het geno t van een ontspannen 
diner, de wetenschap la tend voo r w a t het was.
Ik dank ook alle Parkinsonpatiënten, in to taa l m eer dan 1000, en hun partners, die 
in de loop van vele jaren hun steentje aan d it proefschrift hebben bijgedragen. 
Terwijl zij zich ervan bew ust waren dat d it onderzoek a llerm inst to t  ziektegenezing 
zou leiden, en soms m oe ilijk  g rijpbare  m aterie be tro f, ze tten  zij zich steeds m et 
gro te  inzet en onderzoekstrouw  (ongew oon hoge responspercentages!) in.
Dankbaar ben ik m ijn  p rom otor, Prof. dr. B.R. Bloem. Beste Bas, je  tom eloze 
enthousiasm e, gedrevenheid en razendsnelle inz ich t zijn voo r m ij haast onvoo r­
stelbaar. Ik ken niem and die he t in zijn hoofd  haalt structuree l om  3.00 's nachts te 
m ailen en verbaasd te zijn als het om  8.00 's ochtends nog n ie t gelezen is. Wat 
g ingen we als een speer van start toen ik voo r he t eerst onder jo u w  hoede kwam. 
Soms was he t crisis en zoeken naar de ju is te  a fs tem m ing ... maar sinds we elkaar 
daarin gevonden hebben zijn we als vanouds verder op d it e inddoe l afgestevend!
M ijn  tw eede p rom otor, Prof. dr. G.F. Borm, en m ijn  cop rom oto r, dr. A.C. Kappelle, 
verd ienen ook een be langrijk  w oord  van dank. Beste A rnoud , toen ik aan het 
onderzoek begon had ik no o it kunnen bedenken dat j i j  m ijn  cop rom o to r zou
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w orden, Parkinson is im m ers n ie t per se jo u w  terre in . Maar hoe waardevol jo u w  
bijdrage was is wel gebleken: de stabiele factor in tijden  van tw ijfe l, b loed, zweet en 
tranen; de toez ich thouder op de overvo lle  agenda van Bas. Je hebt me a ltijd  de 
ru im te  gegeven m ezelf te zijn.
Beste George, als j i j  je  erm ee bem oe ide werd alles ineens k inde rlijk  eenvoud ig. 
Hoe eenvoudiger, hoe overtu igender. Jij kun t als geen ander de link leggen tussen 
sta tis tiek en klin iek.
Ik dank de leden van de m anuscrip tcom m issie, Prof. dr. M.G.M. O lde Rikkert, Prof. dr. 
H.P.H. Kremer, en Prof. dr. W.J.G. Oyen, voo r de kritische maar ook zeer snelle 
beoorde ling  van d it m anuscript.
Het g ro te  aantal pa tiën ten in deze stud ie  had ik on m og e lijk  kunnen bereiken 
zonder de enthousiaste inzet van vele co llega-neuro logen. Dr. A. Hovestadt, 
M eander M edisch Centrum  A m ersfoort; dr. E. van Wensen, Gelre Z iekenhuizen 
Locatie Lukas, A pe ldoorn ; dr. P.J.E. Poels, Maasziekenhuis Pantein, Boxmeer; dr. C. 
v.d. Vlasakker, S lingeland Ziekenhuis, Doetinchem ; drs. A.J. Verm eij, Maxima 
M edisch Centrum , E indhoven; Dr. J.P.P. van Vugt, M edisch Spectrum  Twente, 
Enschede; drs. T.F.M. Fennis, St. Jansdal Z iekenhuis, Harderw ijk; dr. R. van 
Koningsveld, Elkerliek Ziekenhuis, Deurne; dr. Th.J.M. Breuer, St Anna Ziekenhuis, 
Geldrop; drs. J. Lion, Bernhoven Ziekenhuis, Veghel; dr. A.G.G.C. Korten, Laurentius 
Ziekenhuis, Roerm ond; dr. J.C.F. van der W ielen, Alysis Zorggroep, Zevenaar; dr. F.E. 
Strijks, Gelre Z iekenhuizen, locatie Het Spittaal, Zu tphen; drs. E.G. Gonera, Isala 
Klinieken, locatie W eezenlanden, Zwolle; dr. J.I. Hoff, Mesos M edisch Centrum, 
locatie O vervecht, U trech t: allen heel ha rte lijk  dank!
Ook de be langeloze hu lp en w arm e on tvangst die ik steeds weer kreeg door het 
ondersteunend personeel in de verschillende ziekenhuizen heb ik als heel b ijzonder 
ervaren.
Dan zijn er de s tudenten die m onnikenw erk hebben ve rrich t om  m ijn  laatste 
database te vu llen , kolom , na kolom , na kolom . Leuk was he t vast n ie t a ltijd , 
waardevol wel! Heel veel dank aan Nynke Kappelle, M arg it Klok, Maaike Schaap en 
A nne tte  van Kerkhof.
Verder w il ik Sebastiaan Overeem bedanken voo r zijn be trokkenhe id  en steun bij 
he t early de tec tion  artike l. Z ijn kritische vragen waren n ie t a ltijd  gem akke lijk  te
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bean tw oorden  maar hebben he t stuk absoluut sterker u it de strijd  doen komen. 
Ook gaat m ijn  dank u it naar de a fde ling  N euro log ie  en m et name naar m ijn  op le ider, 
Prof. dr. G.W.A.M. Padberg, die m ij de ge legenhe id ga f d it  onderzoek te doen.
T ijdens m ijn  t ijd  op "de 5e ve rd ie p in g " was het een kom en en gaan van m ede-on- 
derzoekers. In het b ijzonder w il ik degenen noem en m et w ie ik lie f en leed heb 
gedeeld . Maja, Liselore, Lars, Femke, Loes, M aarten, Nicol, W illem ijn , Susanne en 
Anke. Dank voo r de op en ha rtighe id  en fijne  werksfeer waarin ik me thu is heb 
gevoeld, de lucht afw isselend gevuld m et gedrevenheid en focus, frustra tie , 
on tspann ing , onverm oeibaar cynisme, en op zijn t ijd  m et een enthousiaste 
o p ru im d rift.
Ook op de 5e verd iep ing : alle secretaresses, in het b ijzonder N oortje  Bergevoet, die 
me in drukke tijd e n  m et vele te le foon tjes  en postverzend ingen geho lpen hebben.
Dank aan de (oud)assistenten neuro log ie  voo r hun co lleg ia lite it en n ie t te vergeten 
c rea tiv ite it in onze gezam enlijke bu itenschoolse optredens. Die acht jaar g ingen 
toch sneller dan verw acht!
Ik w il verder graag aan prof. dr. B.G.M. van Engelen m ijn  dank uitspreken. Beste 
Baziel, dank voo r je  e igenzinn ige k ijk  op d ingen en b ijzondere gesprekken die 
on ts tonden  u it zom aar een praatje op de gang. Ook je  steun na he t overlijden van 
M artin  heb ik zeer gewaardeerd.
Ook op m ijn  hu id ige  w erkp lek  (K inderneuro log ie) heb ik tijdens de laatste loodjes 
van d it p roe fsch rift alle steun gekregen die ik me kon wensen. M ichèl (dr. M.A.A.P. 
W illemsen), dank voo r je  ve rtrouw en  da t het in de afgesproken t ijd  ook echt af zou 
kom en. Op Socratische w ijze lie t je  me inzien w a t daarvoor nod ig  was. Je 
enthousiasm e is aanstekelijk, je  em path ie  bewonderensw aard ig , en je  b indend 
verm ogen b innen de groep essentieel. Inge, ik had me geen betere "room ie " en 
pa ran im f kunnen wensen, dankjewel voo r je  hum or en zonn ige hum eur, zelfs toen 
je  op het pu n t stond te bevallen van ju llie  prachtige doch te r (die als gro te  verrassing 
de naam Charlo tte  kreeg!). Jolanda, Corrie en Lilian, dank dat ju llie  me - ieder op 
geheel eigen w ijze - vanaf het begin m et ve rtrouw en  en co lleg ia lite it hebben 
opgenom en in de groep, iets w a t ik als heel b ijzonder heb ervaren. M iel, jo u  dank ik 
voora l als steun en toeverlaat bij het overpeinzen van de vraagstukken des levens 
(en voo r die heerlijke w ijn  die helaas een andere bestem m ing k re e g .) .  Hanneke en
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Jeanne, m et to e w ijd in g  en op z'n t ijd  een persoonlijke no o t maken ju llie  het geheel 
com pleet!
Dan zijn er m ijn lieve vrienden en vriend innen, die ik vaak heb m oeten teleurstellen 
als ik w eer eens n ie t op een feestje  kon kom en om dat ik d ienst had, o f om dat ik me 
een weekend had opgesloten om  te schrijven. Bedankt voo r ju llie  vriendschap, 
be langs te lling , gedu ld  en beg rip  waar da t vast n ie t a ltijd  m akke lijk  en vanze lf­
sprekend was.
Tenslotte m ijn  ouders. Lieve papa en mama, het waren tu rb u le n te  ja ren, n ie t in de 
laatste plaats voo r ons als gezin. Toch heb ik me a ltijd  vo lled ig  do o r ju llie  gesteund 
gevoeld, m et lie fde en vertrouw en . Ik ben b lij en tro ts  dat ju llie  deze afrond ing 
a llebei m ogen meemaken.
En als laatste, maar o zo be langrijk , m ijn  zusje, en nu ook paranim f. Lieve Moyra, 
m ijn  beste "Tschweerzie", "Tweaq" (lees: tw iek), "Kenner der cu ltu ren " en honderd 
andere namen die ik je  inm iddels heb gegeven sinds onze k in d e r t i jd .  De band die 
w ij hebben is uniek en m oet gekoesterd w orden. Laten we blijven drom en over die 
du op rak tijk  voo r u itzonderlijke  en zonderlinge  z ie k te b e e ld e n . (en het vooral bij 
d rom en laten!)
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